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G e n e r a l  i n t r o d u c t i o n 1

General IntroduCtIon
As a consequence of the growing obesity prevalence, type 2 diabetes mellitus (T2DM) has 
become a global epidemic. Currently, this disease affects 171 million individuals globally, with 
an estimated mortality of about 4 million deaths each year (1). The development of T2DM 
is the result of insulin resistance of target organs (i.e. liver, adipose tissue, skeletal muscle) 
and impaired insulin secretion by pancreatic β-cells, ultimately leading to hyperglycemia. In 
addition to glucose metabolism, lipid metabolism is disturbed in T2DM patients, resulting in 
concomitant dyslipidemia.
G l u C o s e  M e ta b o l I s M
Dietary carbohydrates enter the body in complex forms, such as disaccharides and polymers 
(starch). In the gut, these complex carbohydrates are digested into glucose and other simple 
carbohydrates that can be transported across the intestinal wall to the hepatic portal vein and 
delivered to liver parenchymal cells (i.e. hepatocytes) and other tissues. The maintenance 
of narrow-controlled blood glucose concentrations (glucose homeostasis) is essential for a 
constant provision of glucose to the brain.
Glucose homeostasis is regulated by the balance between endogenous production of glucose, 
mainly by the liver, and uptake and utilization of glucose by peripheral tissues. To prevent 
hypoglycemia in the fasted state, glucose is released from the liver (and in small amounts from 
the kidneys (2)) by two pathways: glycogenolysis and gluconeogenesis. Glycogenolysis is the 
biochemical breakdown of stored glycogen to glucose, while gluconeogenesis is the process 
of generating new glucose molecules from non-carbohydrate sources, such as amino acids 
and the glycerol portion of triglycerides. Glucose disposal takes place in peripheral tissues 
like skeletal muscle, adipose tissue and heart. Once glucose is transported into the cell, it can 
undergo glycolysis (catabolism of glucose) to render energy in the form of ATP, e.g. required 
for muscle contraction, or can be stored either as glycogen in liver or muscle or as the glycerol 
moiety of TG in adipose tissue.
Glucose homeostasis is controlled primarily by the anabolic hormone insulin. Several 
catabolic hormones (glucagon, catecholamines, cortisol, and growth hormone) oppose the 
actions of insulin. After a meal containing carbohydrates, plasma glucose levels rise and as 
a result, insulin is secreted by pancreatic β-cells (Fig. 1). Insulin inhibits glycogenolysis and 
gluconeogenesis, and as a result inhibits endogenous glucose production. In addition, insulin 
stimulates glucose disposal in peripheral tissues. The net result of these actions of insulin is a 
normalization of plasma glucose levels after a meal. 
Insulin initiates its effects on target tissues by binding to the insulin receptor (IR), which results 
in the tyrosine phosphorylation of insulin receptor substrates (IRS) by the insulin receptor 
tyrosine kinase. This allows association of IRS with the regulatory subunit of phosphoinositide 
3-kinase (PI3K). PI3K activates 3-phosphoinositide-dependent protein kinase-1 (PDK), which 
activates protein kinase B (PKB)/Akt, a serine kinase. PKB/Akt in turn deactivates glycogen 
synthase kinase 3 (GSK-3), leading to activation of glycogen synthase and thus glycogen 
synthesis. Activation of PKB/Akt also results in the translocation of GLUT4 vesicles from their 
intracellular pool to the plasma membrane, where they allow uptake of glucose into the cell. 
11
ChaPter 1
Furthermore, activated PKB/Akt phosphorylates the nuclear protein Proline-rich Akt substrate 
of 40 kDa (PRAS40), of which the precise function is still under debate.
The golden standard for investigating and quantifying insulin sensitivity in a clinical setting, but 
also in experimental setting in rodents, is the hyperinsulinemic-euglycemic clamp. During the 
hyperinsulinemic-euglycemic clamp, a constant concentration of insulin is infused intravenously. 
In order to prevent hypoglycemia induced by the insulin rise, glucose is infused to maintain plasma 
glucose levels at euglycemic levels. The rate of glucose infusion necessary to maintain euglycemia, 
as determined by checking plasma glucose levels every 5-10 minutes, is a measure for insulin 
sensitivity. A high glucose infusion rate indicates sensitivity to insulin action, whereas a low glucose 
infusion rate indicates that the body is resistant to insulin action. The information obtained by 
the hyperinsulinemic-euglycemic clamp can be extended by the use of glucose tracers. Glucose 
can be labeled with either stable or radioactive atoms, including [1-14C]glucose or [3-3H]glucose 
(3;4). Prior to beginning the hyperinsulinemic period, a tracer infusion enables quantification of 
the basal rate of glucose production. During the clamp, the plasma tracer concentrations enable 
the calculation of whole-body insulin-stimulated glucose disposal, as well as the endogenous 
glucose production (5). The hyperinsulinemic-euglycemic clamp can be further extended using 
radioactive-labeled 2-deoxyglucose. This tracer is administered during the clamp as a bolus when 
steady-state euglycemia is reached to determine organ-specific glucose uptake in organs that are 
unable to glycolyse 2-deoxyglucose (all organs except liver and kidney) (6).
In addition to insulin, other hormones affect glucose metabolism. For example, the thyroid 
hormones (TH) thyroxine (T
4
) and triiodothyronine (T
3
), are tyrosine-based hormones produced 
by the thyroid gland. TH production by thyroid gland is regulated by thyroid-stimulating 
Fig. 1. Schematic representation of insulin’s effect in glucose and fatty acid metabolism. Insulin reduces glucose 
levels by stimulating glucose uptake by peripheral tissues (e.g. muscle) and inhibiting glucose production by the 
liver. The latter involves insulin action in the brain. Insulin reduces fatty acid levels by stimulating fatty acid uptake 
by white adipose tissue and by inhibiting triglyceride secretion by the liver. 
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hormone (TSH) produced by the anterior pituitary, which itself is regulated by thyrotropin-
releasing hormone (TRH) produced by the hypothalamus. TH are crucial regulators of 
metabolism, as illustrated by the profound alterations in metabolism during hyper- and 
hypothyroidism (7). Hyperthyroid animals develop elevated plasma glucose and insulin levels, 
due to increased endogenous glucose production, including increased gluconeogenesis and 
glycogenolysis, and decreased glucose clearance and disposal (8;9). Conversely, in hypothyroid 
animals, basal endogenous glucose production is reduced (10;11), whereas glucose utilization 
and turnover in skeletal muscle and adipose tissue is decreased (12).
fat t y  aC I d  M e ta b o l I s M
The most common lipids in our diet are cholesterol and triglycerides (TG). Since lipids are 
hydrophobic, they are transported in the circulation in water-soluble spherical particles called 
lipoproteins. These lipoproteins carry TG and esterified cholesterol in their core, surrounded by 
a shell of phospholipids, free cholesterol and proteins termed apolipoproteins. Based on their 
composition and origin, lipoproteins can be divided into five major classes i.e. chylomicrons, 
very low lipoproteins (VLDL), intermediate density lipoproteins (IDL), low density lipoproteins 
(LDL) and high density lipoproteins (HDL) (13). 
In the intestine, dietary lipid is emulsified by the action of bile and TG are hydrolyzed into 
monoacylglycerol and fatty acids (FA) by pancreatic lipase. Cholesterol, monoacylglycerol and 
FA are absorbed by the intestinal cells where FA are re-esterified to TG. The TG and cholesterol 
are packaged in chylomicrons. Upon entering the circulation, chylomicrons are processed by 
lipoprotein lipase (LPL) (14). LPL hydrolyzes TG, thereby delivering FA to peripheral tissues, 
where it can be used as energy source (skeletal muscle and heart) or can be stored in adipose 
tissue. The resulting TG-depleted remnant chylomicrons are taken up by the liver. The liver 
can secrete cholesterol and TG, packaged in VLDL particles for transport to peripheral tissues. 
After VLDL enters the circulation, the TG content of VLDL can be hydrolyzed into FA by LPL and 
used as energy source. The processing of VLDL by LPL results in the formation of IDL (or VLDL-
remnant), which can be further processed to become cholesterol-rich LDL. IDL and LDL can be 
cleared by the liver. High levels of chylomicrons, VLDL, IDL and LDL can lead to accumulation 
of lipids in the vascular wall and the development of atherosclerosis. HDL, as formed by the 
liver and intestine, can remove excess cholesterol from peripheral tissues. Next, HDL-derived 
cholesterol can be taken up by the liver. In the liver, excess cholesterol is secreted in the bile, 
thereby maintaining cholesterol homeostasis (15). 
FA are important metabolic substrates. The uptake, transport and storage of FA is intensively 
regulated and plasma FA levels show little variation. TG in TG-rich lipoproteins are hydrolyzed 
into FA by the action of LPL, located at the capillary endothelium. The released FA are taken 
up by the underlying tissue via passive diffusion across cell membrane or via active transport, 
which is facilitated by FA transporters, such as the FA translocase CD36 (16). In WAT, these FA 
can be re-esterified and stored as TG in intracellular lipid droplets. In heart and skeletal muscle, 
these FA are metabolized to produce ATP. Excess FA are complexed to serum albumin and 
transported back to the liver.
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In brown adipose tissue (BAT), FA is metabolized by uncoupling FA oxidation from ATP 
generation, thereby resulting in dissipation of energy as heat. Only recently, it was shown that BAT 
is also present and functional in human adults (17). At birth, human newborns have considerable 
amount of BAT, mostly surrounding the vasculature and organs, to defend the body from cold 
exposure. In adults, BAT is mainly present in the supraclavicular and neck region (18;19). BAT burns 
FA stored as TG in lipid droplets as a response to sympathetic innervation. BAT comprises only a 
small percentage of total body weight and lipids stored in BAT can sustain thermogenesis for only 
a short time. A recent study revealed that TG-rich lipoproteins are an important substrate for heat 
production by BAT (20). Cold exposure accelerates clearance of plasma TG as a result of increased 
uptake into BAT, a process dependent on LPL activity and CD36 (20). 
Insulin exerts direct effects on VLDL production, by accelerating the degradation of apoB 
(the principal apolipoprotein of VLDL), thereby acutely decreasing VLDL secretion by the liver 
(21;22) (Fig. 1). In adipose tissue, insulin stimulates TG storage in adipose tissue in three ways. 
First, insulin activates LPL in the capillary walls of adipose tissue, thereby stimulating lipolysis 
(breakdown of TG into FA and glycerol), enabling FA uptake by adipocytes. Second, insulin 
stimulates glucose transport into adipocytes, providing substrate for the glycerol portion of TG. 
Third, insulin inhibits hormone-sensitive lipase (HSL), thereby inhibiting hydrolysis (breakdown 
of TG into FA and glycerol) in adipocytes. The inhibition of lipolysis in adipose tissue by insulin 
decreases the flux of FFA towards the liver, contributing to decreased hepatic VLDL secretion. 
The role of TH in the regulation of lipid metabolism has been extensively studied ever since the 
link between thyroid function and body weight has been recognized. Plasma concentrations of 
cholesterol and TG are inversely correlated with TH levels. TH stimulate hepatic LDL receptors, 
thereby promoting uptake of (V)LDL. Therefore, hypothyroidism results in decreased LDL 
receptors and increased plasma cholesterol and TG levels. Hypermetabolism is one of the 
hallmarks of hyperthyroidism, reflected in an increase of resting energy expenditure (REE). It 
is unknown whether this increase in REE coincides with an increase in spontaneous physical 
activity. FA are important substrates fuelling the increase in REE during hyperthyroidism (23). 
The FA are provided by several mechanisms. First, lipolysis (breakdown of TG into FA and 
glycerol) is stimulated by TH (24). Second, hepatic de novo lipogenesis is promoted by T3 
via induction of lipogenic enzymes (25). Third, TH increase the amount of available nutrients, 
including FA, by increasing food intake. Although TH stimulate lipolysis, it is still unknown how 
FA fluxes are modulated by TH status in metabolically relevant tissues in vivo. 
r o l e  o f  t h e  b r a I n  I n  G l u C o s e  a n d  fat t y  aC I d 
M e ta b o l I s M
The first evidence that the brain is involved in control of peripheral glucose homeostasis already 
dates back from 1855, when the French physiologist Claude Bernard showed in rabbits that 
punctures in the floor of the fourth ventricle resulted in hyperglycemia. Several brain regions 
from cortex to brainstem are involved in the regulation of homeostasis, but the hypothalamus 
is considered the main integrator and processor of peripheral metabolic information. The 
hypothalamus consists of several nuclei (collection of neuronal cells) involved in metabolism, 
14
General IntroduCtIon
including the arcuate nucleus (ARC), the paraventricular nucleus (PVN), the lateral hypothalamic 
area (LHA), the ventromedial nucleus (VMH), and the dorsomedial nucleus (DMH).
One of the critical neuronal structures involved in the regulation of metabolism is the 
ARC, situated around the base of the third ventricle in the hypothalamus. The ARC contains 
neurons that exert potent effects on food intake, energy expenditure and glucose and FA 
metabolism. Both hormonal and nutrient-related signals regulate these neurons. One group 
of neurons co-express neuropeptide Y (NPY) and agouti-related peptide (AgRP), peptides that 
potently stimulate food intake and reduce energy expenditure, thereby promoting weight 
gain. Another group of neurons co-express pro-opiomelanocortin (POMC) and cocaine- and 
amphetamine-regulated transcript (CART), peptides that decrease food intake and increase 
energy expenditure, thereby promoting weight loss. The expression of these orexigenic 
and anorexigenic neuropeptides is dependent on the fed status and a balance between the 
neuropeptides is essential for maintaining energy homeostasis. 
Studies have shown that the brain is an insulin-sensitive organ and insulin receptors are widely 
distributed in the brain (26). Insulin crosses the blood-brain barrier through insulin-receptor 
mediated active transport (27;28). The origin of insulin in the brain is mostly peripheral and only 
a modest amount is synthesized locally (29). By activating its receptors, insulin decreases the 
expression of NPY and stimulates expression of POMC, both contributing to a decrease in food 
intake and increase in energy expenditure. Activation of insulin signaling in the brain plays an 
important role in the regulation of glucose metabolism (Fig. 1). Central administration of insulin, 
resulting in activation of insulin signaling in the brain without elevating plasma insulin levels, 
is sufficient to decrease plasma glucose levels by inhibiting endogenous glucose production 
(30). Conversely, blockade of central insulin action results in decreased ability of circulating 
insulin to suppress endogenous glucose production (30;31). Insulin may obtain its effects on 
endogenous glucose production by decreasing NPY neuronal activity, as it has been shown that 
central NPY administration impairs the ability of circulating insulin to suppress endogenous 
glucose production (32). The effect of central insulin action on endogenous glucose production 
is dependent on ATP-dependent potassium (K
ATP
) channel activation in the brain. Central 
administration of sulfonylureas (K
ATP
 channel blockers) abolishes the central effects of insulin 
on endogenous glucose production and prevents in part the suppression of endogenous 
glucose production by circulating insulin (30). Moreover, K
ATP
 channel activation per se is 
sufficient to lower plasma glucose levels via inhibition of glycogenolysis and gluconeogenesis 
(33). Although it is established that insulin signaling in the brain is required for inhibitory effect 
of circulating insulin on endogenous glucose production, it is unknown whether the central 
effects of insulin are involved in the stimulation of disposal of glucose by circulating insulin. 
Recently, it was shown that central insulin action is not only involved in peripheral glucose 
metabolism, but also in FA metabolism. Insulin administration in the brain promotes lipogenesis 
and suppresses intracellular lipolysis in white adipose tissue (WAT), which results in increased 
fat mass and adipocyte cell size upon chronic insulin administration (34;35). Furthermore, 
suppression of VLDL secretion by circulating insulin can in part be prevented by central 
administration of NPY (32). However, it is unknown whether the central effects of insulin are 
also involved in the stimulation of uptake of (F)FA and TG by adipose tissue from plasma. 
15
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In addition to insulin, the effects of TH on glucose metabolism are partly mediated via a 
central mechanism. Comparable to peripheral administration, TH administration directly into 
the PVN of the brain increases endogenous glucose production and induces hepatic insulin 
resistance (36;37). Furthermore, both the peripheral as well as the central effects of TH on 
glucose production depend on sympathetic projections to the liver (37;38). 
M e ta b o l I C  d I s t u r b a n C e s  I n  t y P e  2  d I a b e t e s 
M e l l I t u s
T2DM is a multifactorial, chronic disease characterized by hyperglycemia and often accompanied 
by dyslipidemia. T2DM is no immediate life threatening disease, but it does increase the risk 
for developing complications such as cardiovascular disease, retinopathy, neuropathy, and 
nephropathy. The diagnosis of diabetes mellitus is based on WHO recommendations in 2006. 
Criteria include fasting plasma glucose level ≥ 7.0 mmol/l or a 2 h-plasma glucose level of ≥ 11.1 
mmol/l following a glucose load. 
The development of T2DM is the result of both a deficient insulin secretion by pancreatic 
ß-cells and insulin resistance. In the insulin resistant state, skeletal muscle, liver and adipose 
tissue display a decreased responsiveness to insulin mediated glucose disposal. Furthermore, 
hepatic insulin resistance results in decreased insulin-mediated suppression of endogenous 
glucose production. In the early stage of the development of T2DM, insulin resistance leads to 
an increase in insulin secretion by the β-cells to overcome the reduced sensitivity of peripheral 
organs, thereby maintaining normal glucose levels. In a later stage, β-cells fail to compensate, 
leading to progressive hyperglycemia and ultimately T2DM. 
FA metabolism is also disturbed in T2DM patients. Insulin resistance is associated with 
increased intracellular lipolysis of TG in adipose tissue by HSL, resulting in an increased FA flux 
from adipose tissue to liver, skeletal muscle and heart where it is stored as TG, contributing to 
the development of insulin resistance in these tissues (39). The increased storage of TG in liver 
in combination with hepatic insulin resistance results in increased secretion of VLDL (40;41). 
The increased plasma levels of TG in VLDL are a hallmark of the dyslipidemia associated with 
insulin resistance and T2DM. 
As mentioned before, central insulin actions are critical for the maintenance of glucose and 
energy homeostasis. Obesity has been shown to result in elevated insulin levels in cerebrospinal 
fluid (42). Recently it was shown that high-fat feeding induces central insulin resistance already 
following short exposure to the diet, as demonstrated by reduced insulin signaling in the 
brain (43). A high-fat diet induces central insulin resistance independently of adiposity as 
the development of central insulin resistance occurs within days of exposure to the high-fat 
diet. The attenuated insulin signaling in neurons occurs through three mechanisms: first, the 
inactivation of IRS-1 by serine phosphorylation, second, the proteasomal degradation of IRS-1, 
and third, the lysosomal degradation of the IR (44). Since central insulin actions are critical in 




C I r C a d I a n  r h y t h M  a n d  I n s u l I n  s e n s I t I v I t y
A recently described environmental trigger associated with development of T2DM is disturbance 
of circadian rhythms, which can be due to environmental light pollution, reduction of sleep 
duration and/or quality, jet lags and shift work. Circadian rhythms are 24 h cycles generated 
by the suprachiasmatic nucleus (SCN) located in the anterior hypothalamus. The SCN induces 
daily rhythms in body temperature, heart rate, blood pressure, feeding behavior, glucose levels 
and many more. This circadian clock is synchronized to the environmental cycle by light-dark 
information perceived by the eyes. Many hormones involved in metabolism, such as insulin, 
glucagon, cortisol and leptin have been shown to exhibit circadian oscillation (45-49). In 
addition, the circadian clock has been reported to regulate metabolism and energy homeostasis, 
by mediating expression and/or activity of certain metabolic enzymes and transport systems 
involved in e.g. cholesterol metabolism and glycogen and glucose metabolism. Disruption 
of circadian rhythms due to shift work can result in hormone imbalance, psychological and 
sleep disorders, cancer proneness and reduced life span (50;51). Furthermore, shift work 
and reductions in sleep duration result in impaired glucose tolerance (52-55) and increased 
adiposity (56).
The rhythmic expression and activity of the metabolic pathways is mainly attributed to the 
coordinated circadian oscillation of clock genes (Clock, Bmal1, Per1, Per2, Per3, Cry1 and Cry2) 
that are expressed in each organ and cell. By phenotyping clock gene mutant and knockout 
mice, a direct link was made between the circadian clock and metabolic disorders. Homozygous 
Clock mutant mice have greatly attenuated diurnal feeding rhythm, are hyperphagic and obese 
and develop a metabolic syndrome of hyperleptinemia, hyperlipidemia, hepatic steatosis and 
hyperglycemia (57). Bmal-/- mice exhibit suppressed diurnal variations in glucose and TG levels 
as well as abolished gluconeogenesis (58). Mice knockout for Clock and Bmal1 in pancreatic 
β-cells show impaired glucose tolerance, hypoinsulinemia, and defects in size and proliferation 
of pancreatic islets, suggesting that the loss of the pancreatic clock inhibited the β-cells from 
secreting insulin (59). 
The increased prevelance of obesity and T2DM in shift workers can be the result of 
discrepancy between behavior and endogenous phase, as shift workers consume energy at 
times of their cycles when intake is normally absent and energy expenditure levels are low 
(60-63). Studies in mice and rats have confirmed that food intake restricted to the resting phase 
results in abdominal obesity (64-67). However, a disturbed circadian rhythm can alter insulin 
sensitivity without affecting adiposity. For example, a single night of partial sleep deprivation 
is already sufficient to induce insulin resistance in patients with type 1 diabetes mellitus as well 
as in healthy subjects (68;69). Disruption of circadian rhythms accelerates the development of 
diabetes through pancreatic β-cell loss and function, as shown in a diabetes-prone rat model 
(70). In elderly, the SCN is decreased in volume and cell number, thereby losing rhythmicity 
(71-73). This may underlie the high prevalence of profound disturbances of sleep and hormonal 
circadian rhythms, common in the elderly (74-77), which may contribute to the development 
of T2DM. More insight into the role of SCN loss and the role of desynchronized central and 
peripheral clocks in the development of insulin resistance would lead to better understanding 
of the pathophysiology of T2DM in shift workers and elderly. 
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t h e r a P I e s  f o r  t y P e  2  d I a b e t e s  M e l l I t u s
T2DM imposes a major health risk, due to increased morbidity and mortality. Lifestyle changes, 
such as restricted caloric intake and exercise, can often significantly improve the outcome 
of the disease. However, the need for pharmacological strategies remains. The major goal of 
therapeutic intervention in T2DM is to ameliorate hyperglycemia and insulin resistance, but also 
increased risk factors including dyslipidemia and hypertension should be taken into account. 
Sulfonylureas and biguanides are the most prescribed drugs used to treat hyperglycemia in 
T2DM. Insulin therapy is necessary when medication alone is unable to control glucose levels 
and when β-cells fail to produce sufficient insulin. There is much interest in drugs that not only 
improve glucose metabolism, but also have beneficial effects on body weight and dyslipidemia. 
Biguanides are the first-line treatment drug of choice for the treatment of T2DM, in particular 
in overweight patients. Metformin is the sole agent clinically used in this class. The molecular 
mechanisms of  action underlying its beneficial effects on glucose metabolism are not fully 
known, although activation of AMP-activated protein kinase (AMK) in the liver appears critically 
involved (78;79). Metformin decreases hepatic gluconeogenesis, inhibits glycogenolysis and 
improves insulin sensitivity especially in skeletal muscle. As it does not affect insulin secretion, 
it is not associated with hypoglycemia when used as monotherapy. Metformin has modest 
improving effects on LDL cholesterol and TG levels, the underlying mechanism(s) not being 
understood. It does not reduce body weight, but is also not associated with body weight gain.
Sulfonylureas act mainly by stimulating insulin release from the β-cells of the pancreas. They 
bind to K
ATP
 channels on the cell membrane of β-cells. This inhibits a tonic, hyperpolarizing 
efflux of potassium, thus causing the electric potential over the membrane to become more 
positive. This depolarization opens voltage-gated calcium channels. The rise in intracellular 
calcium leads to increased fusion of insulin granules with the cell membrane, and therefore 
increased secretion of insulin. There is some evidence that sulfonylureas also sensitize 
β-cells to glucose, limit endogenous glucose production, decrease lipolysis (breakdown and 
release of FA by adipose tissue) and decrease clearance of insulin by the liver. Hypoglycemia 
is unfortunately a common side-effect as a result of increased insulin release and decreased 
insulin clearance. Since sulfonylureas increase appetite and weight gain, they are not the first 
choice for the management of T2DM in obese patients.
Glucagon-like peptide-1 (GLP1) is a cleavage product of the proglucagon molecule which 
is secreted by the intestinal L-cells and in the brain (80;81). It is released in response to food 
intake in proportion to caloric content to inhibit endogenous glucose production and to 
stimulate glucose-dependent insulin secretion (80;82). In addition, GLP-1 exerts multiple 
other effects, including inhibition of food intake, slowing of gastric emptying and inhibition 
of glucagon secretion (83;84). GLP-1 is known to beneficially affect glucose metabolism in 
T2DM patients (84;85). However, GLP-1 is easily degraded by the enzyme dipeptidyl-peptidase 
IV (DPP-IV), limiting its therapeutic efficacy (86). Therefore, pharmaceutical companies are 
developing GLP-1 analogues resistant to inactivation by DPP-IV. Clinical studies have shown that 
these analogues are very effective in reducing body weight, improving glucose metabolism 
and reducing plasma lipids in patients with T2DM. The anorexic effect and the hepatic insulin 
sensitizing effect of GLP-1 are in part mediated via GLP-1 receptors in the brain (83;87;88). 
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Topiramate, a sulfamate-substituted derivative of the monosaccharide D-fructose (89), is a 
broad-spectrum antiepileptic drug with potentially additional neurotherapeutic applications 
such as bipolar disorder and migraine (90;91). Its precise mechanism of action is unknown, 
although topiramate is considered to produce its antiepileptic effects through at least six 
mechanisms of action in the central nervous system: enhancement of GABA-ergic activity 
(92;93), inhibition of kainite/AMPA receptors (94), inhibition of voltage-dependent sodium 
channels (95), inhibition of high-voltage-activated calcium channels (96), increase in potassium 
conductance (97) and inhibition of carbonic anhydrase (98). Besides its antiepileptic action, 
topiramate is associated with a decrease in body weight. The reduction in body weight upon 
topiramate treatment has been shown in epileptic patients as well as in obese persons (99-101). 
Although loss of appetite resulting in reduced caloric intake can account for initial reductions 
in body weight, other mechanisms might be involved in the long-term effects of topiramate on 
weight, as weight loss continued after caloric intake returned to baseline levels (102). Several 
studies in lean as well as in obese mouse and rat models have confirmed that topiramate also 
reduces food intake and body weight (103;104). Interestingly, studies in obese, diabetic rats 
demonstrate that topiramate treatment reduces plasma glucose levels and improved insulin 
sensitivity independent of weight loss (105;106). It is not known whether the enhancement in 
insulin sensitivity is the result of improved hepatic insulin sensitivity or improved peripheral 
insulin sensitivity. It is also unknown if topiramate improves insulin sensitivity via actions in the 
brain. These observations are of interest for target discovery of new antidiabetic drugs. 
o u t l I n e  o f  t h I s  t h e s I s
The aim of the present thesis was to gain more insight into the role of the brain in the regulation 
of insulin sensitivity. Increasing evidence suggests a link between circadian rhythms and 
insulin sensitivity. Shift workers display a higher incidence of T2DM and already one night of 
partial sleep deprivation leads to reduced insulin sensitivity. Mice mutant for circadian clock 
genes, that as a consequence have a disturbed circadian rhythmicity, develop obesity affected 
glucose homeostasis. Since the causal relation between disturbed circadian rhythm and insulin 
resistance is not known, we determined the effect of a disturbance in circadian rhythm on 
energy metabolism and insulin sensitivity. The circadian rhythm was disturbed in mice either by 
exposure to constant light as this is known to suppress rhythmicity as well as lengthen circadian 
rhythm (chapter 2), or by removal of the SCN by thermic ablation (chapter 3). Glucose 
homeostasis is determined by the balance between endogenous production of glucose and 
by uptake of glucose by peripheral tissues, which is primarily controlled by insulin. Central 
effects of insulin are involved in the inhibition of endogenous glucose production by circulating 
insulin. It is unknown whether central effects of insulin are also involved in stimulation of 
glucose uptake by peripheral tissues. In addition, the effects of high-fat feeding in these central 
effects of circulating insulin are unknown. Therefore, we determined the role of central insulin 
signaling in mice on insulin-stimulated glucose uptake by peripheral tissues and the effect of 
high-fat feeding (chapter 4). The antiepileptic drug topiramate improves insulin sensitivity, but 
the underlying mechanisms are unclear. Therefore, we studied which organs are responsible 
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for this effect of topiramate on insulin sensitivity and whether the central nervous system is 
involved in this effect of topiramate treatment in high fat-fed mice (chapter 5). In addition to 
its role in glucose homeostasis, circulating insulin is involved in FA metabolism as it promotes 
lipogenesis and suppresses intracellular lipolysis in WAT resulting in increased fat storage. Since 
the relative contribution of the indirect effects though the brain are unknown, we determined 
the extent to which central effects of insulin contributed to both TG-derived and albumin-
bound FA uptake by WAT. In addition, we determined the effect of high-fat feeding on these 
central effects of insulin (chapter 6). Thyroid hormones (TH) are crucial regulators of glucose 
and FA metabolism, in part via TH action in the brain. Therefore, we studied the direct effects 
of thyroid status on whole body energy metabolism and on TG-derived and albumin-bound FA 
uptake by muscle, liver, WAT and BAT (chapter 7). The results of the studies described in this 
thesis and the future perspectives are discussed in chapter 8.
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a b s t r aC t
Disturbances in circadian rhythms are associated with increased incidence of obesity and type 
2 diabetes. We examined the effects of a disturbed circadian rhythm on energy metabolism and 
insulin sensitivity by exposing mice to constant light. 
Mice were subjected to 12 h/12 h light/dark cycle (LD) or constant light (LL) for 5 weeks, and 
were fed chow or high-fat diet. Neuronal activity was measured by in vivo electrophysiological 
SCN recordings. During the last 4 days of the experiment, metabolic cage analysis was 
performed. Insulin sensitivity was assessed by hyperinsulinemic-euglycemic clamp in the middle 
of the resting (ZT 6) and active phases of the LD mice (ZT 18). Diet-independent contribution of 
the LL regimen to body weight gain was assessed by mixed model analysis.
Constant light exposure reduced the circadian amplitudes of the suprachiasmatic nucleus’ 
(SCN) neuronal activity pattern by 55% and rhythm strength by 54% within three days. The first 
week in constant light, LL mice had increased total food intake over 24 h and decreased total 
energy expenditure over 24 h, which resulted in immediate body weight gain on both diets 
compared to LD mice. Mixed model analysis revealed that weight gain induced by constant 
light was apparent before high-fat diet resulted in weight gain. After four weeks in constant 
light, the circadian pattern in feeding and energy expenditure was completely lost. Total food 
intake and energy expenditure over 24 h was reduced compared to LD mice, which resulted 
in stabilization of weight gain caused by constant light. LL neutralized the normal circadian 
variation in insulin sensitivity of liver as well as peripheral tissues on both diets.
In conclusion, constant light exposure reduces SCN rhythm strength instantaneously 
and results in a complete absence of rhythm in energy metabolism and insulin sensitivity, 
exacerbating the effect of a high-fat diet. These data indicate that mild rhythm disorders can 
contribute to the pathophysiology of obesity and T2DM and may be of great relevance for 
people having reduced SCN rhythmicity such as, for instance, elderly and shift workers. 
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I n t r o d u C t I o n
The increasing prevalence of obesity and type 2 diabetes during the 20th century coincides 
with environmental light pollution, reduction of sleep duration and/or quality, jet lags and shift 
work, resulting in disruption of circadian rhythm. Circadian rhythms are 24 h cycles generated 
by the suprachiasmatic nuclei (SCN) located in the anterior hypothalamus. The SCN induces 
daily rhythms in hormone concentrations (1-3), body temperature (4), heart rate and blood 
pressure (5), feeding behavior and many other parameters, and adjusts these rhythms to local 
time, mainly by light-dark information received from the eyes (6-8). Disruption of circadian 
coordination may be manifested by endocrine imbalances, psychological and sleep disorders, 
cancer incidence and reduced life span (9). In contrast, the maintenance of robust circadian 
rhythms is associated with well-being and increased longevity (10;11).
Many hormones involved in metabolism, such as insulin, glucagon, corticosterone and leptin 
exhibit circadian oscillations (1-3). Furthermore, enzymes and transport systems involved in 
lipid and glucose metabolism, such as glucose-6-phosphate dehydrogenase and nuclear 
receptors are rhythmically expressed (12;13). Conversely, mice transgenic for clock genes show 
deficits in several aspects of glucose homeostasis (14;15). Disturbances in circadian rhythm due 
to shift work and sleep deprivation are associated with an increased incidence of obesity (16). 
Moreover, chronic disturbances in circadian rhythms have been proposed to be the underlying 
cause for the adverse metabolic and cardiovascular health effects of shift work (17-20). In part, 
this may be due to differences in the circadian pattern of energy intake (21). 
Understanding of the causal relation between a disturbed circadian rhythm and features of 
the metabolic syndrome such as insulin resistance could lead to novel therapeutic strategies for 
patients, elderly and shift workers, who are prone to suffer from circadian rhythm disturbances. 
Importantly, circadian rhythms in these groups are reduced, rather than absent, whereas most 
animal studies have been performed in mouse models that are characterized by a total absence 
of circadian rhythmicity (15;22). Therefore, the aim of the present study was to determine 
the effect of reduced rather than total loss of circadian rhythm on energy metabolism and 
insulin sensitivity in mice. Furthermore, we studied the additive effects of high-fat feeding and 
constant light exposure. To this end, mice were subjected to constant light, which reduces 
the amplitude of circadian rhythms (23-25). In vivo recordings in freely moving mice indeed 
showed a reduction in SCN rhythm amplitude of ~50% in constant light. Remarkably, we found 
that the circadian variation in energy metabolism and insulin sensitivity was completely lost in 
animals housed in constant light, on chow and high-fat diet compared to mice on a light-dark 
cycle. The results indicate that a reduction in SCN rhythmicity strongly impairs glucose and 
energy homeostasis, thereby contributing to development of obesity and insulin resistance. 
M at e r I a l s  a n d  M e t h o d s
animals
Male C57Bl/6J mice (10 weeks old) were housed in a temperature-controlled room on a 12 h/12 h 
light/dark cycle (LD) or in constant light (LL, ≥ 180 lux) for 5 weeks. The mice had free access 
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to chow and water throughout the experiment. In the high-fat experiment, mice were fed ad 
libitum high-fat diet (45 energy% of fat derived from lard; D12451, Research Diet Services, Wijk 
bij Duurstede, The Netherlands). Body weight was monitored twice a week for all individual 
animals throughout the experiment. All animal experiments were performed in accordance 
with the regulations of Dutch law on animal welfare and the institutional ethics committee 
for animal procedures from the Leiden University Medical Center, Leiden, The Netherlands 
approved the protocol.
In vivo  electrophysiological sCn recordings
For electrophysiological SCN recording, an electrode was implanted in the SCN of C57Bl/6J 
mice. For this, mice were anesthetized using a mixture of Ketamine (100 mg/kg, Aescoket, 
Boxtel, the Netherlands), Xylazine (10 mg/kg, Bayer AG, Leverkusen, Germany) and Atropine 
(0.1 mg/kg, Pharmachemie, Haarlem, The Netherlands) and mounted in a stereotactic device 
(Digital Just for Mouse Stereotaxic Instrument, Stoelting Co, Wood Dale, IL, USA). Tripolar 
stainless steel electrodes were used, with two of the electrodes twisted together and a third, 
uninsulated electrode for use as reference (125 μm, Plastics One, Roanoke, Virginia, USA). The 
reference electrode was placed in the cortex and the twisted electrode pair was implanted 
under a 5° angle in the coronal plane and aimed at the SCN, 0.46 mm posterior to bregma, 
0.14 mm lateral to the midline, and 5.2 mm ventral to the surface of the cortex. At the end 
of the experiment, animals were sacrificed and the electrode placement was determined by 
histology. Recordings from animals in which the recording location was outside the SCN were 
excluded from the analysis. 
Following a 7 day recovery period, mice were placed in a recording cage and the electrodes 
were connected to the recording hardware. The connection consisted of lightweight cables 
suspended from a counter-balanced rotating contact, allowing animals to move around freely. 
Water and food was available ad libitum during the recording. Neuronal signals from the 
electrodes were differentially amplified and band-pass filtered (0.5-5 KHz) before being fed into 
amplitude based spike triggers that converted action potentials into pulses that were counted 
every 10 sec and stored on a computer. During the first days of the recording, animals were 
kept in constant darkness (DD) to test for the presence of a circadian rhythm in the recorded 
action potential frequency. If a rhythm was detected, light were turned on and animals were 
exposed to constant light for a minimum duration of 7 days. 
Action potential frequency was calculated for each 10 min interval of the recording. Peak 
and trough levels were quantified by averaging the firing rate over a 2 h interval. To compare 
changes in rhythm in constant light between animals, the amplitude values were normalized 
with respect to the amplitude in constant darkness. 
Circadian rhythm analysis
Behavioral activity of the mice in LD and LL was recorded using passive infrared motion detection 
sensors (Hygrosens Instruments, Löffingen, Germany) that were mounted underneath the lid 
of the cage and connected to a ClockLab data collection system (Actimetrics Software, Illinois, 
U.S.) that recorded the amount of sensor activation in one min bins. The presence of circadian 
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rhythms was determined 25 days into the experiment for 10 consecutive days by F-periodogram 
analysis of activity based on the algorithm of Dörrscheidt and Beck (26).
Plasma corticosterone analysis
Three weeks after initiating the light intervention, blood samples were taken from mice on 
chow and high-fat diet via tail indentation at two different circadian times: one hour after 
the start of the subjective day (CT 1) and one hour before the start of the subjective night 
(CT 11), when corticosterone levels are at their lowest and highest, respectively (27). The 
activity (subjective night) period was determined for each mouse using passive infrared 
motion detection sensors (28). The samples were taken into capillaries, placed on ice and 
centrifuged at 4°C. Total plasma corticosterone concentrations were determined in an assay 
using a 125I double-antibody kit (ICN Diagnostics). The high and low limits of detectability of 
the assay are 1,000 and 7.7 ng/ml, respectively. 
Indirect calorimetry 
To determine energy metabolism of mice in LD or LL, indirect calorimetry (Phenomaster, TSE 
Systems, Bad Homburg, Germany) was performed in individually housed animals on high-
fat diet. Since exposure to constant light deteriorates circadian rhythm over time, these 
observations were obtained in two periods. The first period comprised the first 7 days of 
the continuous light, high-fat diet intervention, and the second period comprised 6 days of 
measurement, 4 weeks after initiation of the light/high-fat diet intervention.
Individual measurements of oxygen consumption and carbon dioxide production were 
performed every 9 min. In addition, food and water intake were measured. Furthermore, 
activity measurements were performed and pooled data were exported every 1 min. Before 
and after each experiment, animals were weighed to the nearest 100 mg. Since the LL regime 
lengthens the circadian period (29;30), activity patterns of individual animals were analyzed and 
corrected for the subjective day and subjective night periods. Total length of an individual day 
was determined as the time elapsed between two consecutive periods of high physical activity. 
Subjective day and night were set at 50% of that elapsed time. 
hyperinsulinemic-euglycemic clamp
Five weeks after initiating the light intervention, insulin sensitivity of mice on chow or high-
fat diet was determined in a hyperinsulinemic-euglycemic clamp performed in the middle of 
the resting (ZT 6) and active phase of the LD mice (ZT 18). Since the LL regimen disrupts the 
circadian rhythm by elongating the circadian period, the exact circadian time at which a stable 
hyperinsulinemic-euglycemic infusion rate was established was subsequently calculated for each 
mouse in the LL group individually. Before the start of the experiment, mice fasted for 16 h were 
anesthetized with Acepromazine (6.25 mg/kg, Alfasan, Woerden, The Netherlands), Midazolam 
(6.25 mg/kg, Roche, Mijdrecht, The Netherlands), and Fentanyl (0.31  mg/kg, Janssen-Cilag, 
Tilburg, The Netherlands). Anaesthesia as well as body temperature was maintained throughout 
the procedure. At the end of the basal as well as the end of the hyperinsulinemic period, 
hematocrit values were determined to ensure that the animals were not anemic. 
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First, basal rates of glucose turnover were determined by primed (0.8 μCi), constant 
(0.02 μCi/min) intravenous (i.v.) infusion of 3-3H-glucose (Amersham, Little Chalfont, U.K.) for 
60 minutes. Subsequently, insulin (Actrapid, Novo Nordisk, Denmark) was administered i.v. by 
primed (4.1 mU), constant (6.8 mU/h) infusion, with continuation of infusion of 3-3H-glucose for 
90 min. A variable i.v. infusion of a 12.5% D-glucose solution was used to maintain euglycemia 
as determined at 10-min intervals via tail bleeding (<3 μl, Accu-chek, Sensor Comfort; Roche 
Diagnostics, Mannheim, Germany). In the last 20 min, blood samples were taken with intervals 
of 10 min. At the day of the hyperinsulinemic-euglycemic clamp, body composition was 
determined by dual-energy X-ray absorptiometry (DEXA) using the Norland pDEXA Sabre 
X-Ray Bone Densitometer (Norland Strateq, Hampshire, U.K.). Subsequently, the mice were 
sacrificed.
Plasma analysis
During the hyperinsulinemic-euglycemic clamp studies, blood samples were taken from the 
tail tip into chilled capillaries. The tubes were placed on ice and centrifuged at 4°C. Plasma 
glucose levels were determined using a commercially available kit and standard according to 
the instructions of the manufacturer (Instruchemie, Delfzijl, The Netherlands) in 96-wells plates 
(Greiner Bio-One, Alphen a/d Rijn, The Netherlands). Plasma insulin levels were measured 
using a mouse-specific insulin ELISA kit (Crystal Chem Inc., Downers Grove, U.S.). Total plasma 
3-3H-glucose was determined in supernatant of 7.5 μl plasma, after protein precipitatation using 
20% trichloroacetic acid and evaporation to eliminate tritiated water. Turnover rates of glucose 
(Rd, μmol/min/kg) were calculated in basal and hyperinsulinemic conditions as the rate of 
tracer infusion (dpm/min) divided by plasma specific activity of 3-3H-glucose (dpm/μmol) 
corrected for body mass. Endogenous glucose production (EGP) during the hyperinsulinemic 
period, was calculated as the difference between the tracer-derived rate of glucose turnover 
and the glucose infusion rate. 
statistical analysis
To assess the circadian variation of insulin sensitivity, clamp data from chow and high-fat fed 
mice was used for linear regression analysis. Data from mice in LD and LL was plotted against 
the calculated circadian time (CT; the time at which stable glucose infusion rates (GIR) were 
achieved) and linear regression analysis was performed with GIR as dependent and CT as 
independent variable using GraphPad Prism version 5.0 for Windows (GraphPad Software, La 
Jolla California U.S.). Slope deviation from 0 was assessed for the LD and LL group individually. 
Unpaired student T-Tests were performed to compare GIR, endogenous glucose production 
and glucose disposal rates obtained at ZT 6 and ZT 18 of the LD mice.
A mixed effects model was used to investigate the effect of the constant light and high-fat 
diet intervention on body weight gain. The model assumed body weight to increase linearly 
with time in the control group (LD mice on chow) and included subject specific random 
intercepts and slopes to model individual deviations from the group average. Additional effects 
of the light and high-fat diet intervention were modeled by time dependent covariates. The 
model allowed possible nonlinear time dependencies in weight gain and a possible interaction 
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between the high-fat diet and the light regimen. The within subject error was assumed to have 
an autoregressive covariance structure of order one. 
r e s u lt s
sCn recording and circadian rhythm analysis 
The effect of constant light (LL) on the circadian rhythm in SCN neuronal activity was determined 
by in vivo electrophysiological recordings in the SCN of freely moving mice (Fig. 1). A circadian 
rhythm in neuronal activity was observed in seven mice, showing high activity during the 
day and low activity during the night. Upon exposure to LL, peak firing rate levels in the SCN 
decreased, whereas trough firing rate increased, causing a dampening of the amplitude of the 
rhythm (Fig. 1A, B). In LL, the amplitude was 73 ± 5% on day 1, 60 ± 3% on day 2, reaching a steady 
amplitude of 46 ± 4% from day 3 onwards (Fig. 1C, P < 0.01) compared to day 0. F-periodogram 
analysis over 10 days in LL revealed that the rhythm strength of locomotor activity under LL was 
46 ± 6% of the rhythm strength in the LD control mice (n=12 per group, P < 0.001). 
body weight gain 
Body weights of LD and LL mice on chow or high-fat diets measured during the course of 
the experiments are shown in Fig. 2A. LL mice were heavier compared to LD mice, both on 
chow and high-fat diet. To determine the isolated contribution of constant light to weight 
development as well as to assess its possible interaction with high-fat diet, a mixed effect 
Fig. 1
Fig. 1
Fig. 1. Longterm in vivo multiunit activity recordings were performed in freely moving, awake mice (n=7) using 
implanted microelectrodes. Representative recordings under constant darkness (DD) followed by constant 
light (LL) (A, B). Action potential frequency (black trace) is indicated with a 10 min time resolution. Background 
represents light exposure, with grey representing lights off, and white representing lights on. After 3 cycles in 
DD, animals were exposed to LL. Analysis of the time course of the SCN rhythm deterioration and stabilization 
after 3 days of LL (C). Bars show the amplitude of the rhythm, normalized for each animal relative to the average 
amplitude during the last 3 cycles in DD (grey bars) and 7 cycles in LL (white bars). * P < 0.01.
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model was developed, including light regimen and diet as covariates. The developed mixed 
effects model predicted group averages as shown in Fig. 2B. 
Both the constant light intervention covariate and high-fat diet intervention covariate were 
found to be highly significant (P < 0.00001 for both covariates), showing that both interventions 
independently caused additional weight gain compared to the chow diet and light-dark regime. 
The interaction term did not reach statistical significance (P = 0.081). Interestingly, the time 
dependency in the LL and high-fat diet covariate was nonlinear, as the exponents of the fitted 
power functions were significantly different from one (P < 0.00001 for both covariates): the 
LL effect on weight gain was described by a power function with an exponent of 0.6 while the 
high-fat diet effect had an exponent of 2.4. This indicates that the onset and speed of weight 
gain is different for both interventions. Indeed, the constant light intervention immediately 
affected weight gain (Fig. 2C) and stabilized later on whereas the effect of high-fat diet 
became manifest at a later stage (Fig. 2D), indicating that exposure to constant light increases 
body weight faster than high-fat diet. These data clearly show that LL and high-fat diet have 
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Fig. 2. A mixed effects model to investigate the effect of constant light (LL) and high-fat diet on body weight 
gain: average body weight (A), average body weight predicted by the mixed effect model (B), time dependent 
effect of the LL intervention on weight gain (C), the time dependent effect of the high-fat diet intervention on 


















































































Corticosterone levels in plasma were determined at two different circadian times: one hour after 
the start of the subjective day (expected lowest corticosterone levels, CT 1) and one hour before 
the start of the subjective night (expected peak in corticosterone levels, CT 11) as determined 
for each mouse individually using passive infrared motion detection sensors. Indeed, LD mice 
on chow as well as on high-fat diet had lowest corticosterone levels one hour after the start 
of the subjective day, which increased dramatically one hour before the start of the subjective 
night: from 12 ± 2 to 90 ± 32 ng/ml on chow (P < 0.01) and from 19 ± 5 to 82 ± 24 ng/ml on high-fat 
diet (P < 0.01) (Fig. 3). In LL mice on a chow diet, corticosterone levels were similar to LD mice 
one hour before the start of the subjective day but significantly lower one hour before the start 
of the subjective night (28 ± 16 to 42 ± 34 ng/ml, ns). In addition, corticosterone levels did not 
differ within the LL group when the two sampling times were compared. On the high-fat diet, 
the differences between the LL and the LD group were similar, as corticosterone levels were 
similar one hour before the start of the subjective day but significantly lower in the LL group 
one hour before the start of the subjective night (high-fat diet from 16 ± 3 to 43 ± 21 ng/ml, 
P < 0.01). Interestingly, in contrast to the chow diet, levels did differ significantly within the LL 
group when the two sampling times were compared. These data show that the LL regimen did 
not result in a chronic stress response, and that corticosterone levels were lower compared to 








































Fig. 3. Corticosterone plasma levels of chow (A) and high-fat (B) fed mice in LD or LL obtained at time of expected 
lowest (CT 1, open bars) and peak (CT 11, filled bars) corticosterone levels. Values represent means ± SD for 7-12 
mice per group. * P < 0.01.
Indirect calorimetry
Short term 
At the start of the light/high-fat intervention was started, body weight did not differ between 
the two groups of mice (LD, 25.5 ± 1.8 vs. LL, 25.6 ± 1.4 g, ns). LL mice had a higher energy intake 
measured over a circadian period compared to LD mice and consumed a larger fraction of the 
total circadian intake during the subjective day (44% vs. 36%, P = 0.06, Fig. 4A). Respiratory 
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Fig. 4. Indirect calorimetric analysis of mice under light/dark (LD, n=8) and constant light (LL, n=8) conditions 
on high-fat diet analyzed for subjective day, subjective night and total 24 h levels. Energy intake (A), respiratory 
exchange rate (RER, B) and energy expenditure (C) during the first 6 days of the intervention. Panels D, E and F 
represent the same parameters measured in the same mice, for a period of 6 days, after 4 weeks of intervention. 
Values represent means ± SD. * P < 0.05.
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exchange rate (RER) was significantly higher in the LL mice during the subjective day period 
indicating a higher relative carbohydrate to fat oxidation ratio (Fig. 4B). RER did not differ 
between groups during the night period. Total energy expenditure over a period of a circadian 
period was significantly lower in the LL mice (Fig. 4C), due to a significant reduction in energy 
expenditure during the subjective night period. Energy expenditure levels also tended to be 
lower during the subjective day period (P = 0.06). 
Long term
As expected from the higher energy intake and lower energy expenditure rates measured during 
the short term period, body weights in the LL mice (33.8 ± 2.5 vs. 29.4 ± 1.8 g, P < 0.01) as well as 
body weight gain (8.1 ± 1.4 vs. 4.0 ± 1.6 g, P < 0.01) were significantly higher compared to LD mice. 
Interestingly, at the long term, total energy intake measured over a period of a circadian period 
was significantly lower in the LL mice, whereas energy intake during the subjective day was higher 
compared to LD mice (55 vs. 19%, P < 0.01, Fig. 4D). The circadian rhythm in energy intake present 
in LD mice, with higher energy intake during the night and lower energy intake during the day, was 
absent in LL mice. Reflecting the higher subjective day energy intake, RER was significantly higher 
in the LL mice (Fig. 4E). Interestingly, RER did not differ between groups during the night period, 
even though energy intake was higher in the LD group. Furthermore, RER strongly correlated to 
energy intake during both the subjective day and night period in the LD mice (R2 = 0.70 and 0.63, 
P = 0.01 and P < 0.01, respectively), but not in the LL mice (R2 = 0.03 and 0.03, ns for both periods). 
Total energy expenditure over a period of a circadian period was still significantly lower in the 
LL mice (Fig. 4F), due to a reduction during the subjective night period as well as subjective day 
period. Energy expenditure during the subjective night was strongly correlated to energy intake 
in the LD mice (R2 = 0.55, P < 0.05). Interestingly, in the LL mice, the higher energy intake during the 
subjective day was not associated with an increase in energy expenditure. 
hyperinsulinemic-euglycemic clamp analysis
Insulin sensitivity was determined in body-weight matched mice on chow and high-fat diet 
by hyperinsulinemic-euglycemic clamp analysis at two different circadian times: during the 
middle of the resting (ZT 6) and during the middle of the active phase (ZT 18) of the LD mice. 
Since the LL regimen disrupts the circadian rhythm by elongating the circadian period, the 
exact circadian time at which stable hyperinsulinemic-euglycemic infusion rate was achieved 
was subsequently determined for each individual mouse in LL. 
Chow diet
Basal endogenous glucose production (EGP) did not differ at ZT 6 and ZT 18 between LD or 
LL mice (Table 1). In LD mice fed a chow diet, glucose infusion rates (GIR) depended on the 
clock times at which the clamp studies were performed. GIR was significantly higher at ZT 18 
compared to ZT 6 (87.5 ± 9.2 vs. 51.6 ± 7.4 μmol/min/kg, P < 0.01, Fig. 5A). Furthermore, there 
was a strong correlation between GIR and circadian time (CT) in chow fed LD mice (R2 = 0.84, 
P < 0.01, Fig. 5D). In chow fed LL mice, there was no difference in the GIR between ZT 6 and ZT 
18 (65.7 ± 20.8 vs. 75.2 ± 9.7 μmol/min/kg, Fig. 5A). There was no relation found between GIR and 
CT in LL mice (R2 = 0.01, ns, Fig. 5D). Interestingly, not only was the circadian rhythm of insulin 
sensitivity absent in LL mice, the GIR in LL mice was set at approximately 50% of the minimal 
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Fig. 5. Glucose infusion rate (GIR, A, D), endogenous glucose production (EGP, B, E) and glucose disposal (Rd, 
C, F) in chow fed mice under light/dark (LD, black) and constant light (LL, grey) conditions as measured in 
hyperinsulinemic-euglycemic clamp. GIR (A), EGP (B) en Rd (C) as measured at ZT 6 (open bars) or ZT 18 (filled 
bars) as determined for LD mice. Linear regression analysis of the GIR (D), EGP (E) and Rd (F) against the circadian 
time (CT) for LD mice (n=21) and LL mice (n=20). Values represent means ± SD for at least 7 mice per group. 
* P < 0.05 vs. control.
to maximal GIR seen in LD mice. This is in agreement with the similar reduction in SCN output 
(Fig. 1). In LD mice, EGP was significantly lower during the hyperinsulinemic-euglycemic clamp 
conditions at ZT 18 compared to ZT 6 (5.4 ± 8.8 vs. 20.5 ± 9.1 µmol/min/kg, respectively, P < 0.05, 
Fig. 5B). In addition, hyperinsulinemic-euglycemic glucose disposal rates (Rd) were higher at 
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ZT 18 compared to ZT 6 (89.7 ± 7.2 vs. 72.1 ± 14.2 μmol/min/kg, respectively, P < 0.05, Fig. 5C). 
Both EGP and Rd correlated with CT in the LD group (R2 = 0.44 and 0.41, respectively, P < 0.01 for 
both parameters, Fig. 5E, F). In LL mice, hyperinsulinemic-euglycemic EGP and Rd rates did not 
differ significantly between ZT 6 and ZT 18 (EGP, 11.8 ± 18.4 vs. 10.4 ± 8.8 and Rd, 81.7 ± 23.8 vs. 
84.7 ± 13.2 μmol/min/kg, respectively, ns, Fig. 5B, C). Furthermore, EGP and Rd did not correlate 
with CT in chow fed LL mice (R2 = 0.04 and 0.02, respectively, ns, Fig. 5E, F). These data show 
that the circadian variation in tissue-specific insulin sensitivity that is normally present in chow 
fed LD conditions was absent in mice subjected to constant light.
High-fat diet
LD mice fed a high-fat diet were more insulin resistant as GIR was lower at both time points 
compared to LD mice on chow diet (GIR -45% at ZT 6, P < 0.01 and -76% at ZT 18, P < 0.01). The 
lower insulin sensitivity was associated with diet-induced liver and peripheral insulin resistance, 
as hyperinsulinemic EGP was higher (EGP +48% at ZT 6, P = 0.07 and +117% at ZT18, P = 0.09) and 
hyperinsulinemic Rd was lower (Rd -7% at ZT 6, not significant and -35% at ZT 18, P < 0.01), when 
compared to chow fed LD mice. Basal EGP did not differ significantly at ZT 6 and ZT 18 between LD 
or LL mice (Table 2). GIR for LD mice on high-fat diet was significantly higher at ZT 18 compared to ZT 
6 (49.7 ± 13.0 vs. 35.7 ± 7.4 μmol/min/kg, P < 0.01, Fig. 6A), but the magnitude of difference between 
ZT 6 and ZT 18 in LD mice on high-fat diet was less compared to LD mice on chow diet. Linear 
regression of GIR against CT still revealed a strong association with time in LD mice (R2 = 0.31, P < 0.01, 
Fig. 6D). This dependency of GIR to time was absent in LL mice, as there was no difference in the GIR 
between ZT 6 and ZT 18 (31.1 ± 13.1 vs. 39.1 ± 8.4 μmol/min/kg, ns, Fig. 6A) and no correlation of GIR 
with CT (R2 = 0.01, ns, Fig. 6D). In the LD mice, EGP during clamp conditions were significantly lower 
at ZT 18 compared to ZT 6 (11.7 ± 6.5 vs. 30.4 ± 12.9 μmol/min/kg, P < 0.05, Fig. 6B). Hyperinsulinemic 
Rd rates were not different between ZT 6 and ZT 18 (67.4 ± 18.8 vs. 58.2 ± 11.9  μmol/min/kg, ns, 
Fig. 6C). Linear regression analysis confirmed these data, as EGP was correlated with CT (R2 = 0.50, 
P < 0.01, Fig. 6E), but Rd was not (R2 = 0.09, ns, Fig. 6F). In LL mice, there was a small difference in 
EGP during the clamp studies at ZT 6 and ZT 18 (24.6 ± 4.9 vs. 17.0 ± 7.2 μmol/min/kg, respectively, 
Table 1. Results obtained from the hyperinsulinemic-euglycemic clamp performed in LD and LL mice on chow 
diet. Data is represented as mean ± SD, * P < 0.05 LL vs. LD, $ P < 0.05 ZT 6 vs. ZT 18.
LD LL
ZT 6 ZT 18 ZT 6 ZT 18
Body weight (g) 25.4 ± 1.2 22.7 ± 0.9 $ 25.0 ± 2.5 23.9 ± 1.3
Basal hematocrit (%) 39.8 ± 1.7 42.4 ± 1.2 39.8 ± 0.9 41.1 ± 1.9
Clamp hematocrit (%) 36.9 ± 1.1 38.8 ± 1.0 37.0 ± 1.9 38.7 ± 1.1
Basal insulin (ng/ml) 0.4 ± 0.1 0.4 ± 0.2 0.6 ± 0.3 * 0.4 ± 0.1
Clamp insulin (ng/ml) 7.6 ± 1.4 6.7 ± 0.9 7.0 ± 1.4 5.2 ± 1.6 *
Basal glucose (mmol/l) 4.0 ± 0.3 5.0 ± 0.5 4.6 ± 0.6 5.0 ± 0.9
Clamp glucose (mmol/l) 4.3 ± 0.5 4.6 ± 0.5 4.7 ± 0.7 5.0 ± 0.6
Basal EGP (μmol/min/kg) 47.3 ± 20.5 43.3 ± 5.6 56.5 ± 20.3 43.9 ± 7.6
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Fig. 6. Glucose infusion rate (GIR, A, D), endogenous glucose production (EGP, B, E) and glucose disposal (Rd, 
C, F) in high-fate fed mice under light/dark (LD, black) and constant light (LL, grey) conditions as measured in 
hyperinsulinemic-euglycemic clamp. GIR (A), EGP (B) en Rd (C) as measured at ZT 6 (open bars) or ZT 18 (filled 
bars) as determined for LD mice. Linear regression analysis of the GIR (D), EGP (E) and Rd (F) against the circadian 
time (CT) for LD mice (n=19) and LL mice (n=10). Values represent means ± SD for at least 7 mice per group. 
* P < 0.05 vs. control.
P < 0.05, Fig. 6B). However, there was no relation between EGP and CT (R2 = 0.05, ns, Fig. 6E). Rd 
rates did not differ at ZT 6 and ZT 18 for LL mice (54.3 ± 11.1 vs. 50.2 ± 12.7 µmol/min/kg, respectively, 
ns, Fig. 6C) and Rd did not correlate with CT (R2 = 0.00, ns, Fig. 6F). These data show that, even 
though high-fat feeding results in an obesity/insulin resistance phenotype, insulin sensitivity was 
still under circadian control. Furthermore, even in in obese, insulin resistant mice, LL resulted in a 
further deterioration of the circadian rhythm of insulin resistance.Fig. 6
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d I s C u s s I o n
This study addressed the effect of a decline in rhythm amplitude on energy metabolism and 
insulin sensitivity. C57Bl/6J mice were exposed to constant light (LL) or a light-dark cycle (LD) 
as control. In vivo recordings showed that constant light resulted in an immediate decrease 
in SCN amplitude, which stabilized within 3 days at a level of 46%. Furthermore, constant light 
stimulated weight gain, even before high-fat diet resulted in weight gain. Finally, constant 
light exposure resulted in a complete loss of circadian rhythm in energy metabolism and 
hepatic and peripheral insulin sensitivity. Collectively, these data indicate that constant light 
exposure strongly reduces the circadian function of the central clock, as observed in aging 
and neurodegenerative diseases, associated with weight gain and insulin resistance. 
The SCN generates a circadian rhythm in neuronal activity and neurotransmitter release 
that serves as a timing signal by downstream target nuclei. The SCN receives input on 
environmental light levels by a direct projection from a subset of ganglions in the retina 
(31). Under regular 12 h/12 h light/dark cycles, this input pathway keeps individual SCN 
neurons synchronized to each other and the environment with a majority of neurons that 
are active during the day and silent during the night. Exposing animals to constant light 
causes a desynchronization among neurons of the SCN, which results at the tissue level 
in a dampened circadian rhythm (32;33). Metabolic processes that manifest circadian 
fluctuations are regulated by a combination of excitatory and inhibitory inputs, with 
rhythmic SCN output regulating the balance between excitation and inhibition as a function 
of the time of day (34). To quantify the amplitude decrease and time course of the rhythm 
deterioration of the SCN output rhythm in our mice, we performed longitudinal behavioral 
activity recordings as well as a series of in vivo SCN electrophysiological recordings. These 
in vivo recordings are of great relevance as previous investigations on LL influence on 
SCN rhythm were exclusively performed in the isolated SCN in vitro (1;33), which did not 
allow for a quantitative estimation of the effect of constant light on the SCN rhythm in 
vivo. Our SCN recordings show that the desynchronizing effects of constant light occur 
Table 2. Results obtained from the hyperinsulinemic-euglycemic clamp performed in LD and LL mice on 
high-fat diet. Data is represented as mean ± SD, * P < 0.05 LL vs. LD, $ P < 0.05 ZT 6 vs. ZT 18.
LD LL
ZT 6 ZT 18 ZT 6 ZT 18
Body weight (g) 32.4 ± 3.6 27.4 ± 2.5 $ 32.5 ± 3.2 27.5 ± 1.8 $
Basal hematocrit (%) n.a. 44.1 ± 1.8 n.a. 43.6 ± 1.1
Clamp hematocrit (%) n.a. 40.6 ± 1.6 n.a. 40.5 ± 2.0
Basal insulin (ng/ml) 0.7 ± 0.3 0.8 ± 0.3 0.7 ± 0.7 0.9 ± 0.2
Clamp insulin (ng/ml) 5.9 ± 0.8 6.7 ± 0.9 5.4 ± 1.0 7.2 ± 1.2
Basal glucose (mmol/l) 5.0 ± 0.7 5.7 ± 0.7 $ 5.8 ± 1.0 5.0 ± 0.5 $*
Clamp glucose (mmol/l) 5.6 ± 0.7 5.7 ± 1.1 6.2 ± 1.1 5.5 ± 0.6
Basal EGP (μmol/min/kg) 38.1 ± 12.9 41.5 ± 8.7 32.6 ± 15.3 38.1 ± 11.8
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immediately, resulting in an amplitude reduction of 73% and 60% on days 1 and 2, and 
stabilizing at an amplitude of 54% of the original value from day 3 onwards. Importantly, this 
dampening of SCN function was caused by the combined effects of increased trough levels 
and decreased peak levels. This is consistent with the finding that dampening is caused 
by a desynchronization among SCN neurons (32;33). These effects lead to stronger output 
signals during the night and weaker signals during the day. In agreement with the effects 
within the SCN, home cage locomotor activity recordings show that the rhythm strength is 
reduced by 54% under constant light.
Alterations in light regime typically are considered stressful. In our study, constant light 
disturbed corticosterone rhythm, resulting in lower corticosterone peak levels, which is in 
line with previous studies showing that constant light exposure does not lead to increased 
corticosterone levels (35-37). As corticosterone release is mediated by hypothalamic nuclei 
that receive strong input from the SCN (38), the dampening of the corticosterone rhythm may 
be a direct result of the dampening of SCN neuronal activity. 
Body weight development of all mice was measured twice a week. Disturbing circadian 
rhythm by constant light exposure resulted in higher body weights compared to mice on 
a normal light regime, independent of the diet. A mixed effects model was developed to 
determine the isolated contributions of constant light exposure and high-fat diet to weight 
gain as well as to assess the possible interaction between constant light exposure and high-fat 
feeding. Constant light exposure immediately affected weight gain, which stabilized later on, 
whereas the high-fat diet effect on body weight gain became manifest at a later stage. Our 
data are in line with a previous study showing that exposing chow fed Swiss-Webster mice to LL 
increases body weight compared to mice in LD only for the first two weeks. After this period, 
body weight gain in LL mice is equal to LD mice (35). The present study shows for the first time 
the independent effect of constant light exposure to weight gain in chow and high-fat fed mice 
and shows that the weight gain as a result of constant light exposure is evident before high-fat 
diet affects body weight gain. This immediate effect of constant light exposure on body weight 
coincides with the direct reduction in SCN output, suggesting that reduced SCN rhythmicity 
instantaneously affects energy homeostasis. 
Disturbing circadian rhythm by constant light exposure aggravated diet-induced obesity and 
resulted in a shift of energy intake towards the period when energy intake is normally low. 
Furthermore, we show that constant light is associated with a reduction in energy expenditure. 
These disturbed circadian rhythms in energy metabolism deteriorated over time. Within the 
first days of the experiment, exposure to constant light led to lengthening of circadian rhythm 
in food intake, RER and energy expenditure. During the experiment, the circadian rhythm 
weakened further. This is in agreement with our findings that the amplitude of rhythmic SCN 
output dampened in constant light over time. Furthermore, LL mice showed an impaired 
oxidative response towards food intake, as was indicated by the absence of correlation between 
the respiratory exchange rate and energy intake. A blunted response of metabolism towards 
food intake, also known a metabolic inflexibility (39), has been shown to be associated with 
impaired insulin sensitivity and obesity (40). It is therefore likely that the reduced metabolic 
flexibility of the LL mice is a reflection of reduced insulin sensitivity.
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We assessed the effect of disturbed circadian rhythm on insulin sensitivity in mice on chow 
as well as on high-fat diet. We determined insulin sensitivity by hyperinsulinemic-euglycemic 
clamp analysis at two different time points that corresponded to the middle of the resting phase 
(ZT 6) and middle of the active phase (ZT 18) for the LD mice. For the LL mice, the individual 
CT at the time of the clamp analysis was obtained afterwards on the basis of the activity period 
of each individual mouse. In line with studies form La Fleur et al. (41), LD mice on chow show 
a circadian variation in insulin sensitivity, with higher hepatic insulin sensitivity and higher 
insulin-stimulated glucose uptake by peripheral organs in the subjective night. Remarkably, 
the circadian variation of insulin sensitivity was lost in constant light. Moreover, the insulin 
sensitivity of LL mice was approximately 50% of the variation in insulin sensitivity of LD mice, 
which is in agreement with the ~50% reduction in SCN output. 
In a previous study it was shown that disturbing circadian rhythm by light intervention results 
in deregultation of glucoregulatory genes in liver, such as phosphoenolpyruvate carboxykinase 
(PEPCK), glucose transporter 2 (GLUT2) and glucose-6-phosphatase (G6PC) (42). In muscle, 
glucoregulatory gene expression is dependent on circadian time (43) and glucose uptake in 
isolated muscle from rats show a circadian pattern (44). Deregulation in glucoregulatory genes 
in liver and muscle may underlie the disturbed insulin sensitivity we found in constant light 
exposed mice. Furthermore, disturbing circadian rhythm using constant light also accelerates 
loss of beta-cell mass and function (45). Together with the results obtained in our study, more 
insight is gained in how disturbances in circadian rhythm, for instance due to shift work, may 
lead to the development of obesity and T2DM.
Our studies provide more insight on the relation between disturbances in endogenous 
rhythms and the increase in the risk of obesity and T2DM. Specifically, we have shown that a 
decrease in SCN rhythm amplitude of about 50% is sufficient to completely abolish circadian 
rhythm in energy metabolism and insulin sensitivity. Furthermore, we have shown that the 
immediate reduction in SCN output by constant light coincides with an instantaneous increase 
in body weight. These findings indicate that a relatively mild decrease in rhythm amplitude, 
which is observed in sleeping disorders, degenerative diseases and aging, are a serious concern 
for health (46), as they may lead to secondary metabolic pathophysiology. SCN recordings in 
old and middle aged mice have in fact shown a reduction in SCN rhythm amplitude of about 
50% (22). The data indicate that new avenues for prevention and treatment programs for 
patients with mild rhythm disturbances should include life style or light treatment programs to 
improve rhythm amplitude.
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a b s t r aC t
The suprachiasmatic nucleus (SCN) functions as a central pacemaker in the circadian system. 
Disturbances in the circadian system are associated with the development of type 2 diabetes 
mellitus (T2DM). Here, we studied the direct contribution of the SCN in the development of 
insulin resistance. Bilateral microlesions of the SCN in male C57Bl/6J mice resulted in loss of 
circadian rhythm in locomotor activity. Histological verification by immunocytochemistry was 
performed to analyze the precision of the lesion. Exclusive SCN lesioned (SCNx) mice showed 
a small, but significant increase in body weight (+17%), which was accounted for by an increase 
in fat mass. In contrast, mice with collateral damage to the ventromedial hypothalamus (VMH) 
and paraventricular nucleus (PVN) showed severe obesity and insulin resistance. In mice with 
exclusive SCN ablation, indirect calorimetry/metabolic cage analysis four weeks after lesioning, 
revealed a loss of circadian rhythm in oxygen consumption and food intake. Hyperinsulinemic-
euglycemic clamp analysis showed that the glucose infusion rate, required to maintain 
euglycemia, was significantly lower in SCNx mice compared to sham operated mice (-63%). 
While insulin potently inhibited endogenous glucose production (-84%), this was greatly 
reduced in SCNx mice (-7%), indicating severe hepatic insulin resistance. Our data indicate that 
malfunction of the SCN plays an important role in the development of insulin resistance, and 
underscore a direct role of the central pacemaker in the ontogeny of metabolic disorders. 
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I n t r o d u C t I o n
Obesity and type 2 diabetes mellitus (T2DM) have an increasing prevalence in modern society. 
In the past decade, a strong and potentially causal relationship between metabolic disorders 
and disturbances of the circadian system has been elucidated (1). The circadian system is 
responsible for 24 h rhythms in a wide variety of physiological and behavior functions (2;3). 
Generation of these rhythms occurs in the suprachiasmatic nuclei (SCN) of the anterior 
hypothalamus (2, 3) and is explained by a transcriptional-translational feedback loop, involving 
the clock genes CLOCK and BMAL1, Period (Per) and Cryptochrome (Cry) (1). The rhythms of 
the SCN are synchronized to the environmental 24 h cycle mainly by light-dark information 
perceived by the eyes. Rhythmic information is transferred from the SCN to the central nervous 
system and to peripheral organs of the body (4;5). This output is crucial for synchronization of 
many metabolic and endocrine factors such as glucose, insulin (6;7), cortisol (8), leptin, ghrelin 
(9;10) and neuropeptide Y (11). 
Disturbances in circadian rhythms occur as a consequence of shift work and transitions in 
time zones, but also from irregular sleep-wake patterns (12), aging, or neurodegenerative 
disorders (13). Animal studies have indicated a link between clock gene mutations and metabolic 
disturbances. For instance, CLOCK-/- mutant mice have a greatly attenuated diurnal feeding 
rhythm, are hyperphagic and obese and develop a metabolic syndrome of hyperleptinemia, 
hyperlipidemia, hepatic steatosis and hyperglycemia (14). As clock gene mutants are not 
specific to the SCN, the detrimental effects of disturbed rhythms may have their origin in 
peripheral organs, other than the SCN. It is not clear, therefore, to what extent the SCN itself 
is involved in metabolic disorders. Given the accumulating evidence for disturbances of SCN 
cellular organization in aging (15), neurodegenerative disorders and dementia (13;16), this 
question is also clinically relevant, as it would explain comorbidity between various disorders. 
To assess the role of disturbed function of the SCN per se in the development of obesity and 
T2DM, we performed bilateral microlesions of the SCN in male C57Bl/6J mice. Since the SCN 
is anatomically surrounded by areas regulating energy homeostasis, such as the ventromedial 
hypothalamus (VMH) and paraventricular nucleus (PVN), great care was taken to distinguish 
between exclusively SCN lesioned (SCNx) mice and mice with collateral damage to surrounding 
nuclei. We studied the effects of SCN ablation on energy expenditure, food intake and locomotor 
activity by analysis in metabolic cages employing indirect calorimetry. In addition, we assessed 
changes in body composition by dual energy x-ray absorptiometry (DEXA). Insulin sensitivity 
was assessed by hyperinsulinemic-euglycemic clamp analysis. We show that selective ablation 
of the SCN results in the development of severe hepatic insulin resistance. 
M at e r I a l s  a n d  M e t h o d s
animals
All animal experiments were approved by the Animal Ethic Committee from the Leiden 
University Medical Center (Leiden, the Netherlands) in accordance with the principles and 
guidelines established by the European Convention for the Protection of Laboratory Mice. 
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Male C57Bl/6J mice were obtained from Charles River Laboratories at an age of 9 weeks and 
acclimatized up to an age of 13 weeks at the Leiden University Medical Center animal facility. 
Mice were housed individually in a controlled environment (21°C, 40-50% humidity) under a 
12 h/12 h light/dark cycle (07:00-19:00) unless otherwise mentioned. Food (chow, RM3, Special 
Diet Services, Sussex, UK) and tap water were available ad libitum during the whole experiment. 
Body weight was monitored weekly for all individual mice. Monitoring started 2 weeks prior to 
SCN lesions, and continued throughout the experiment. 
sCn lesioning
At the age of 13 weeks, bilateral ablation of the SCN was performed as described before 
(17). Mice were anesthetized using a mixture of Ketamine (100 mg/kg, Aescoket, Boxtel, the 
Netherlands), Xylazine (10 mg/kg, Bayer AG, Leverkusen, Germany) and Atropine (0.1 mg/kg, 
Pharmachemie, Haarlem, The Netherlands) and mounted in a stereotactic device (Digital Just 
for Mouse Stereotaxic Instrument, Stoelting Co, Wood Dale, IL, USA). After identification of 
bregma, a hole was drilled through which the lesion electrode was inserted into the brain. 
Lesion needles were made by isolating a 0.3 mm stainless steel insect pin using isolating resin 
except for 0.2 mm at the tip. The electrode tip was aimed at the SCN, 0.46 mm posterior to 
bregma, 0.15 mm lateral to the midline, and 5.2 mm ventral to the surface of the cortex (Paxinos 
Mouse Brain Atlas, Franklin 2001). Bilateral SCN lesions were made by passing a 0.6 mA current 
through the electrode for duration of 10 s. The sham lesioned mice underwent the same 
operation, but no current was passed through the electrode. 
Circadian rhythm analysis
Following SCN lesioning, all mice were housed in constant dark (DD) for 10 consecutive 
days to determine circadian rhythmicity in behavioral activity of each animal using passive 
infrared motion detection sensors (Hygrosens, Löffingen, Germany) that were mounted 
underneath the lid of the cage and connected to a ClockLab data collection system 
(Actimetrics, IL, USA) that recorded the amount of sensor activation in 1 min bins. The 
presence of circadian rhythms was determined by F-periodogram analysis based on the 
algorithm of Dörrscheidt and Beck (18). Mice were included in the lesion group when no 
significant rhythm was present. 
Positional check of the sCn lesion
The SCN lesions were checked as described previously (10). To verify the position of the SCN 
lesions, brains were removed and fixed by immersion with 4% paraformaldehyde in 0.1 M 
phosphate buffer (pH 7.4) at 4°C. For cryoprotection, the brain tissue was equilibrated for 48 h 
with 30% sucrose in 0.1 M Tris-buffered saline (TBS) before sectioning. Thereafter, the brain 
tissue was cut into 30 μm sections and divided into two equal vials for immunocytochemical 
stainings. The two vials of brain sections were incubated overnight at 4°C with either rabbit 
anti-vasopressin or rabbit anti-VIP primary antibodies. Sections were then rinsed in 0.1 M TBS, 
incubated 1 h in biotinylated goat anti-rabbit IgG, and subsequently for 1 h in avidin-biotin 
complex (ABC, Vector Laboratories, Inc., Burlingame, CA, USA). The reaction product was 
visualized by incubation in 1% diaminobenzidine (DAB) with 0.01% hydrogen peroxide for 
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5-7 min. Nickel ammonium sulphate (0.05%) was added to the DAB solution to darken the 
reaction product (DAB/Ni). All sections were mounted on gelatine-coated glass slides, dried, 
run through ethanol and xylene and covered for observation by light microscopy. For every 
animal we blindly scored the amount of damage to the SCN and surrounding hypothalamic 
nuclei involved in metabolism (PVN and VMH). 
Indirect calorimetry/metabolic cages
Individual measurements by indirect calorimetry were performed for a period of at least 
4 consecutive days (Comprehensive Laboratory Animal Monitoring System, Columbus 
Instruments, Columbus Ohio, USA) (19-21). A period of 24 h was included at the start of the 
experiment to allow acclimatization of the mice to the cages. Experimental analysis started at 
09:00. Analyzed parameters included real-time energy and water intake and locomotor activity. 
Oxygen consumption (energy expenditure) measurements were performed at intervals of 
7 min throughout the whole period. Oxygen consumption, activity and energy intake were 
analyzed separately for day and night.
hyperinsulinemic-euglycemic clamp analysis 
Five weeks after SCN lesioning, hyperinsulinemic-euglycemic clamp experiments were 
performed as previously described (20;22-24) to determine insulin sensitivity. Clamp 
experiments were performed after an overnight fast. Mice were anesthetized by i.p. 
injection with a combination of Acepromazin (6.25 mg/kg, Sanofi Sant Nutrition Animale, 
Libourne Cedex, France), Midazolam (6.25 mg/kg, Roche, Mijdrecht, The Netherlands) and 
Fentanyl (0.31 mg/kg, Janssen-Cilag, Tilburg, The Netherlands). Anaesthesia as well as body 
temperature was maintained throughout the procedure. At the end of the basal and the 
hyperinsulinemic period, hematocrit values were determined to ensure that the mice were 
not anemic. During the basal period, 3-3H-glucose was infused in the tail vein at a constant 
rate of 0.8 μCi/h (specific activity, 9.6 GBq/mmol; Amersham, Little Chalfont, UK). After 50 
and 60 min of infusion, basal parameters of glucose and insulin were determined. Glucose 
rate of disposal (Rd, in μmol/min.kg) was determined as the rate of tracer infusion (dpm/
min) divided by the plasma specific activity of 3-3H-glucose (dpm/μmol) at both time points. 
The hyperinsulinemic period was started by a bolus of insulin (4.5 mU, Actrapid; Novo 
Nordisk, Chartres, France). Subsequently, insulin was infused at a constant rate (3.5 mU/min). 
Comparable to the basal period, 3-3H-glucose was infused at a rate of 0.8 μCi/h. A variable 
infusion of 12.5% D-glucose (in PBS) was also started to maintain euglycemia, as measured 
by hand every 10 min (AccuCheck, Roche Diagnostics, The Netherlands). After reaching 
a steady state glucose infusion rate (GIR) for at least 30 min, blood samples were taken at 
10 min intervals for 30 min to determine 3-3H-glucose. Hyperinsulinemic Rd was determined 
similar to the basal period. The endogenous glucose production (EGP) was calculated as 
the difference between Rd and the GIR. Following the hyperinsulinemic-euglycemic 
clamp, body composition (lean vs. fat mass) was determined by DEXA using the Norland 
pDEXA Sabre X-Ray Bone Densitometer (Norland, Hampshire, U.K.). All data was analyzed 
according using the software and recommendations of the manufacturer. Subsequently, the 
mice were sacrificed.
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Plasma analysis
Blood samples were taken from the tail tip into chilled capillaries coated with paraoxon to 
prevent ex vivo lipolysis. The tubes were placed on ice and centrifuged at 4°C. Plasma levels 
of free fatty acids (FFA) and glucose were determined using commercially available kits and 
standards according to the instructions of the manufacturer (Instruchemie, Delfzijl, The 
Netherlands) in 96-well plates (Greiner Bio-One, Alphen a/d Rijn, The Netherlands). Plasma 
insulin concentrations were measured by ELISA (Crystal Chem Inc., Downers Grove, USA). 
For measurement of plasma 3-3H-glucose, trichloroacetic acid (final concentration 2%) was 
added to 10 μl plasma to precipitate proteins using centrifugation. The supernatant was dried 
to remove water and resuspended in milliQ. The samples were counted using scintillation 
counting (Packard Instruments, Downers Grove, USA).
statistical analysis
Statistical analysis was performed using SPSS 17 for Windows (SPSS Inc, Chicago, IL, USA). 
Unpaired T-Tests were performed for all comparisons, with statistical significance threshold 
set at P = 0.05.
r e s u lt s
behavioral and histological verification of sCn lesions
Periodogram analysis of locomotor activity showed that all sham operated mice retained 
a strong circadian rhythm (Fig. 1A), whereas SCN lesioned mice lost their circadian rhythm 
in activity after the lesion procedures (Fig. 1B). Histological analysis revealed SCN lesions 
without collateral damage in 6 mice (example shown in Fig. 2B). In addition to ablation of 
the SCN, 4 other mice had unilateral damage to the paraventricular nucleus (PVN), 10 other 
mice had bilateral damage to the PVN and 9 other mice had damage to both the PVN and the 
ventromedial hypothalamus (VMH). Sham operated controls (n=17) did not reveal damage to 
any of the aforementioned brain areas (example shown in Fig. 2A). 
selective sCn lesions
Body weight and composition
Five weeks after SCN lesioning, body mass of mice with an exclusive SCN lesion was 17% higher 
compared to the sham mice (24.9 ± 1.2 vs. 29.2 ± 1.9 g, P < 0.01, Fig. 3). Assessment of body 
composition by DEXA scan analysis revealed that fat mass was significantly higher in SCNx mice 
compared to sham (5.8 ± 2.6 vs. 1.9 ± 1.0 g, P < 0.01), whereas lean mass did not differ (17.7 ± 2.2 vs. 17.2 
± 1.7 g, ns). This indicates that SCN ablation results in only mild overweight compared to sham mice.
Indirect calorimetry
Metabolic cage data on oxidative metabolism, food intake and spontaneous physical activity 
data were obtained over a period of minimal 4 consecutive days and were analyzed separately 
for day and night. During the night, oxygen consumption rates were higher compared to the 
day in sham mice (3386 ± 174 vs. 2992 ± 155 ml/kg/h, P < 0.01, Fig. 4A). This circadian rhythm in 
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Fig. 1. Representative double-plotted actograms analyses of sham operated (A) and SCN lesioned (SCNx, B) mice 




Fig. 2. Microphotographs of mouse brain sections at the level of the SCN. Middle region of the SCN is shown for 
sham operated (A) and SCN-lesioned (SCNx, B) mice. Note the relatively small size of the SCN lesion, leaving the 
paraventricular nuclei and ventromedial hypothalamus intact (B).
oxygen consumption was lost in SCNx mice, resulting in higher oxygen consumption during the 
day in SCNx mice compared to sham mice (3321 ± 252 vs. 2992 ± 155 ml/kg/h, P < 0.01). Total 24 h 
oxygen consumption was not different between sham and SCNx mice (76531 ± 3854 vs. 79518 ± 
7595 ml/kg/day, ns). During the night, sham mice were more active compared to the day (195 ± 68 
vs. 79 ± 33 beam breaks (bb), P < 0.01, Fig. 4B). In line with the oxygen consumption rates, circadian 
pattern in locomotor activity was lost in SCNx mice (123 ± 48 vs. 128 ± 38 bb, ns). This loss in activity 
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Fig. 3. Body mass and composition of sham (white bars) and SCN lesioned (SCNx, black bars) mice at the time of 
the hyperinsulinemic-euglycemic clamp. Total body mass, lean body mass and fat mass were determined. Data is 


































































































) Fig. 4. Indirect calorimetry/
metabolic cage analysis of 
sham and SCN lesioned (SCNx) 
mice: oxygen consumption (A), 
locomotor activity (B) and energy 
intake (C). White bars represent 
the average value during the day, 
black bars during the night. Data 
is represented as mean ± SD, ** P < 
0.01. bb, beam breaks.
pattern in SCNx mice, resulted in increased activity levels during the day (128 ± 38 vs. 79 ± 33 bb, 
P < 0.01) and reduced activity levels during the night compared to sham mice (123 ± 48 vs. 195 ± 
68 bb, P < 0.01). Total 24 h activity, however, was not different between sham and SCNx mice (273 
± 96 vs. 251 ± 81 bb, ns). Sham mice consumed 68% of their total food during the night (night vs. 
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day; 3.2 ± 0.5 vs. 1.5 ± 0.2 g, P < 0.01, Fig 4C), whereas SCNx mice consumed only 54% during the 
night (night vs. day; 1.9 ± 0.3 vs. 1.6 ± 0.9 g, ns). This resulted in reduced food intake during the 
night for SCNx mice compared to sham mice (1.9 ± 0.3 vs. 3.2 ± 0.5 g, P < 0.01). Furthermore, total 
24 h food intake was also reduced for SCNx mice compared to sham mice (3.5 ± 1.2 vs. 4.7 ± 0.5 g, 
P < 0.01). Calculating the respiratory exchange rate (RER) showed that SCNx mice had a lower RER 
compared to sham mice during the day (0.86 ± 0.04 vs. 0.90 ± 0.01, P < 0.05) as well as during the 
night (0.87 ± 0.01 vs. 0.96 ± 0.02, P < 0.01). These data clearly show that ablation of the SCN results 
in a loss of circadian rhythm in respiratory metabolism and food intake.
Hyperinsulinemic-euglycemic clamp studies
Insulin sensitivity was determined by hyperinsulinemic-euglycemic clamp analysis in overnight 
fasted mice. Hematocrit levels were similar at the basal and the hyperinsulinemic period for 
sham and SCNx mice, indicating that the mice were not anemic. At the start of the clamp, 
insulin, glucose and FFA plasma levels were significantly higher in SCNx mice compared to sham 
controls (table 1). During the hyperinsulinemic period, insulin levels were increased to a similar 
extent for both the sham and SCNx mice (table 1). All mice were clamped at their individual 
fasting plasma glucose level. At the end of the hyperinsulinemic period, circulating glucose 
levels were comparable to the fasting levels for sham as well as for SCNx mice, resulting in 
significantly higher glucose levels in the hyperinsulinemic period for SCNx mice compared to 
sham mice (table 1, Fig. 5A). At the end of the clamp, FFA levels were decreased compared to 
basal plasma levels in sham and SCNx mice, although this failed to reach statistical significance 
in SCNx mice (P = 0.08). GIR needed to maintain euglycemia were determined over the final 
20 min of the clamp studies at stable plasma glucose values and were significantly lower in SCNx 
mice compared to sham controls (27.6 ± 19.5 vs. 74.7 ± 21.1 μmol/min/kg, P < 0.01, Fig. 5B, C). 
In the basal period, endogenous glucose production (EGP), which equals glucose disposal, 
was not different between sham and SCNx mice (53.6 ± 16.6 vs. 65.0 ± 8.6 μmol/min/kg, ns, 
Fig. 6A). In the hyperinsulinemic-euglycemic period, glucose disposal was increased by 57% in 
the sham mice compared to the basal period (83.9 ± 23.8 vs. 53.6 ± 16.6 μmol/min/kg, P < 0.01) 
and by 27% in the SCNx mice, although this failed to reach statistical significance (82.8 ± 15.9 vs. 
65.0 ± 8.6 μmol/min/kg, P = 0.06). Hyperinsulinemic glucose disposal rate was not significantly 
different between sham and SCNx mice. In the hyperinsulinemic-euglycemic period, EGP was 
Table 1. Body mass and hyperinsulinemic-euglycemic clamp parameters of sham and SCN lesioned (SCNx) mice. 
FFA, free fatty acids. Data are represented as mean ± SD, $ P < 0.05 basal vs. hyperinsulinemic-euglycemic clamp 
period, * P < 0.05 vs. sham, ** P < 0.01 vs. sham.
Sham SCNx
Basal Clamp Basal Clamp
Body mass (g) 24.9 ± 1.2 29.2 ± 1.9**
Insulin (ng/ml) 0.5 ± 0.3 5.2 ± 1.1$ 1.0 ± 0.3** 4.8 ± 1.9$
Glucose (mmol/l) 4.9 ± 0.8 4.7 ± 0.9 6.7 ± 1.2** 6.8 ± 1.2**
FFA (mmol/l) 0.9 ± 0.2 0.6 ± 0.3$ 1.2 ± 0.3* 0.8 ± 0.2
Hematocrit (%) 41.6 ± 4.7 38.5 ± 2.3 41.7 ± 2.7 40.5 ± 0.7
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decreased by 84% in sham operated mice compared to the basal period (8.8 ± 12.2 vs. 53.6 ± 
16.6 μmol/min/kg, P < 0.01, Fig. 6B), whereas EGP was decreased by only 7% in SCNx mice (60.3 
± 25.8 vs. 65.0 ± 8.6 μmol/min/kg, ns). These data indicate that bilateral ablation of the SCN 
induces severe hepatic insulin resistance. 
SCN lesion with collateral hypothalamic damage
SCN lesioned mice with collateral damage to hypothalamic nuclei involved in metabolism were 
analyzed separately. SCNx mice with additional, but selective unilateral damage to the PVN had 
modestly increased body mass compared to sham lesioned mice (29.9 ± 3.6 vs. 24.9 ± 1.2 g, 
P < 0.01, Fig. 7A), which was the result of increased fat mass (7.9 ± 2.5 vs. 1.9 ± 1.0 g, P < 0.01), but 
not lean mass (16.2 ± 1.0 vs. 17.2 ± 1.7 g, ns). SCNx mice with bilateral damage to the PVN were 
considerably heavier than the sham mice (42.5 ± 3.3 vs. 24.9 ± 1.2 g, P < 0.01), which was the result 
of increased fat mass (21.3 ± 4.8 vs. 1.9 ± 1.0 g, P < 0.01), but also coincided with a decrease in lean 
mass (13.6 ± 2.2 vs. 17.2 ± 1.7 g, P < 0.01). SCNx mice with collateral damage to both the PVN and 
the VMH developed extreme obesity compared to sham mice (49.3 ± 5.1 vs. 24.9 ± 1.2 g, P < 0.01), 
which was the result of an excessive increase in fat mass (24.7 ± 3.6 vs. 1.9 ± 1.0 g, P <  0.01), 
whereas lean mass was not different (16.8 ± 3.3 vs. 17.2 ± 1.7 g, ns). 
Insulin sensitivity in SCNx mice with collateral damage was determined by hyperinsulinemic-
euglycemic clamp analysis. Glucose infusion rates (GIR) needed to maintain euglycemia, 



































































































































Fig. 5. Hyperinsulinemic-euglycemic 
clamp analysis of sham (white) and 
SCN lesioned (SCNx, black) mice. Line 
graphs represent the plasma glucose 
levels (A) and glucose infusion rates 
(GIR,  B) during the hyperinsulinemic 
period of the clamp. Bar graph 
represents the clamped steady state 
GIR (C). Data is represented as mean ± 
SD, ** P < 0.01.
56
ChaPter 3
lower in all SCNx mice with collateral damage (SCNx + unilateral PVN damage; 41.3 ± 
11.0 μmol/min/kg, SCNx + bilateral PVN damage; 23.9 ± 13.1 μmol/min/kg, SCNx + PVN/VMH 
damage; 15.4 ± 13.5 μmol/min/kg) compared to sham controls (74.7 ± 21.1 μmol/min/kg, Fig. 7B), 
suggesting insulin resistance. 
d I s C u s s I o n
This study addressed the effects of thermic, bilateral ablation of the SCN on energy metabolism 
and insulin sensitivity in mice. Since adjacent hypothalamic nuclei, such as PVN and VMH, are 
involved in energy metabolism, great care was taken to distinguish between SCN lesioned 
mice and mice with collateral damage to these nuclei. We show that lesioning of the SCN 
Fig. 6



































Fig. 6. Rates of glucose disposal (Rd, A) and endogenous glucose 
production (EGP, B) in basal period (white bars) and hyperinsulinemic-
euglycemic clamp period (black bars) of sham and SCN lesioned (SCNx) 
mice. Data is represented as mean ± SD, ** P < 0.01.
Fig. 6
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Chapter 3, Fig. 7
Fig. 7. Body mass and composition (A) and hyperinsulinemic-
euglycemic clamp analysis (B) of sham (white bars) and SCN lesioned 
mice with collateral damage (striped bars): unilateral paraventricular 
nucleus (PVN), bilateral PVN and PVN plus ventromedial hypothalamus 
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disrupts the circadian pattern of energy intake, activity and energy expenditure, as expected. 
However, although selective SCN ablation resulted in only mild overweight compared to sham 
mice, hepatic insulin sensitivity was severely impaired. Therefore, disturbed SCN function has 
profound metabolic effects. 
Anatomically, the SCN is connected with the VMH and the PVN through the subparaventricular 
zone of the hypothalamus (25). In mice with collateral damage to the PVN and/or VMH, the 
obesity and insulin resistance phenotypes were very profound. This is in line with previous data 
showing that lesions of the PVN (26;27) and VMH (28-31) result in hyperphagia, obesity and 
obesity-related hyperinsulinemia. Interestingly, unilateral PVN damage in SCN lesioned mice 
resulted in only mild overweight, comparable to SCN lesion alone. Apparently, PVN damage 
results in obesity only when the PVN is damaged bilaterally. In light of our data, it is of utmost 
importance to ascertain correct and exclusive lesioning of the SCN to study the role of the 
circadian pacemaker in the context of metabolism. In the current study we included 6 mice 
with exclusive and total SCN lesions, 23 SCN lesioned mice with collateral damage and 17 sham 
lesioned mice.
The mild increase in weight gain in mice with exclusive SCN lesions compared to sham 
mice (+17%) is in contrast to a previous finding in rats (10). In rats, lesioning the SCN did not 
induce an increase in body mass, whereas the effect on body composition was not determined. 
This discrepancy in body weight gain between the previous study and our study may be due 
to the use of the obesogenic C57Bl/6J mouse strain in our study, whereas the rat study was 
performed in Wistar rats. Wistar rats only become obese upon hypercaloric food intake (32). 
We studied the contribution of the SCN in the circadian regulation of energy metabolism and 
insulin sensitivity in C57Bl/6J mice, a mouse strain shown to be an excellent model to study 
development of obesity en insulin resistance (33-35).
Previously, it has been shown that the SCN is involved in the regulation of energy 
homeostasisin mice (36) and rats (37). In the present study, indirect calorimetry/metabolic 
cage analysis revealed that ablation of the SCN induced a loss of circadian rhythm in oxygen 
consumption and physical activity without affecting the 24 h average level of oxygen 
consumption or activity. This loss of circadian rhythm in homeostasis is in line with previous 
findings, where SCN lesions eliminated a wide range of rhythms, including leptin (10). 
Although total food intake over a period of one day and one night was reduced by 26% in 
SCN lesioned mice, the SCN lesioned mice consumed more during the light part of the day 
compared to sham mice (46% vs. 32% of total food intake). Recently, it has been shown that 
mice and rats fed only during the day gained significantly more weight than mice fed only 
at night (38;39). In another study, the time of intake of a high-fat diet was a determinant of 
weight gain, adiposity, glucose intolerance, hyperinsulinemia and hyperleptinemia (40). In 
the aforementioned studies, obesity resulted from a dissociation between the timing of food 
intake and the intrinsic rhythm of energy expenditure and, thus, animals were eating “against 
their clock time”. In our study, on the other hand, the protocol was essentially different, and 
animals were not eating at the other part of the cycle, but rather, their circadian system was 
impaired. Therefore, it remains unclear how the mice with selective SCN lesion developed mild 
overweight. As it has been shown that the SCN has exerts excitatory effects on thermogenesis 
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by brown adipose tissue (BAT) (41), the mild weight gain in mice with a selective SCN lesion 
could be the result of reduced BAT activity. 
Indirect calorimetry/metabolic cage analysis further revealed that SCN lesioned mice had 
lower RER during the day as well as during the night as compared to sham mice. This shows 
that SCN ablation results in lower relative carbohydrate oxidation rates and, conversely, higher 
fat oxidation rates compared to sham mice. These data suggest that the oxidative response to 
food intake is less directed to carbohydrate metabolism when SCN is lesioned, a hallmark for 
an impaired metabolic flexibility (42). Impaired metabolic flexibility has been associated with 
impaired insulin sensitivity in humans (43).
We assessed insulin sensitivity by hyperinsulinemic-euglycemic clamp analysis. Compared to 
the sham operated mice, SCN lesioned mice were hyperglycemic and hyperinsulinemic in the 
postabsorptive state. Furthermore, at the start of the clamp, the SCNx mice had increased FFA 
levels compared to sham animals, suggesting a possible removal of inhibitory input from the 
SCN to the adipose tissue, thereby increasing the basal rate of lipolysis. Increased circulating 
levels of FFA have been implicated as a possible pathway for developing insulin resistancein 
obesity (44). Severe hepatic insulin resistance, but not peripheral insulin resistance, was 
present even though body fat mass was increased only minimally. The SCN is crucial for the 
circadian control of glucose production and glucose uptake (45-48). Furthermore, there is 
a direct control of hepatic glucose metabolism resulting from cross communication of the 
SCN and PVN, further mediated by innervation of the liver (49). It is, therefore, likely that the 
impaired hepatic insulin sensitivity found in the SCNx groups is, at least in part, a direct result of 
the disrupted SCN mediated control of glucose and FFA metabolism. 
Assessment of insulin sensitivity by hyperinsulinemic-euglycemic clamp technique revealed 
that all SCNx mice with collateral damage to PVN and/or VMH were very insulin resistant 
compared to sham mice. Surprisingly, SCNx with or without collateral damage were insulin 
resistant to a similar extent, even though SCNx mice with bilateral PVN damage and SCNx mice 
with PVN and VMH damage were much more obese that SCNx mice with unilateral PVN damage 
or mice with a clean SCN lesion, i.e., the amount of adiposity is not a direct determinant of the 
insulin resistance. These data further support the conclusion that, independent of obesity, the 
SCN output is crucial in determining hepatic insulin sensitivity.
We have clamped all mice at their respective basal glucose levels, as it has been shown that 
alterations in basal fasting glucose levels by itself are sufficient to affect insulin sensitivity (50). 
As SCN lesioned mice had increased basal glucose levels compared to the sham operated mice, 
the hyperinsulinemic glucose levels were also higher in the SCNx mice. However, clamping the 
mice at similar glucose levels, would have resulted in even larger differences in glucose infusion 
rates between sham and SCNx mice. Therefore, the degree of insulin resistance present in the 
SCNx mice may even have been underestimated using our clamp protocol. 
In conclusion, we demonstrate that exclusive deletion of the SCN induces loss in circadian 
rhythms in energy metabolism and food intake. Although ablation of the SCN resulted in only 
mild overweight, SCNx mice were severely insulin resistant in the liver. Great care was taken 
to distinguish between exclusive SCN lesioned mice from mice that had collateral damage to 
the PVN and VMH areas, as the latter resulted in severe obesity. It was previously shown that 
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mice with mutations in clock genes have altered energy homeostasis and glucose metabolism 
(14;51). Together, the data from the several studies provide solid evidence that the SCN is 
crucially involved in the maintenance of energy balance and hepatic insulin sensitivity. 
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a b s t r aC t
Insulin inhibits endogenous glucose production (EGP) and stimulates glucose uptake in 
peripheral tissues. Hypothalamic insulin signaling is required for the inhibitory effects of insulin 
on endogenous glucose production. We examined the contribution of central insulin signaling 
on circulating insulin-stimulated tissue-specific glucose uptake. Tolbutamide, an inhibitor of 
ATP-sensitive potassium channels, or vehicle was infused into the lateral ventricle in the basal 
state and during hyperinsulinemic-euglycemic conditions in postabsorptive, chow fed C57Bl/6J 
mice and in postabsorptive, diet-induced obese C57Bl/6J mice. Whole body glucose uptake 
was measured by D-[14C]glucose kinetics and tissue-specific glucose uptake by 2-deoxy-D-[3H]
glucose uptake.
During clamp conditions, intracerebroventricular (i.c.v.) administration of tolbutamide 
impaired the ability of insulin to inhibit EGP by ~20%. In addition, i.c.v. tolbutamide diminished 
insulin-stimulated glucose uptake in muscle (by ~59%), but not in heart or adipose tissue. In 
contrast, in diet-induced obese, insulin resistant mice, i.c.v tolbutamide did not affect the 
effects of insulin during clamp conditions on EGP or glucose uptake by muscle.
In conclusion, insulin stimulates glucose uptake in muscle in part through effects via ATP-
sensitive potassium channels in the central nervous system, in analogy with the inhibitory 
effects of insulin on EGP. High-fat diet-induced obesity abolished the central effects of insulin 
on liver and muscle. These observations stress the role of central insulin resistance in the 
pathophysiology of diet-induced insulin resistance.
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I n t r o d u C t I o n
In response to nutrients, insulin is rapidly released from pancreatic β-cells and decreases 
plasma glucose levels by inhibiting endogenous glucose production (EGP) and stimulating 
glucose transport into skeletal muscle, heart and white adipose tissue (WAT). Intake of high-
fat diets can lead to insulin resistance, which plays a primary pathophysiological role in the 
development of T2DM (1;2). Insulin resistance in the liver results in a decreased capacity of 
insulin to suppress EGP, whereas insulin resistance in peripheral tissues, including muscle, 
results in reduced insulin-mediated glucose uptake. 
In addition to direct effects of insulin on peripheral tissues, insulin acts in the hypothalamus, 
where it exerts anorexigenic properties by stimulating proopiomelanocortin (POMC)/
cocaine and amphetamine regulated transcript (CART) neurons and by inhibiting agouti-
related peptide (AgRP)/neuropeptide Y (NPY) neurons (3-5). In fact, hypothalamic insulin 
signaling appeared necessary for the inhibitory effect of insulin on EGP (6-8). Insulin activates 
ATP-sensitive potassium channels (K
ATP 
channels) in neurons of the hypothalamus, including 
POMC/CART- and AgRP/NPY expressing neurons (9;10). Inhibition of these neuronal K
ATP 
channels by intracerebroventricular (i.c.v.) administration of sulfonylurea (either tolbutamide 
or glibenclamide) impairs the inhibitory effect of insulin on EGP (7). Conversely, activation of 
hypothalamic K
ATP 
channels enhances insulin-mediated inhibition of EGP (11). 
Although the importance of this central action of insulin for the inhibition of EGP is now 
well established, the role of the central effects of insulin on glucose disposal is still unknown. 
Therefore, the aim of the present study was to determine the role of the central effect of insulin 
on tissue-specific insulin-stimulated glucose disposal in mice without and with diet-induced 
insulin resistance. To this end, we infused tolbutamide, an inhibitor of K
ATP
 channels, into the 
lateral ventricle and quantified glucose disposal in mice on a regular diet, both in the basal 
state and during hyperinsulinemic-euglycemic conditions. We show that the central effects of 
insulin are not only required for inhibition of EGP, but also enhances insulin-mediated glucose 
uptake in muscle. Furthermore, we show that these central effects of insulin on EGP and 
tissue-specific uptake of glucose are lost in diet-induced obese mice, stressing the role of 
central insulin resistance in the pathophysiology of diet-induced insulin resistance. 
M at e r I a l s  a n d  M e t h o d s
animals
Male C57Bl/6J mice (15 weeks old) were housed in a temperature-controlled room on a 12-hour 
light-dark cycle. Animals had free access to water and diet (chow or high-fat (45 energy% of 
fat derived from palm oil; Research Diet Services BV, Wijk bij Duurstede, The Netherlands)). 
All animal experiments were performed in accordance with the regulations of Dutch law on 
animal welfare and the institutional ethics committee for animal procedures from the Leiden 
University Medical Center, Leiden, The Netherlands approved the protocol.
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surgical procedure
For i.c.v. cannula implantation, 15-week-old male mice were anaesthetized with 0.5 mg/
kg Medetomidine (Pfizer, Capelle a/d IJssel, The Netherlands), 5 mg/kg Midazolam (Roche, 
Mijdrecht, The Netherlands) and 0.05 mg/kg Fentanyl (Janssen-Cilag, Tilburg, The Netherlands) 
and placed in a stereotactic device (TSE systems, Homburg, Germany). A 25 gauge guide 
cannula was implanted into the left lateral ventricle using the following coordinates from 
Bregma: 1.0 mm lateral, 0.46 mm posterior and 2.2 mm ventral. The guide cannula was secured 
to the skull surface with dental cement (GC Europe N.V., Leuven, Belgium) and the anesthesia 
was antagonized using 2.5 mg/kg Antipamezol (Pfizer, Capelle a/d IJssel, The Netherlands), 
0.5 mg/kg Flumazenil (Roche, Mijdrecht, The Netherlands) and 1.2 mg/kg Naloxon (Orpha, 
Purkersdorf, Austria). After a recovery period of 1 week, cannula placement was verified. Mice 
that ate >0.3 g in 1 h in response to i.c.v. injection of 5 μg NPY (Bachem, St. Helens, UK) in 1 μl of 
artificial cerebrospinal fluid (aCSF, Harvard Apparatus, Natick, MA, US) were considered to have 
the cannula correctly placed and were included in the study (12;13). 
basal and insulin-stimulated glucose metabolism
Postabsorptive (i.e. overnight fasted), body weight-matched male mice were anaesthetized 
with 6.25 mg/kg Acepromazine (Alfasan, Woerden, The Netherlands), 6.25 mg/kg Midazolam 
(Roche, Mijdrecht, The Netherlands), and 0.31 mg/kg Fentanyl (Janssen-Cilag, Tilburg, The 
Netherlands). Tissue-specific glucose uptake was determined, in the basal state and in the 
hyperinsulinemic-euglycemic state, in separate experiments (Fig. 1). aCSF or the K
ATP
 channel 
blocker tolbutamide, dissolved in 5% DMSO to a final concentration of 4.8 mM in aCSF, was 
continuously infused i.c.v. at a rate of 2.5 μl/h using a Harvard infusion pump (7;14). Thirty min 
after starting the i.c.v. infusion of tolbutamide or vehicle, i.v. infusions were started. In the basal 
state study, D-[14C]glucose (0.3 μCi/kg/min; Amersham, Little Chalfont, U.K.) was continuously 
infused for 90 min. In the hyperinsulinemic-euglycemic clamp study, insulin (Actrapid, Novo 
Nordisk, Denmark) was administered i.v. by primed (4.1 mU), continuous (6.8 mU/h) infusion 
to attain steady-state insulin levels together with D-[14C]glucose (0.3 μCi/kg/min; Amersham) 
for 90 min. This infusion rate of insulin was chosen based on previous dose-response studies 
of hyperinsulinemia, aimed at a five-fold increase in insulin levels which both inhibited EGP and 
stimulated glucose uptake (15). A variable intravenous infusion of a 12.5% D-glucose solution 
was used to maintain euglycemia as determined at 10-min intervals via tail bleeding (< 3 μl, Accu-
chek, Sensor Comfort; Roche Diagnostics, Mannheim, Germany). In a separate experiment, 
aCSF or the K
ATP
 channel activator diazoxide (dissolved in 5% DMSO, to a final concentration of 
2 μg/μl in aCSF) was continuously infused i.c.v. in high-fat fed mice during hyperinsulinemic-
euglycemic clamp. To assess basal and insulin-mediated glucose uptake in individual tissues, 
2-deoxy-D-[3H]glucose (2-[3H]DG; Amersham) was administered as a bolus (1  μCi) 30 min 
before the end of both experiments. In the last 20 min of both experiments, blood samples 
were taken with intervals of 10 min. Subsequently, the mice were sacrificed, perfused with PBS 




Blood samples were taken from the tail tip into chilled paraoxon-coated capillaries to prevent 
ex vivo lipolysis. The tubes were placed on ice and centrifuged at 4°C. Plasma levels of glucose 
and free fatty acids (FFA) were determined using commercially available kits and standards 
according to the instructions of the manufacturer (Instruchemie, Delfzijl, The Netherlands). 
Plasma insulin levels were measured using a mouse-specific insulin ELISA kit (Crystal Chem Inc., 
Downers Grove, U.S.). Total plasma 14C-glucose and 3H-glucose were determined in supernatant 
of 7.5 μl plasma, after protein precipitation using 20% trichloroacetic acid and evaporation to 
eliminate tritiated water. 
tissue analysis
For determination of tissue 2-[3H]DG uptake, homogenates of brain, heart, skeletal muscle 
(upper hindlimb) and WAT (epigonadal, visceral and subcutaneous) were boiled, and the 
supernatants were subjected to an ion-exchange column to separate 2-[3H]DG-6-phosphate 
(which is trapped within the organ and not phosphorylated) from 2-[3H]DG as described 
previously (16-18).
Calculations
Turnover rates of glucose (μmol/min/kg) were calculated for the basal state and for the 
hyperinsulinemic-euglycemic state as the rate of tracer infusion (dpm/min) divided by plasma 
specific activities of 14C-glucose (dpm/μmol). The ratio was corrected for body weight. EGP was 
calculated as the difference between the tracer-derived rate of glucose appearance and the 
glucose infusion rate. 
Tissue-specific glucose uptake in brain, muscle and WAT was calculated from tissue 2-[3H]DG 
content, corrected for plasma specific activity and expressed as micromoles per gram of tissue. 
western blot analysis
Whole hypothalami and skeletal muscles (upper hindlimb) of mice receiving i.c.v. aCSF in basal 
state and hyperinsulinemic-euglycemic state (n=5) were homogenized by Ultra-Turrax (22.000 
rpm; 2x5 sec) in a 6:1 (v/w) ratio of ice-cold buffer containing: 50 mM HEPES (pH 7.6), 50 mM 
NaF, 50 mM KCl, 5 mM TSPP (sodium pyrophosphate), 1 mM EDTA, 1 mM EGTA, 5 mM β-GP, 1 mM 
Na3VO4, 1 mM DTT, 1% NP40 and protease inhibitors cocktail (Complete, Roche, Mijdrecht, 
The Netherlands). Homogenates were centrifuged (13, 200 rpm; 15 min, 4°C) and the protein 
content of the supernatant was determined using a bicinchoninic acid (BCA) protein assay kit 
(BCA Protein Assay Kit, Thermo Scientific Pierce Protein Research Products, Rockford, US). 
Proteins (20-50 μg) were separated by 7-10% SDS-PAGE followed by transfer to a PVDF transfer 
membrane. Membranes were blocked for 1 h at room temperature in Tris-buffered saline with 
Tween-20 buffer and 5% non-fat dry milk followed by an overnight incubation with phospho-
specific or total antibodies (all from Cell Signaling Technology, Beverly, US). Blots were then 
incubated with HRP-conjugated secondary antibodies for 1 h at room temperature. Bands were 
visualized by enhanced chemiluminescence and quantified using Image J (NIH, US).
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statistical analysis
Differences between groups were determined by Mann-Whitney nonparametric tests for 
two independent samples. The criterion for significance was set at P < 0.05. All values shown 
represent means ± SEM.
r e s u lt s
I.c.v. tolbutamide administration in post-absorptive, chow fed mice
Plasma parameters and body weight
The design of the infusion studies is shown in Figure 1. In the basal and in the hyperinsulinemic 
state, body weight, plasma glucose, FFA and insulin levels did not differ between tolbutamide- 
and vehicle-treated chow fed mice (Table 1). As expected, in the hyperinsulinemic-euglycemic 
state, insulin levels were five-fold higher and FFA levels were ~50% lower than the values in the 
basal state, both in the tolbutamide- and vehicle-treated groups. In agreement with the rise 
in plasma insulin levels, hypothalamic insulin signaling was activated in the hyperinsulinemic-
euglycemic state as phosphorylation of PKB on Thr308 (1.2 ± 0.1 vs. 1.0 ± 0.1, P = 0.08) and its 
downstream target PRAS40 on Thr246 (1.5 ± 0.1 vs. 1.0 ± 0.1, P < 0.05) were increased compared 
to basal state (Fig. 2).
0 30 60 90 120 min





I.v. 12.5% glucose variable infusion
  
0 30 60 90 120 min












- 107 - 
Fig. 1. Schematic representation 
of the experimental procedures. 
(A) Basal state. At t=0 min, a 
continuous i.c.v. infusion of vehicle 
or tolbutamide was started and 
maintained throughout the entire 
experiment. At t=30 min, a primed, 
continuous i.v. infusion of 14C-
glucose was initiated and maintained 
for the remainder of the experiment. 
At t=90 min, an i.v. bolus of 2-[3H]
DG was administered. At t=0, 100, 
110 and 120 min, blood samples 
were obtained and at t=120 min, the 
animals were sacrificed and organs 
harvested. (B) Hyperinsulinemic-
euglycemic state. At t=0 min, 
a continuous i.c.v. infusion of 
vehicle or tolbutamide was started 
and maintained throughout the 
entire experiment. At t=30 min, a 
hyperinsulinemic-euglycemic clamp 
was started by primed, continuous 
infusion of insulin together with 
14C-glucose. A variable infusion of 
12.5% glucose was used to maintain 
euglycemia. At t=90 min, an i.v. 
bolus of 2-[3H]DG was administered. 
At t=0, 100, 110 and 120 min, blood 
samples were obtained and at t=120 





In the hyperinsulinemic-euglycemic clamp study, the rate of glucose infusion (GIR) necessary 
to maintain euglycemia was significantly lower in tolbutamide-treated animals compared to 
vehicle-treated animals (average GIR 87 ± 6 vs. 104 ± 13 μmol/min/kg for the last 20 min of the 
experiment, P < 0.05, Fig. 3A), in the presence of similar glucose levels (average plasma glucose 
5.4 ± 0.2 vs. 5.6 ± 0.1 mmol/l for the last 20 min of the experiment, ns, Fig. 3B), indicating that 
i.c.v. tolbutamide decreased insulin sensitivity. The glucose specific activities measured at 
10 min intervals in all experiments indicated the presence of steady-state conditions in all 
groups (Table 2). 
Endogenous glucose production and glucose disposal
In the basal state, endogenous glucose production (EGP), which equals glucose disposal, 
was not different between i.c.v. tolbutamide- and i.c.v vehicle-treated animals (36 ± 4 vs. 30 ± 
2 μmol/min/kg, respectively, ns, Fig. 4A). In the hyperinsulinemic-euglycemic state, EGP was 
significantly decreased compared to the basal state (1 ± 1 vs. 30 ± 2 μmol/min/kg, respectively, 
P < 0.01). I.c.v. tolbutamide in the hyperinsulinemic state diminished the inhibitory effects of 
insulin on EGP (12 ± 4 vs. 1 ± 1 μmol/min/kg, P < 0.05). 
Table 1. Plasma parameters of chow fed mice, in basal or hyperinsulinemic-euglycemic state, as measured at 
the end of the experiments. Throughout the experiments, mice received i.c.v. infusion of vehicle or tolbuta-
mide. Values are means ± SEM for at least 8 mice per group. FFA, free fatty acids. * P < 0.01 basal vs. hyperin-
sulinemic state.
Basal state Hyperinsulinemic state
vehicle tolbutamide vehicle  tolbutamide
Body weight (g) 23.5 ± 0.4 23.6 ± 0.4 22.8 ± 0.2 22.8 ± 0.5
Glucose (mmol/l) 5.2 ± 0.2 5.8 ± 0.4 6.2 ± 0.5 6.4 ± 0.5
FFA (mmol/l) 0.6± 0.1 0.6 ± 0.1  0.3 ± 0.1 *  0.3 ± 0.1 *
Insulin (ng/ml) 0.9 ± 0.1 1.0 ± 0.1  5.5 ± 0.4 *  4.9 ± 0.2 *
Hematocrit (%) 44.1 ± 0.7 44.3 ± 1.0 42.2 ± 0.6 42.5 ± 1.1
Table 2. Specific activity of glucose (dpm/mmol) in the postabsorptive state or in the hyperinsulinemic euglyc-
emic state of chow-fed mice. Throughout the experiment, mice received i.c.v. infusion of aCSF or tolbutamide. 
Values are means ± SEM for at least 8 mice per group.
Postabsorptive state
100 min 110 min 120 min
vehicle 11.9 ± 0.4 x 103 11.4 ± 0.9 x 103 11.8 ± 0.5 x 103
tolbutamide 11.0 ± 1.1 x 103 11.3 ± 0.9 x 103  9.4 ± 1.1 x 103
Hyperinsulinemic state
100 min 110 min 120 min
vehicle 4.1 ± 0.5 x 103 4.0 ± 0.7 x 103  4.3 ± 1.6 x 103
tolbutamide 4.1 ± 0.3 x 103 3.8 ± 0.2 x 103 4.2 ± 0.3 x 103
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Fig. 2. Phosphorylation state of PKB and PRAS40 in basal state (white bars) or hyperinsulinemic-euglycemic state 
(black bars) in hypothalamus of chow fed mice. The corresponding quantification of the western blot data was 
normalized for total protein or actin and expressed as fold change compared to basal state. Values represent 
means ± SEM for 5 mice per group. * P < 0.05 vs. vehicle. 
Fig. 3. Glucose infusion rates (GIR, A) and glucose concentrations (B) during hyperinsulinemic-euglycemic 
clamp in chow fed mice. Throughout the experiment, mice received i.c.v. infusion of vehicle (open circles) 
or tolbutamide (closed circles). Values represent means ± SEM for at least 8 mice per group. *P < 0.05, vehicle 
vs. tolbutamide.
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Glucose disposal was increased by ~300% in the hyperinsulinemic-euglycemic state 
compared to the basal state (120 ± 12 vs. 30 ± 2 μmol/min/kg, respectively, P < 0.01, Fig. 4B), 
whereas i.c.v. tolbutamide in the hyperinsulinemic state tended to reduce glucose disposal 
(97 ± 3 vs. 120 ± 12 μmol/min/kg, P = 0.07). 
Tissue-specific glucose uptake
In the basal and hyperinsulinemic-euglycemic states, 2-[3H]DG uptake was measured in brain, 
muscle (cardiac and skeletal) and WAT (epigonadal, subcutaneous and visceral fat) (Fig. 5). In 
brain, 2-[3H]DG uptake did not differ between the basal and the hyperinsulinemic states (12 ± 2 
vs. 15 ± 4 μmol/g tissue, respectively, ns) and was not affected by i.c.v. tolbutamide (11 ± 1 vs. 14 ± 
1 μmol/g tissue for basal and hyperinsulinemic state, respectively, ns). In heart, insulin increased 
2-[3H]DG uptake six-fold in the hyperinsulinemic state compared to the rate of uptake measured 
in the basal state (12 ± 1 vs. 2 ± 1 μmol/g tissue, respectively, P < 0.05), but this increase was not 
affected by i.c.v. tolbutamide. In muscle, insulin increased 2-[3H]DG uptake considerably in the 
hyperinsulinemic state compared to the basal state (11 ± 3 vs. 1 ± 1 μmol/g tissue, respectively, 
P < 0.05). Remarkably, i.c.v. tolbutamide inhibited the insulin-mediated increase in 2-[3H]DG 
uptake by muscle by ~59% (5 ± 1 vs. 11± 3 μmol/g tissue, P < 0.05). Phosphorylation of PKB on 
Ser473 (14 ± 1 vs. 14 ± 1, ns) and Thr308 (8 ± 1 vs. 8 ± 1, ns) and its downstream target PRAS40 
on Thr246 (14 ± 1 vs. 12 ± 1, ns) were not different between i.c.v. vehicle and i.c.v. tolbutamide 
infused mice in hyperinsulinemic conditions (Fig. 6). In all fat pads, insulin stimulated 2-[3H]
DG uptake in the hyperinsulinemic state compared to the basal state, but this increase was not 
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Fig. 4. Rates of endogenous glucose production (EGP, A) and glucose disposal (B) in basal state (white bars) or 
hyperinsulinemic-euglycemic state (black bars) in chow fed mice. Throughout the experiment, mice received 
i.c.v. infusion of vehicle or tolbutamide. Values represent means ± SEM for at least 8 mice per group. **P < 0.01 
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Fig. 5. Tissue-specific glucose uptake in basal state (white bars) or hyperinsulinemic-euglycemic state (black 
bars) in chow fed mice. Throughout the experiment, mice received i.c.v. infusion of vehicle or tolbutamide. 
Values represent means ± SEM for at least 7 mice per group. *P < 0.05 basal vs. hyperinsulinemic state, # P < 0.05, 
hyperinsulinemic state: vehicle vs. tolbutamide.
Table 3. Plasma parameters of diet-induced obese mice, in basal or hyperinsulinemic-euglycemic state, as 
measured at the end of the experiments. Throughout the experiments, mice received i.c.v. infusion of vehicle 
or tolbutamide. Values are means ± SEM for at least 6 mice per group. FFA, free fatty acids. * P < 0.01 basal vs. 
hyperinsulinemic state.
Basal state Hyperinsulinemic state
vehicle vehicle  tolbutamide
Body weight (g) 36.4 ± 0.8 37.6 ± 1.5 37.4 ± 0.7
Glucose (mmol/l) 5.1 ± 0.4 5.8 ± 0.4 6.2 ± 0.3
FFA (mmol/l) 0.7 ± 0.1 0.3 ± 0.1 * 0.3 ± 0.1 *
Insulin (ng/ml) 1.4 ± 0.4 7.5 ± 0.5 * 7.9 ± 0.6 *
Hematocrit (%) 44.3 ± 0.6 42.2 ± 1.0 42.4 ± 0.8
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I.c.v. tolbutamide administration in postabsorptive, diet-induced 
obese mice
Plasma parameters and body weight
Since all parameters in the basal state were not different between i.c.v tolbutamide- and i.c.v. 
vehicle-treated animals in chow fed conditions, we assessed the effects of i.c.v. tolbutamide in 
high-fat treated mice only in hyperinsulinemic-euglycemic clamp conditions. Body weight of 
the diet-induced obese mice was markedly higher compared to chow fed mice (37 ± 1 vs. 23 ± 
1 g, respectively, P < 0.01, Table 3). Plasma glucose and hematocrit levels were similar in basal 
and hyperinsulinemic conditions. In the hyperinsulinemic-euglycemic state, insulin levels were 
five-fold higher compared to the basal state, resulting in a decrease of ~50% in FFA levels. There 
were no differences observed in body weight, plasma glucose, FFA, insulin and hematocrit 
levels between i.c.v. tolbutamide- and i.c.v. vehicle-treated animals in the hyperinsulinemic-
euglycemic state.
Endogenous glucose production and glucose disposal
The GIR necessary to maintain euglycemia, was not different between tolbutamide- and vehicle-
treated animals (Fig. 7). Plasma glucose specific activities obtained during the last 20 min of the 
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Fig. 6. Phosphorylation state of PKB and PRAS40 in basal state (white bars) or hyperinsulinemic-euglycemic state 
(black bars) in muscle of chow fed mice receiving i.c.v. infusion of vehicle or tolbutamide. The corresponding 
quantification of the western blot data was normalized for total protein and expressed as fold change compared 
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Fig. 7. Glucose infusion rates (GIR, 
A) and glucose concentrations 
during a hyperinsulinemic-
euglycemic clamp (B) in diet-
induced obese mice. Throughout 
the experiment, mice received 
i.c.v. infusion of aCSF (open 
circles) or tolbutamide (closed 
circles). Values represent mean ± 




























































































Fig. 8. Rates of endogenous glucose production (EGP, A) and glucose disposal (B) in basal state (white bars) 
or hyperinsulinemic-euglycemic state (black and hatched bars) in diet-induced obese mice. Throughout the 
experiment, mice received an i.c.v. infusion of vehicle (white and black bars) or tolbutamide (hatched bars). 
Values represent means ± SEM for at least 7 mice per group. **P < 0.01 basal vs. hyperinsulinemic state.
In the hyperinsulinemic-euglycemic state, insulin decreased EGP compared to the basal 
state by ~74% (6 ± 3 vs. 23 ± 2 μmol/min/kg, respectively, P < 0.01, Fig. 8A), but surprisingly 
i.c.v. tolbutamide did not attenuate this effect of insulin in these diet-induced mice (i.c.v. 
tolbutamide- v . i.c.v. vehicle-treated animals: 10.0 ± 4 vs. 6.3 ± 3 μmol/min/kg, ns).
76
ChaPter 4
In the hyperinsulinemic-euglycemic state, insulin increased glucose disposal only by ~161% 
compared to the basal state (60 ± 5 vs. 23 ± 2 μmol/min/kg, respectively, P < 0.01, Fig. 8B). 
However, this effect of insulin was not affected by i.c.v. tolbutamide (i.c.v. tolbutamide- vs. 
vehicle-treated animals: 62 ± 6 vs. 60 ± 5 μmol/min/kg, ns). 
Comparison of the data from this experiment with the previously mentioned chow fed 
experiments indicated that the obese mice were considerably insulin resistant. Muscle glucose 
uptake under hyperinsulinemic-euglycemic conditions in high-fat fed mice was significantly 
lower compared to chow fed mice (7.9 ± 1.1 vs. 10.6 ± 2.6 μmol/min/kg, P < 0.05). In addition, 
glucose disposal rate was lower (60.2 ± 4.9 vs. 120.1 ± 11.7 μmol/min/kg, P < 0.05) and EGP was 
higher (6.4 ± 2.8 vs. 1.2 ± 1.0 μmol/min/kg, P < 0.05), indicating both hepatic and peripheral 
insulin resistance in the diet-induced obese mice.
Tissue-specific glucose uptake
In diet-induced obese mice, we measured tissue-specific 2-[3H]DG uptake in brain, muscle 
(cardiac and skeletal) and WAT (epigonadal, subcutaneous and visceral fat) in the basal state 
and in the hyperinsulinemic-euglycemic state (Fig. 9). In muscle, insulin stimulated 2-[3H]
DG uptake compared to the basal state (8 ± 1 vs. 2 ± 1 μmol/g tissue, respectively, P < 0.05). In 
contrast to chow fed mice, in diet-induced obese mice there was no effect of i.c.v. tolbutamide 
on insulin-mediated muscle glucose uptake. In accordance with the observation in chow fed 
mice, insulin increased 2-[3H]DG uptake in the hyperinsulinemic state compared to the basal 
state in heart and WAT, but not in brain, whereas i.c.v. tolbutamide did not affect 2-[3H]DG 
uptake in any of these organs.
I.c.v. diazoxide administration in postabsorptive, diet-induced 
obese mice 
In high-fat fed mice we assessed the effects of i.c.v. diazoxide, a K
ATP
 channel activator, on 
insulin-stimulated muscle glucose uptake (Table 5). There were no differences observed in 
body weight and plasma glucose between i.c.v. diazoxide and vehicle treated animals. The GIR 
necessary to maintain euglycemia, glucose disposal and 2-[3H]DG uptake by muscle was not 
different between i.c.v. diazoxide and vehicle treated animals. 
Table 4. Specific activity of glucose (dpm/mmol) in the postabsorptive state or in the hyperinsulinemic eug-
lycemic state of high fat diet-induced obese mice. Throughout the experiment, i.c.v. tolbutamide or aCSF was 
administered. Values are means ± SEM for at least 8 mice per group.
Postabsorptive state
100 min 110 min 120 min
vehicle 11.2 ± 0.9 x 103 11.1 ± 0.7 x 103 14.0 ± 1.0 x 103
Hyperinsulinemic state
100 min 110 min 120 min
vehicle 4.0 ± 0.4 x 103 4.3 ± 0.5 x 103 4.3 ± 0.3 x 103
tolbutamide 4.6 ± 0.4 x 103 4.2 ± 0.3 x 103 4.3 ± 0.2 x 103
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Fig. 9. Tissue-specific glucose uptake in basal state (white bars) or hyperinsulinemic-euglycemic state (black and 
hatched bars) in diet-induced obese mice. Throughout the experiment, mice received i.c.v. infusion of vehicle 
(white and black bars) or tolbutamide (hatched bars). Values represent means ± SEM for at least 7 mice per group. 
*P < 0.05 basal vs. hyperinsulinemic state.
Table 5. Plasma parameters of high-fat fed mice, in hyperinsulinemic-euglycemic state. Throughout the experi-
ments, mice received i.c.v. infusion of vehicle or diazoxide. Values are means ± SEM for at least 5 mice per group. 
Hyperinsulinemic state
vehicle  diazoxide
Body weight (g) 31.3 ± 1.7 30.8 ± 0.3
Glucose (mmol/l) 5.6 ± 0.2 5.2 ± 0.4
GIR (μmol/min/kg) 52.4 ± 4.8 54.3 ± 4.6
Glucose disposal (μmol/min/kg) 52.7 ± 4.3 52.1 ± 5.0
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d I s C u s s I o n
This study addressed the effect of central antagonism of insulin signaling on tissue-specific 
glucose uptake in normal weight and diet-induced obese mice. Inhibition of the central action 
of insulin by i.c.v. tolbutamide, a K
ATP
 channel blocker, decreased the inhibitory effects of insulin 
on EGP as well as the insulin-stimulated muscle glucose uptake in chow fed mice. In contrast, 
in diet-induced obese mice, the effects of insulin on EGP and muscle glucose uptake were not 
affected by i.c.v. tolbutamide. Collectively, these data indicate that the central effects of insulin 
are not only required for inhibition of EGP, but also for muscle glucose uptake. In addition, 
these data indicate that these central effects of insulin on EGP and muscle glucose uptake are 
absent after 12 weeks of high-fat feeding.
We assessed insulin-mediated effects on EGP and glucose disposal by hyperinsulinemic-
euglycemic clamp studies designed to increase plasma insulin concentrations by approximately 
five-fold above basal levels. This increase resulted in complete inhibition of EGP and a four-
fold stimulation of glucose disposal. In complete accordance with the results of Obici et al. 
(7), i.c.v. tolbutamide blunted the effect of hyperinsulinemia on EGP by ~20%. Therefore, this 
observation confirms that insulin inhibits EGP in part via its action in the CNS. In addition, 
our results indicate that the central effects of insulin contribute to the stimulatory effects of 
insulin on muscle glucose uptake, since this effect of insulin was in part inhibited (~59%) by 
i.c.v. tolbutamide. This inhibition of muscle glucose uptake coincided with a trend in decreased 
whole body glucose disposal (~20%, P = 0.07), which did not reach statistical significance 
probably due to the limited size of the mouse groups.
The present study indicates that i.c.v. tolbutamide decreased insulin-stimulated muscle 
glucose uptake in chow fed mice, not by decreasing insulin signaling in skeletal muscle as 
phosphorylation of PKB and PRAS40 were unaffected by i.c.v. tolbutamide, but, through 


















































- 116 - 
Fig. 10. Phosphorylation state of AMPK in 
basal state (white bars) or hyperinsulinemic-
euglycemic state (black bars) in muscle of 
chow fed mice receiving i.c.v. infusion of 
vehicle or tolbutamide. The corresponding 
quantification of the western blot data was 
normalized for total protein and expressed as 
fold change compared to basal state. Values 
represent means ± SEM for 5 mice per group. * 
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muscle glucose uptake has been suggested in a previous study on cerebral control of 
muscle glucose uptake (19). In that study, i.c.v. insulin increased glucose storage in muscle 
as glycogen. Together with the results obtained in our study, a concept emerges of an 
insulin-dependent central pathway targeted at skeletal muscle. I.c.v. NPY or AgRP did 
not stimulate muscle glucose uptake (20). Chronic (7-day) i.c.v. infusion of a-MSH, a POMC 
derivative, enhanced insulin-stimulated peripheral glucose uptake, although this effect 
could not be reproduced in an acute setting (21;22). However, i.c.v. infusion of melanotan II, 
a MC3/4 agonist, enhanced insulin-stimulated muscle glucose uptake (23;24). Therefore, we 
hypothesize that POMC/CART neurons are potential mediators of the central effect of insulin 
on muscle glucose uptake. 
Previous studies focusing on the role of central K
ATP
 channels in glucose metabolism could not 
show an effect on glucose disposal (7;11). There are some methodological differences between 
the studies, including insulin levels and duration of fasting. In previous experiments, we carefully 
characterized insulin dose-response characteristics on EGP vs. glucose disposal in C57Bl/6J mice 
(14). The data obtained in this dose-finding study indicate that increased insulin levels up to 
three times the basal levels inhibit EGP, but do not stimulate glucose disposal. Therefore, in the 
current study we aimed at five-fold increased insulin levels during the clamp as compared to 
the basal levels, compared to two- to three-fold levels in previous studies (6;11). Using these 
insulin levels, we were not only capable in reproducing the central effects of insulin on EGP as 
reported by Obici et al., but in addition to document central effects of insulin on muscle glucose 
uptake. Therefore, we speculate that the discrepancy in the effects of central K
ATP
 channel 
modulation on insulin-mediated glucose uptake during hyperinsulinemia between our study 
and previous studies is explained by the higher insulin levels in our study. Furthermore, Obici 
et al. (7) studied rats fasted for 6 hours and did not find an inhibition of glucose disposal rate by 
i.c.v. administration of tolbutamide, in contrast to our observations in overnight fasted mice. 
In a previous study, we documented that 16 h of (overnight) fasting increases muscle insulin 
sensitivity compared to a shorter duration of fasting (25). Therefore, differences between the 
duration of fasting may be involved to explain the differential effects of i.c.v. tolbutamide on 
insulin-stimulated glucose uptake between both studies. Nonetheless, this does not invalidate 
our conclusions, since the duration of fast was identical in all experiments of our study. 
Glucose utilization in skeletal muscle can be stimulated by sympathetic nervous system (SNS) 
activation and i.c.v. insulin in rats increases SNS activity to the hindlimb (26). Therefore, the observed 
effect on insulin-mediated glucose uptake in muscle following central K
ATP 
channel inhibition could 
be the result of reduced insulin-induced activation of the SNS towards muscle. Since the stimulation 
of muscle glucose uptake by α-adrenergic stimulation involves 5’-AMP-activated protein kinase 
(AMPK), we measured AMPKα phosphorylation in muscle (27). However, i.c.v. infusion of insulin 
or K
ATP 
channel inhibition under hyperinsulinemic conditions did not affect activity of AMPK in 
muscle (Fig. 10). Apparently, the stimulation of muscle glucose uptake by central insulin effects is 
independent of AMPK activation in muscle. At present, the involvement of autonomic pathways in 
mediating the central effects of insulin on muscle glucose uptake remains unclear.
Insulin stimulated glucose uptake in heart and WAT. Interestingly, this effect of insulin was 
greater in visceral fat compared to the other fat compartments, in accordance with previous 





 channel activation, since i.c.v. tolbutamide did not affect tissue-specific glucose 
uptake in these tissues. 
We also assessed the effects of high-fat diet on the central effects of insulin on EGP and 
tissue-specific glucose uptake. The study was designed for the mice to develop obesity in 
combination with partial, rather than complete, insulin resistance, and, as a result, effects 
of central insulin antagonism in these diet-induced obese mice could still be obtained. 
Indeed, the high-fat diet caused partial insulin resistance, since insulin was still able, 
although to a lesser extent, to inhibit EGP and stimulate glucose disposal. The high-fat 
diet abolished the inhibitory effect of i.c.v. tolbutamide on insulin-mediated inhibition of 
EGP. Furthermore, the inhibitory effect of i.c.v administration of tolbutamide on insulin-
stimulated glucose uptake by skeletal muscle was abolished. Our in vivo observations in 
diet-induced obese mice extend the in vitro observations by Spanswick et al., showing that 
physiological levels of insulin activate K
ATP
 channels in glucose responsive neurons of lean, but 
not of obese rats, suggesting that K
ATP
 channels are already inhibited in the insulin resistant 
state (10;31-33). Moreover, stimulation of K
ATP
 channels by i.c.v. diazoxide did not improve 
muscle glucose uptake under hyperinsulinemic-euglycemic clamp conditions in diet-induced 
obese insulin resistant mice. The absence of effects of i.c.v. tolbutamide in diet-induced 
obese mice might also involve reduced insulin transport across the blood brain barrier 
(34). Although the precise mechanism remains to be elucidated, the present study indicates 
that high-fat diet decreases the central effects of insulin on both EGP and muscle glucose 
uptake, which may contribute to the pathophysiology of diet-induced insulin resistance. High-
fat feeding strongly reduced insulin-stimulated glucose disposal, indicating peripheral 
insulin resistance. Interestingly, in quantitative terms, insulin-stimulated muscle glucose 
uptake in chow fed conditions during i.c.v. tolbutamide infusion, was not different from 
muscle glucose uptake during high-fat conditions (5.2 ± 0.6 vs. 7.1 ± 1.0 μmol/g tissue, ns). 
This remarkable observation indicates that muscle-specific insulin resistance was present 
for the centrally mediated effects of insulin, rather than for the direct effects of insulin on 
muscle, at least within the constraints of our high-fat diet mouse model. 
Recently, methodological issues have been raised concerning the application of the 
hyperinsulinemic-euglycemic clamp method in mice (35). To support the validity of our 
experimental procedures, we documented that we reached steady-state conditions with 
respect to GIR, plasma glucose concentrations and isotopes, the latter enabling reliable 
calculations using steady-state comparisons. Another issue that has been raised is that the 
mice may be subject to serious hemodilution during the clamps. Our data indicate that 
hemodilation hardly occurred at the end of the clamps in our mice as hematocrit levels 
remained similar. Furthermore, our clamp procedure was performed in anesthetized mice. 
However, since all groups received identical sedation, the differences between groups 
cannot be related to sedation. 
Recently, we also documented central effects of insulin on FA uptake (12). Those 
studies show that i.c.v. tolbutamide administration in hyperinsulinemic-euglycemic clamp 
conditions, identical to the current conditions, decreases insulin-stimulated retention of 
FA specifically in WAT. Therefore, the notion emerges that regulation of FA and glucose 
uptake by modulation of central insulin signaling is tissue-specific. In addition, both 
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studies indicate that these effects are mediated, at least in part, via K
ATP
 channel activation 
in the CNS and are absent after high-fat feeding.
We conclude that insulin signaling in the brain not only substantially contributes to 
the inhibitory effect of insulin on glucose production, but also to the insulin-stimulated 
glucose uptake by muscle. In diet-induced obese mice, these central effects of insulin on 
glucose homeostasis are lost. These observations stress the role of central insulin signaling 
in normal physiological conditions and central insulin resistance in the pathophysiology of 
diet-induced insulin resistance. 
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a b s t r aC t
Topiramate is associated with improvement in insulin sensitivity, in addition to its antiepileptic 
action. However, the mechanism underlying this insulin-sensitizing effect of topiramate is 
unknown. In the present study, we investigated the insulin-sensitizing effects of topiramate 
and the underlying mechanism both in vivo and in vitro.
Male C57Bl/6J mice were fed a run-in high-fat diet for 6 weeks, before receiving topiramate 
or vehicle mixed in high-fat diet for 6 weeks. In basal and hyperinsulinemic-euglycemic clamp 
conditions, whole body glucose kinetics was measured using D-[14C]glucose and tissue-specific 
glucose uptake using 2-deoxy-D-[3H]glucose. In addition, we determined the extent to which 
these effects of topiramate were mediated through the central nervous system by concomitant 
infusion of vehicle vs. tolbutamide, an inhibitor of ATP-sensitive potassium channels in neurons, 
into the lateral ventricle. In vitro, we examined the direct effects of topiramate on glucose 
uptake and insulin signaling in C2C12 muscle cells.
Therapeutic concentrations of topiramate (~4 μg/ml) improved insulin sensitivity (glucose 
infusion rate +58%), which was the result of improved insulin-mediated glucose uptake by heart 
(+92%), muscle (+116%) and adipose tissue (+586%). Upon infusion of tolbutamide this insulin-
sensitizing effect of topiramate was completely abrogated in hyperinsulinemic-euglycemic 
clamp conditions. Topiramate did not alter glucose uptake or insulin signaling in normal and 
insulin-resistant C2C12 muscle cells.
Topiramate stimulates insulin-mediated glucose uptake in vivo through the central nervous 
system. These observations illustrate the possibility of pharmacological modulation of 
peripheral insulin resistance through a target in the central nervous system. 
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I n t r o d u C t I o n
Type 2 diabetes mellitus (T2DM) is a syndrome characterized by impaired insulin secretion in 
relation to decreased insulin sensitivity. Many drugs have been developed that act on these 
pathophysiological mechanisms. In recent years, evidence has accumulated that the central 
nervous system is also involved in the pathophysiology of T2DM. Experimental models have 
indicated that insulin-mediated effects on different organs are mediated in part through 
the central nervous system (1-4). Importantly, in insulin resistant conditions these effects of 
circulating insulin through the central nervous system are lost (1;4). The question arises whether 
the loss of these effects of insulin, mediated by the central nervous system, are amendable to 
pharmacological intervention. 
Topiramate, a sulfamate-substituted derivative of the monosaccharide D-fructose (5), is used 
as an antiepileptic drug (6;7). The antiepileptic effects of topiramate are mediated through 
at least six mechanisms of action within the central nervous system (8-14). Studies in obese, 
diabetic rats demonstrated that topiramate treatment reduced plasma glucose levels and 
improved insulin sensitivity independently of weight loss (15;16). However, the mechanism 
underlying this pharmacological, insulin-sensitizing effect of topiramate is unknown. 
We hypothesized that topiramate improves insulin sensitivity not by a direct effect on 
peripheral organs, but rather through effects within the central nervous system. Therefore, we 
studied in high-fat fed mice the effects of i.c.v. administered vehicle vs. tolbutamide on top of 
the effects of topiramate on tissue-specific insulin-mediated glucose uptake. Tolbutamide is 
an inhibitor of ATP-sensitive potassium (K
ATP
) channels in neurons and i.c.v. administration of 
tolbutamide blocks the action of circulating insulin in the brain (1;3;4). In addition, we assessed 
the effects of topiramate in C2C12 muscle cells in order to evaluate the possibility of direct effects 
of topiramate on insulin signaling and glucose uptake. In this study we show that topiramate 
improves peripheral insulin sensitivity at least in part by improving insulin sensitivity in the brain. 
M at e r I a l s  a n d  M e t h o d s
animals
Male C57Bl/6J mice obtained from Charles River Laboratories at an age of 8 weeks were housed 
in a temperature-controlled room on a 12 h light-dark cycle. From the age of 12 weeks, mice 
were fed ad libitum a run-in high-fat diet for 6 weeks (45 energy% of fat derived from lard; 
Research Diets Inc, New Brunswick, US), which has previously been shown to induce insulin 
resistance (17). Subsequently, the animals were randomized according to body weight and 
fasting plasma glucose levels and were fed ad libitum for 6 weeks a high-fat diet containing 
3.33% anise (anise cubes, De Ruijter, The Netherlands) with or without 0.12% (w/w) topiramate 
(Abbott Products GmbH, Hannover, Germany). The mice had free access to water throughout 
the experiment. Food intake and body weight were measured regularly throughout the 
experiment. All animal experiments were performed in accordance with the regulations of 
Dutch law on animal welfare and the institutional ethics committee for animal procedures from 
the Leiden University Medical Center, Leiden, The Netherlands approved the protocol.
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I.c.v. cannula implantation 
For i.c.v. cannula implantation, 15-week-old male mice were anaesthetized with 0.5 mg/kg 
Medetomidine (Pfizer, Capelle a/d IJssel, The Netherlands), 5 mg/kg Midazolam (Roche, Mijdrecht, 
The Netherlands) and 0.05 mg/kg Fentanyl (Janssen-Cilag, Tilburg, The Netherlands) and placed 
in a stereotactic device (TSE systems, Homburg, Germany). A 25 gauge guide cannula was 
implanted into the left lateral ventricle using the following coordinates from Bregma: 1.0 mm 
lateral, 0.46 mm posterior and 2.2 mm ventral. The guide cannula was secured to the skull surface 
with dental cement (GC Europe N.V., Leuven, Belgium) and the anesthesia was antagonized 
using 2.5 mg/kg Antipamezol (Pfizer, Capelle a/d IJssel, The Netherlands), 0.5 mg/kg Flumazenil 
(Roche, Mijdrecht, The Netherlands) and 1.2 mg/kg Naloxon (Orpha, Purkersdorf, Austria). After 
a recovery period of 1 week, cannula placement was verified. Mice that ate >0.3 g in 1 h in response 
to i.c.v. injection of 5 μg NPY (Bachem, St. Helens, UK) in 1 μl of artificial cerebrospinal fluid (aCSF, 
Harvard Apparatus, Natick, MA, US) were considered to have the cannula correctly placed and 
were included in the study (1;18). 
hyperinsulinemic-euglycemic clamp studies
Overnight fasted, body weight-matched male mice were anaesthetized with 6.25 mg/kg 
Acepromazine (Alfasan, Woerden, The Netherlands), 6.25 mg/kg Midazolam (Roche, Mijdrecht, 
The Netherlands), and 0.31 mg/kg Fentanyl (Janssen-Cilag, Tilburg, The Netherlands). First, 
basal rates of glucose turnover were determined by administration of a primed continuous 
intravenous (i.v.) infusion of D-[1-14C]glucose (0.3 μCi/kg/min; Amersham, Little Chalfont, UK) 
for 60 minutes. Subsequently, insulin (Actrapid, Novo Nordisk, Denmark) was administered 
i.v. by primed (4.1 mU), continuous (6.8 mU/h) infusion to attain steady-state hyperinsulinemia 
together with D-[1-14C]glucose (0.3 μCi/kg/min; Amersham, Little Chalfont, UK) for 90 min. 
A variable i.v. infusion of a 12.5% D-glucose solution was used to maintain euglycemia as 
determined at 10-min intervals via tail bleeding (<3 μl, Accu-chek, Sensor Comfort; Roche 
Diagnostics, Mannheim, Germany). To assess insulin-mediated glucose uptake in individual 
tissues, 2-deoxy-D-[3-3H]glucose (2-[3H]DG; Amersham, Little Chalfont, UK) was administered 
as a bolus (1 μCi) 30 min before the end of both experiments. In the last 20 min of both 
experiments, blood samples were taken with intervals of 10 min. Subsequently, the mice were 
sacrificed and after perfusion, organs were harvested and snap-frozen in liquid nitrogen. 
I.c.v. tolbutamide treatment during clamp
As of thirty minutes before the start of the hyperinsulinemic-euglycemic clamp, aCSF or the 
K
ATP
 channel blocker tolbutamide, dissolved in 5% DMSO to a final concentration of 4.8 mM in 
aCSF, was continuously infused i.c.v. at a rate of 2.5 μl/h (3;19). 
Plasma analysis
Blood samples were taken from the tail tip into chilled paraoxon-coated capillaries to prevent 
ex vivo lipolysis. The tubes were placed on ice and centrifuged at 4°C. Plasma levels of glucose 
and free fatty acids (FFA) were determined using commercially available kits and standards 
according to the instructions of the manufacturer (Instruchemie, Delfzijl, The Netherlands) in 
96-well plates (Greiner Bio-One, Alphen a/d Rijn, The Netherlands). Plasma insulin levels were 
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measured using a mouse-specific insulin ELISA kit (Crystal Chem Inc., Downers Grove, U.S.). 
Total plasma 14C-glucose and 3H-glucose were determined in supernatant of 7.5 μl plasma, 
after protein precipitation using 20% trichloroacetic acid and evaporation to eliminate 
tritiated water. 
tissue analysis
For determination of tissue 2-[3H]DG uptake, homogenates of heart, skeletal muscle and 
adipose tissue were boiled, and the supernatants were subjected to an ion-exchange column 
(described previously (20-22)) to isolate 2-[3H]DG-6-phosphate, a metabolic end-product of 
2-[3H]DG that accumulates in muscle and fat cells.
C2C12 cells
C2C12 skeletal muscle cells were cultured in a humidified atmosphere containing 5% CO
2 
in Dulbecco’s modified Eagle’s Medium (DMEM) containing 25 mM glucose, glutamine and 
pyruvate (Invitrogen) supplemented with 10% fetal bovine serum (FBS) and 100 units/ml 
penicillin and 100 μg/ml streptomycin (Invitrogen). For deoxyglucose uptake assay ~15, 000 
cells/well were seeded and cultured on 12-well plates (Greiner Bio-One). For Western blot 
analysis ~25, 000 cells/well were seeded and cultured on 6-well plates (Greiner Bio-One). When 
reaching confluence, the cells were differentiated into myotubes by replacing the complete 
growth medium with differentiation medium (same DMEM medium containing antibiotics, but 
supplemented with 2% horse serum (HS) instead of 10% FBS). The differentiation medium was 
changed every 48 h. The myotubes were used for experiments at day 7 of differentiation. 
Palmitate-induced insulin resistance in C2C12 myotubes
Palmitate-containing medium was prepared to induce insulin resistance in C2C12 myotubes. 
DMEM basic medium was supplemented with antibiotics and 2% FFA-free bovine serum albumin 
(BSA). Palmitate was first dissolved in ethanol and then added to medium containing BSA at a 
final concentration of 0.75 mM. The final medium was sonicated for 5 min and warmed at 55°C 
for 10 min to allow complex formation between BSA and palmitate. Differentiated myotubes 
(day 6) were then treated with palmitate for 16 h before performing deoxyglucose uptake assay.
deoxyglucose uptake assay in C2C12 myotubes
C2C12 myotubes were serum-starved for 4 h before the experiment. After serum starvation, 
cells were washed once with PBS and once with buffer (50 mM HEPES, 138 mM NaCl, 1.85 mM 
CaCl
2
, 1.3 mM MgSO
4
 and 4.8 mM KCl, pH 7.4) followed by incubation with the same buffer 
for 45 min at 37 °C in the presence of topiramate (1 or 100 μM) or vehicle. At the end of 
incubation, cells were challenged with or without 1 μM insulin (Sigma-Aldrich, St. Louis, 
Missouri, US) for 10 min in the presence of topiramate or vehicle. 2-Deoxy-D-[1-14C] glucose 
was added to the cells for another 10 min (0.012 μCi/dish). The reaction was ended by 
washing three times with ice-cold PBS and addition of a lysis buffer containing 1% SDS/0.2 M 
NaOH. The lysates were transferred into plastic vials, 2 ml of scintillation liquid (Instagel 
Plus, PerkinElmer, Waltham, Massachusetts, US) was added and radioactivity was measured 




C2C12 myotubes were serum-starved for 4 h then washed once with PBS and once with 2DG 
buffer followed by incubation with the same buffer for 45 min at 37°C in the presence of 
topiramate (1 or 100 μM) or vehicle. At the end of incubation, cells were stimulated with 1 μM 
insulin. After 20 min, cells were rapidly washed one time with ice-cold PBS and lysed by addition 
of a buffer containing 12.5% glycerol, 3% SDS and 100 mM TrisPO4, pH 6.8. The cell lysates 
were then immediately boiled for 5 min and stored at -20°C until use. Protein content was 
determined using the bicinchoninic acid protein assay (Pierce, Rockford, Illinois, US). Proteins 
(10 μg) were separated by 10% SDS-PAGE followed by transfer to a PVDF transfer membrane. 
Membranes were blocked for 1 h at room temperature in Tris Buffer Saline Tween20 (TBST) 
buffer with 5% non-fat dry milk followed by an overnight incubation with phospho-Ser473-PKB 
antibody or a mix of PKBα and PKBβ antibodies (all from Cell Signaling Technology, Beverly, 
US). Blots were then incubated with HRP-conjugated secondary antibodies for 1 h at room 
temperature. Bands were visualized by enhanced chemiluminescence and quantified using 
Image J (NIH, US).
Calculations
Turnover rates of glucose (μmol/min/kg) were calculated in basal and hyperinsulinemic 
conditions as the rate of tracer infusion (dpm/min) divided by plasma specific activity of 
14C-glucose (dpm/μmol). The ratio was corrected for body weight. Endogenous glucose 
production was identical to the glucose appearance rate under basal conditions and calculated 
as the difference between the tracer-derived rate of glucose appearance and the glucose 
infusion rate under hyperinsulinemic-euglycemic clamp conditions. 
Tissue-specific glucose uptake in heart, skeletal muscle and adipose tissue was calculated 
from tissue 2-[3H]DG content, corrected for plasma specific activity and expressed as 
micromoles per gram of tissue. 
statistical analysis 
Differences between groups were determined by Mann-Whitney nonparametric tests for 
two independent samples. The criterion for significance was set at P < 0.05. All values shown 
represent means ± SEM.
r e s u lt s
In vivo  studies
After 6 weeks of run-in high-fat diet, mice were randomized on body weight (26.6 ± 0.5 vs. 26.7 
± 0.6 g) and fasting plasma glucose levels (4.2 ± 0.2 vs. 4.3 ± 0.2 mmol/l) and received high-fat 
diet containing topiramate or vehicle during 6 subsequent weeks. After 5 weeks of topiramate 
treatment, the topiramate concentration in plasma, determined by liquid chromatography 
tandem mass spectrometry assay as previously described (23), was 3.7 ± 0.2 μg/ml. After 6 
weeks of topiramate treatment, the topiramate concentration in the brains of overnight fasted 
mice was 115 ± 18 ng/g brain tissue. 
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effect of topiramate on insulin sensitivity in mice 
After 6 weeks of topiramate treatment, insulin sensitivity was assessed using hyperinsulinemic-
euglycemic clamp studies. Body weight did not differ between topiramate and vehicle treated 
mice (table 1). In the basal period of the hyperinsulinemic-euglycemic clamp, endogenous 
glucose production (EGP), which equals glucose disposal (Rd), was not different between 
topiramate and vehicle treated animals. 
Table 1. Results obtained during the hyperinsulinemic-euglycemic clamp study in vehicle and topiramate 
treated animals. Data are represented as means ± SEM for at least 7 animals per group. There were no significant 
differences between any of the parameters.
Vehicle Topiramate
Body weight (g) 25.7 ± 0.4 24.9 ± 0.8
Basal hematocrit (%) 40.3 ± 0.2 38.5 ± 0.2
Clamp hematocrit (%) 36.8 ± 0.2 34.9 ± 0.5
Basal insulin (ng/ml) 0.5 ± 0.1 0.5 ± 0.1
Clamp insulin (ng/ml) 5.1 ± 0.4 4.3 ± 0.5 
Basal glucose (mmol/l) 4.1 ± 0.1 4.2 ± 0.1
Clamp glucose (mmol/l) 4.5 ± 0.3 4.0 ± 0.2
Table 2. Specific activity of 14C-glucose (dpm/mmol) in the basal period or in the hyperinsulinemic euglycemic 
period in vehicle and topiramate treated animals. Values are means ± SEM for at least 7 mice per group. There 
were no significant differences between vehicle vs. topiramate treated animals.
Basal period Hyperinsulinemic euglycemic period
-10 min 0 min 70 min 80 min 90 min
Vehicle 6.7 ± 0.6 x 103 6.2 ± 0.6 x 103 6.8 ± 0.4 x 103 6.2 ± 0.5 x 103 6.3 ± 0.4 x 103
Topiramate 6.6 ± 0.5 x 103 7.4 ± 0.6 x 103 5.3 ± 0.3 x 103 5.1 ± 0.2 x 103 5.0 ± 0.3 x 103
The glucose infusion rate (GIR) necessary to maintain euglycemia was significantly higher 
in topiramate treated animals compared to vehicle treated animals (average GIR 84 ± 8 vs. 56 
± 4 μmol/min/kg for the last 20 min of the experiment, P < 0.05, Fig. 1A and Fig. 2B), in the 
presence of similar glucose levels (table 1 and Fig. 2A), indicating that topiramate improved 
insulin sensitivity. The specific activity of 14C-glucose measured at 10 min intervals indicated the 
presence of steady-state conditions in all groups (table 2). 
In the hyperinsulinemic-euglycemic period, insulin inhibited EGP to the same extent in both 
groups of mice (92 ± 8 vs. 80 ± 7 %, ns, Fig. 1B). Insulin-mediated Rd, however, was increased 
in the topiramate treated group compared to the vehicle treated group (96 ± 16 vs. 47 ± 9 %, 
respectively, P < 0.05, Fig. 1C), indicating that topiramate treatment improved peripheral insulin 
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sensitivity. Assessment of tissue-specific 2-[3H]DG uptake revealed that topiramate treatment 
increased insulin-stimulated glucose uptake in heart, skeletal muscle and adipose tissue 
(gonadal fat pad) (Fig. 1D). 
Fig. 1











































































































Fig. 1. Glucose infusion rate (GIR, A), endogenous glucose production (EGP, B), glucose disposal (Rd, C) in vehicle 
treated (white) and topiramate treated (black) animals as measured in hyperinsulinemic-euglycemic clamp 
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Fig. 2. Glucose concentrations (A) and glucose infusion rates (GIR, B) in vehicle treated (white) and topiramate 
treated (black) animals as measured in hyperinsulinemic-euglycemic clamp studies. Values represent means 
± SEM for 7-10 mice per group. *P < 0.05, Topiramate vs. control.
Glucose concentration Glucose infusion rate
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effect of i.c.v. administration of tolbutamide on the effects of 
topiramate on insulin sensitivity in mice
To determine whether topiramate improved peripheral insulin sensitivity by affecting insulin 
signaling in the brain, tolbutamide, an inhibitor of ATP-sensitive potassium (K
ATP
) channels 
in neurons, or vehicle was infused into the lateral ventricle (i.c.v.) during hyperinsulinemic-
euglycemic clamp experiments. In agreement with the first experiment, topiramate treated 
animals receiving vehicle (aCSF) had higher GIR compared to vehicle treated animals receiving 
aCSF (average GIR 85 ± 9 vs. 55 ± 11 μmol/min/kg for the last 20 min of the experiment, P < 0.05, 
Fig. 3A and Fig. 4B), in the presence of similar glucose levels (table 3 and Fig. 4A). I.c.v. 
tolbutamide administration in vehicle treated animals did not affect GIR compared to i.c.v. aCSF 
(66 ± 8 vs. 55 ± 11 μmol/min/kg for the last 20 min of the experiment, ns). I.c.v. administration of 
tolbutamide decreased GIR compared to topiramate treated animals receiving aCSF (average 
GIR 75 ± 7 vs. 85 ± 9 μmol/min/kg for the last 20 min of the experiment, P < 0.05), indicating that 
i.c.v. tolbutamide counteracted, at least in part, the improvement in insulin sensitivity induced 
Fig. 3. Glucose infusion rate (GIR, A), endogenous 
glucose production (EGP, B), glucose disposal (Rd, C) 
and organ-specific glucose uptake (D) in vehicle treated 
(white) and topiramate treated animals (black) receiving 
i.c.v. vehicle (artificial cerebrospinal fluid, aCSF) or 
tolbutamide. Values represent means ± SEM for at least 
7 animals per group. *P < 0.05 vs. vehicle. Av, average.
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Table 3. Results of i.c.v. administration of aCSF and tolbutamide obtained from the hyperinsulinemic-euglyc-
emic clamp study in vehicle and topiramate treated animals. Data are represented as means ± SEM for at least 8 
animals per group. There were no significant differences between vehicle vs. topiramate treated animals. aCSF, 
artificial cerebrospinal fluid; FFA, free fatty acids.
Vehicle Topiramate
aCSF Tolbutamide aCSF Tolbutamide
Body weight (g) 28.6 ± 0.7 28.7 ± 0.7 27.7 ± 0.5 27.8 ± 0.3
Basal hematocrit (%) 40.3 ± 0.2 39.0 ± 0.8 38.5 ± 0.2 37.1 ± 0.3
Clamp hematocrit (%) 36.8 ± 0.2 36.3 ± 0.2 34.9 ± 0.5 34.4 ± 0.4
Basal insulin (ng/ml) 0.6 ± 0.1 0.7 ± 0.1 0.6 ± 0.1 0.6 ± 0.1
Clamp insulin (ng/ml) 4.1 ± 0.4 3.3 ± 0.1 3.4 ± 0.2 3.8 ± 0.4
Basal glucose (mmol/l) 5.0 ± 0.2 5.4 ± 0.3 5.5 ± 0.2 4.9 ± 0.2
Clamp glucose (mmol/l) 5.6 ± 0.3 6.0 ± 0.5 5.8 ± 0.3 5.2 ± 0.3
Basal FFA (mmol/l) 0.7 ± 0.0 0.6 ± 0.1 0.6 ± 0.0 0.7 ± 0.0
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Fig. 4. Glucose concentrations (A) and glucose infusion rates (GIR, B) in vehicle treated (white) and topiramate 
treated animals (black) receiving i.c.v. vehicle (aCSF) or tolbutamide. Values represent means ± SEM for 7-10 mice 
per group. *P < 0.05, Topiramate vs. other groups.
by topiramate. The specific activity of 14C-glucose measured at 10 min intervals indicated 
the presence of steady-state conditions in all groups (table 4). In the basal period as well as 
in the hyperinsulinemic period, EGP was not different between all groups of mice (Fig. 3B). 
Insulin-stimulated Rd was again significantly higher in topiramate treated animals compared 
to vehicle treated animals receiving aCSF (101 ± 15 vs. 71 ± 12 %, respectively, P < 0.05, Fig. 3C). 
I.c.v. tolbutamide administration in vehicle treated animals did not affect Rd compared to i.c.v. 
aCSF (57 ± 16 vs. 71 ± 12 μmol/min/kg for the last 20 min of the experiment, ns). However, i.c.v. 
administration of tolbutamide in topiramate animals diminished the topiramate-improved 
Rd (81 ± 12 vs. 101 ± 15 %, respectively, P < 0.05). In accordance, topiramate treated animals 
had higher 2-[3H]DG uptake in heart, skeletal muscle and adipose tissue compared to vehicle 
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treated animals (Fig. 3D). In line with Rd, i.c.v. tolbutamide did not affect 2-[3H]DG uptake 
compared to i.c.v. aCSF in vehicle treated animals. I.c.v. tolbutamide in topiramate-treated 
animals abrogated the improvement in insulin-stimulated 2-[3H]DG uptake in heart, skeletal 
muscle and adipose tissue. 
Table 4. Specific activity of 14C-glucose (dpm/mmol) in the basal period or in the hyperinsulinemic euglycemic 
period in vehicle and topiramate treated animals. Values are means ± SEM for at least 7 mice per group. There 
were no significant differences between vehicle vs. topiramate treated animals.
Basal period Hyperinsulinemic euglycemic period
-10 min 0 min 70 min 80 min 90 min
Vehicle aCSF 7.2 ± 1.0 x 103 7.7 ± 0.7 x 103 4.3 ± 0.5 x 103 4.4 ± 0.4 x 103 4.4 ± 0.4 x 103
Topiramate aCSF 5.8 ± 0.5 x 103 6.0 ± 0.5 x 103 3.3 ± 0.2 x 103 3.1 ± 0.2 x 103 3.2 ± 0.3 x 103
Vehicle Tolbutamide 6.7 ± 0.9 x 103 6.9 ± 0.6 x 103 3.5 ± 0.3 x 103 3.3 ± 0.4 x 103 3.8 ± 0.3 x 103
Topiramate Tolbutamide 7.9 ± 1.0 x 103 8.0 ± 0.9 x 103 3.9 ± 0.2 x 103 4.4 ± 0.6 x 103 3.9 ± 0.3 x 103
In vitro  studies
Effect of topiramate on glucose uptake in differentiated myotubes
To exclude that topiramate directly increased glucose uptake at the tissue level, we investigated 
the direct effects of topiramate on glucose uptake in differentiated C2C12 myotubes (Fig. 5A). 
Cells were treated with increasing concentrations of topiramate (1 or 100 μM) or vehicle for 
45 min and glucose uptake was then measured during the last 20 min, after addition, or not, 
of 1 μM insulin. Insulin stimulated glucose uptake by about +25% in control condition, i.e. 
without topiramate. Topiramate did not increase basal or insulin-stimulated glucose uptake 
(Fig. 5A).
Effect of topiramate on insulin signaling in differentiated myotubes
Western blot analyses were performed to determine whether topiramate affects the insulin 
signaling pathway in differentiated myotubes by assessing the phosphorylation state of Akt/PKB 
(Fig. 5B). As expected, insulin increased the phosphorylation state of Akt/PKB on Ser473 by +583% 
in control condition. Topiramate did not affect basal or insulin-stimulated phosphorylation of 
Akt/PKB (Fig. 5B).
Effect of topiramate on glucose uptake in insulin-resistant myotubes
Next, we investigated whether topiramate was able to reverse palmitate-induced insulin 
resistance in C2C12 myotubes (Fig. 6). After incubation with palmitate for 16 h, C2C12 myotubes 
were incubated with increasing concentrations of topiramate (1 or 100 μM) for 45 minutes 
and challenged with or without 1 μM of insulin for 20 min. At maximal concentration of 
insulin, glucose uptake was increased by +25% in control condition, i.e. without palmitate and 
topiramate (Fig. 6A). Preincubation with palmitate resulted in a decrease of insulin-stimulated 
glucose uptake. There was no effect of topiramate on basal or insulin-stimulated glucose 
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Fig. 5. Glucose uptake (A) and insulin signaling (B) in C2C12 myotubes at basal (white) or insulin-stimulated 
(black) condition with topiramate (1 or 100 µM) or vehicle. The quantification was normalized for total protein 
and expressed as fold change compared to vehicle at basal condition. Data are represented as means ± SEM for 












































































































































Fig. 6. Glucose uptake (A-C) by 
healthy or palmitate-induced 
insulin resistant C2C12 myotubes at 
basal (white) or insulin-stimulated 
(black) condition with topiramate 
(1 or 100 µM) or vehicle. The 
quantification was normalized for 
total protein and expressed as 
fold change compared to vehicle 
at basal condition. Data are 
represented as means ± SEM for 
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d I s C u s s I o n
In the present study, topiramate improved insulin sensitivity by increasing glucose uptake by 
skeletal and cardiac muscle and by adipose tissue in high-fat fed mice. In addition, inhibition 
of the central action of circulating insulin by i.c.v. administration of tolbutamide, a K
ATP
 channel 
blocker in neurons, prevented this insulin-sensitizing effect of topiramate. In vitro, topiramate 
had no direct effect on basal or insulin-stimulated glucose uptake. Collectively, these data 
indicate that topiramate improves peripheral insulin sensitivity indirectly via the brain, rather 
than directly, in peripheral organs. 
The mice were fed a high-fat diet for 6 weeks to reduce insulin sensitivity before topiramate 
treatment was started, as topiramate exerts its greatest effects in obese, insulin resistent 
subjects (24). The half-life of topiramate in humans is 21 h, whereas the half-life in rodents is only 
1-2 h (25). To obtain stable concentrations of topiramate in plasma of our mice, topiramate was 
mixed through the diet with addition of 3.33% anise to cover bitter taste. The dose of topiramate 
used in the present study resulted in concentrations in plasma within the therapeutic range 
(~4 μg/ml). Hyperinsulinemic-euglycemic clamp analyses revealed that topiramate improved 
insulin sensitivity, in agreement with previous studies. Those studies indicated that topiramate 
improved insulin sensitivity independent of weight loss (16;26;27). In the present study, we 
extend these observations by showing that this insulin-sensitizing effect of topiramate was 
present in cardiac and skeletal muscle, as well as in adipose tissue. In contrast, topiramate did 
not improve hepatic insulin sensitivity. This improved insulin sensitivity in muscle and adipose 
tissue, but not in liver, has previously been associated with enhanced AMPK phosphorylation 
in muscle but not in liver (26). As α-adrenergic stimulation enhances AMPK phosphorylation, 
the increased glucose uptake by peripheral organs might be related to increased sympathetic 
nervous system (SNS) activation (28). Furthermore, the topiramate concentration in plasma 
correlates with that in cerebral spinal fluid (CSF) (29). Moreover, the effects of topiramate on 
body weight, body composition and energy metabolism have been associated with altered 
neuropeptide expression in the hypothalamus (30). Combined with the absence of direct 
effects of topiramate on insulin sensitivity in muscle cells, we therefore hypothesized that the 
brain mediated the effects of topiramate on insulin sensitivity.
The indirect effects of circulating insulin, through the central nervous system, on peripheral 
glucose uptake are blocked by i.c.v. administration of tolbutamide (1;3). Insulin activates ATP-
sensitive potassium channels (K
ATP 
channels) in neurons of the hypothalamus (31;32). I.c.v. 
administration of tolbutamide inhibits activation of these neuronal K
ATP 
channels by insulin 
(1;3). To test our hypothesis that the central nervous system is involved in the anti-diabetic 
effects of topiramate by improving insulin signaling in the brain, we administered tolbutamide 
i.c.v. in topiramate-treated animals during hyperinsulinemic-euglycemic clamp conditions. 
Interestingly, i.c.v. administration of tolbutamide abolished the improvement of insulin 
sensitivity by topiramate during clamp conditions. In other words, the insulin-sensitizing effect 
of topiramate apparently originates from an insulin sensitization effect in the brain. In previous 
studies, we showed that high-fat feeding results in insulin resistance in the brain (1;4). In the 
present study, high-fat feeding resulted in similar central insulin resistance as these previous 
studies, since i.c.v. tolbutamide in vehicle treated animals had no effect on insulin-inhibited 
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glucose production or insulin-stimulated glucose uptake. I.c.v. tolbutamide in topiramate 
treated animals abolished the insulin-sensitizing effect of topiramate, suggesting that the brain 
mediates the effects of topiramate on insulin sensitivity.
Topiramate did not exert any direct effects on basal or insulin-stimulated glucose uptake 
and insulin signaling in insulin-sensitive or insulin-resistant C2C12 myotubes. Our data are in 
contrast to a previous study that reported that topiramate increases glucose uptake in cultured 
insulin-sensitive L6 cells, a rat skeletal muscle cell line, via an AMP-activated protein kinase 
(AMPK)-mediated pathway (33). Treatment of C2C12 myotubes with topiramate did not increase 
phosphorylation level of AMPK (Thr172) (data not shown). Stimulation of a rat insulinoma-
derived INS-1E cell line with topiramate did not affect glucose-stimulated insulin secretion by 
these beta cells (data not shown), in line with a previous study (34). Our data support the notion 
that the effects of topiramate on insulin sensitivity are most likely not the result of direct effects 
on peripheral organs.
In conclusion, topiramate improves insulin sensitivity in high-fat fed mice by stimulating 
glucose uptake by skeletal muscle, heart and adipose tissue through effects within the central 
nervous system. Inhibition of K
ATP
 channel activation in the brain abrogates the insulin-sensitizing 
effect of topiramate in these mice. These observations indicate that the anti-diabetic effects 
of topiramate are the result of action in the brain, rather than direct effects of topiramate on 
peripheral organs. These observations illustrate the possibility of pharmacological treatment of 
peripheral insulin resistance through targets in the central nervous system. 
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a b s t r aC t
Insulin signaling in the central nervous system (CNS) is required for the inhibitory effect of 
insulin on glucose production. Our aim was to determine whether the CNS is also involved in 
the stimulatory effect of circulating insulin on the tissue-specific retention of fatty acid (FA) 
from plasma. In wild-type mice, hyperinsulinemic-euglycemic clamp conditions stimulated the 
retention of both plasma triglyceride-derived FA and plasma albumin-bound FA in the various 
white adipose tissues (WAT), but not in other tissues including brown adipose tissue (BAT). 
Intracerebroventricular (i.c.v.) administration of insulin induced a similar pattern of tissue-
specific FA partitioning. This effect of i.c.v. insulin administration was not associated with 
activation of the insulin signaling pathway in adipose tissue. I.c.v. administration of tolbutamide, 
a K
ATP
 channel blocker, considerably reduced (during hyperinsulinemic-euglycemic clamp 
conditions) and even completely blocked (during i.c.v. administration of insulin) WAT-specific 
retention of FA from plasma. This central effect of insulin was absent in CD36 deficient mice, 
indicating that CD36 is the predominant FA transporter in insulin-stimulated FA retention by 
WAT. In diet-induced insulin resistant mice, these stimulating effects of insulin (circulating or 
i.c.v. administered) on FA retention in WAT were lost. In conclusion, in insulin-sensitive mice, 
circulating insulin stimulates tissue-specific partitioning of plasma-derived FA in WAT in part 
through activation of K
ATP
 channels in the CNS. Apparently, circulating insulin stimulates fatty 
acid uptake in WAT, but not in BAT, directly, and indirectly, through the CNS. 
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I n t r o d u C t I o n
The central nervous system (CNS) is highly sensitive to insulin (1-6). Insulin in the brain is 
mostly derived from the circulation, and only a modest amount, if any, is produced locally 
(6;7). Circulating insulin can cross the blood-brain barrier (8;9) and exert metabolic effects in 
peripheral organs via the CNS. Intracerebroventricular (i.c.v.) administration of insulin decreases 
food intake, resulting in reduced body weight (3;10;11). In addition, the central action of insulin 
plays a crucial role in the inhibitory effect of the hormone on hepatic glucose production (4;12). 
Recently, a novel regulatory function for the effects of insulin through the CNS with regard 
to adipose tissue metabolism has been proposed, suggesting that intracellular lipolysis and 
lipogenesis in WAT is under the neuronal control of central insulin (13;14). Furthermore, it 
has been shown that central glucose lowers plasma triglyceride (TG) levels by inhibiting the 
secretion of TG-rich lipoproteins by the liver (15). Taken together, these observations imply an 
important role of the CNS in general and of central effects of insulin in the CNS in particular in 
the regulation of whole body TG metabolism. 
The aim of the present study was to determine whether circulating insulin affects tissue-
specific fatty acid (FA) partitioning from plasma through effects in the CNS. Using a dual 
tracer method, we report here that circulating insulin stimulates the uptake of TG-derived FA 
as well as albumin-bound FA specifically in WAT during hyperinsulinemic-euglycemic clamp 
conditions. Short-term (2.5 h) i.c.v. administration of insulin stimulates the retention of FA 
in WAT in a similar fashion. This effect, which requires the presence of the long chain FA 
transporter CD36, was prevented by inhibition of central adenosine triphosphate-dependent 
potassium (K
ATP
) channels. Moreover, we show that the increase in FA retention in WAT, 
induced by hyperinsulinemic-euglycemic clamp conditions, is considerably reduced by 
inhibition of K
ATP
 channels in the CNS, demonstrating that the well-known effect of circulating 
insulin on insulin-mediated FA retention in WAT is mediated to a considerable extent by the 
effects of circulating insulin in the CNS. Finally, we show that these stimulating effects of 
insulin on FA retention through the CNS in WAT are lost in diet-induced obese mice.
M at e r I a l s  a n d  M e t h o d s
animals
Male wild-type (WT) and CD36-/- mice (15 weeks old, both on C57Bl/6J background) were 
housed in a temperature-controlled room on a 12-hour light-dark cycle and were fed a standard 
mouse chow diet with free access to water. In the diet-induced obesity experiment, mice were 
fed ad libitum high-fat diet for 12 weeks (45 energy% of fat derived from palm oil; Research Diet 
Services BV, Wijk bij Duurstede, The Netherlands). All animal experiments were performed in 
accordance with the regulations of Dutch law on animal welfare and the institutional ethics 
committee for animal procedures from the Leiden University Medical Center, Leiden, The 




For i.c.v. cannula implantation, the mice were anaesthetized with 0.5 mg/kg Medetomidine 
(Pfizer, Capelle a/d IJssel, The Netherlands), 5 mg/kg Midazolam (Roche, Mijdrecht, The 
Netherlands) and 0.05 mg/kg Fentanyl (Janssen-Cilag, Tilburg, The Netherlands) and placed 
in a stereotactic device (TSE systems, Homburg, Germany). A 25 gauge guide cannula 
was implanted into the left lateral ventricle using the following coordinates from Bregma: 
1.0 mm lateral, 0.46 mm posterior and 2.2 mm ventral. The guide cannula was secured to the 
skull surface with dental cement (GC Europe N.V., Leuven, Belgium) and the anesthesia was 
antagonized using 2.5 mg/kg Antipamezol (Pfizer, Capelle a/d IJssel, The Netherlands), 0.5 mg/
kg Flumazenil (Roche, Mijdrecht, The Netherlands) and 1.2 mg/kg Naloxon (Orpha, Purkersdorf, 
Austria). After a recovery period of 1 week, cannula placement was verified. Mice that ate >0.3 g 
in 1 h in response to i.c.v. injection of 5 μg neuropeptide Y (NPY, Bachem, St. Helens, UK) in 1 μL 
of artificial cerebrospinal fluid (aCSF) (Harvard Apparatus, Natick, MA, US) were considered to 
have the cannula correctly placed and were included in the study (16). 
Preparation of radiolabeled emulsion particles
Protein-free VLDL-like triglyceride (TG)-rich emulsion particles were prepared from 100 mg 
total lipid at a weight ratio of triolein (Sigma, St. Louis, MA, US): egg yolk phosphatidylcholine 
(Lipoid, Ludwigshafen, Germany): lysophosphatidylcholine (Sigma, St. Louis, MA, US): 
cholesteryl oleate (Janssen, Beersse, Belgium): cholesterol (Sigma, St. Louis, MA, US) of 70: 22.7: 
2.3: 3.0: 2.0 in the presence of 200 μCi of glycerol tri[9, 10(n)-3H]oleate ([3H]TG) (GE Healthcare, 
Little Chalfont, UK), as previously described (17). Lipids were hydrated in 10 mL of 2.4 M sodium 
chloride, 10 mM Hepes, 1 mM ethylenediaminetetraacetic acid (EDTA), pH 7.4, and sonicated 
for 30 min at 10 μm output using a Soniprep 150 (MSE Scientific Instruments, UK) equipped 
with a water bath for temperature (54°C) maintenance. Subsequently, the emulsion particles 
were divided into fractions with a different average size by density gradient ultracentrifugation. 
Intermediate sized (80 nm) [3H]TG-labeled particles were mixed with a trace amount of [14C]
oleic acid ([14C]FA) (GE Healthcare, Little Chalfont, UK) complexed with bovine serum albumin 
(BSA) in a 3H:14C ratio of 3:1.
tissue-specific tG and fa partitioning
Postabsorptive (mice were fasted for 15 h with food withdrawn at 18:00h the day prior to the 
study), body weight-matched male mice were anaesthetized with 6.25 mg/kg Acepromazine 
(Alfasan, Woerden, The Netherlands), 6.25 mg/kg Midazolam (Roche, Mijdrecht, The 
Netherlands), and 0.31 mg/kg Fentanyl (Janssen-Cilag, Tilburg, The Netherlands). In the 
hyperinsulinemic-euglycemic clamp studies, insulin (Actrapid, Novo Nordisk, Bagsværd, 
Denmark) was administered intravenously (i.v.) by primed (4.5 mU), continuous (6.8 mU/h 
for 2.5 h) infusion to attain steady-state circulating insulin levels of ~ 4 ng/mL (16;18;19). A 
variable intravenous infusion of a 12.5% D-glucose solution was used to maintain euglycemia 
as determined at 10-min intervals via tail bleeding (<3 μL, Accu-chek, Sensor Comfort; Roche 
Diagnostics, Mannheim, Germany). Insulin (0.5 mU/h) (Actrapid, Novo Nordisk, Bagsværd, 
Denmark) or the K
ATP
 channel blocker tolbutamide (12 nmol/h, (4;20) (Sigma, St. Louis, MA, US) 
dissolved in aCSF was infused i.c.v. at a constant rate of 2.5 μL/h during the entire experiment 
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using a Harvard infusion pump. The dose of i.c.v. insulin was ascertained in a dose-finding study, 
to ensure that plasma insulin and glucose levels did not change. Control animals received 5% 
DMSO in aCSF. Thirty minutes after the start of the i.c.v. infusions or thirty minutes after the 
start of the hyperinsulinemic-euglycemic clamp experiments (as indicated), an i.v. infusion 
of the glycerol tri[3H]oleate-labeled emulsion particles (0.33 nmol/h) together with albumin-
bound [14C]oleic acid (10.22 nmol/h) was started at a rate of 100 μL/h and maintained for 2 h. 
Blood samples were taken at baseline and 2 h after starting the i.v. infusion. Subsequently, the 
mice were sacrificed and organs were quickly harvested and snap-frozen in liquid nitrogen. 
Plasma analysis
Blood samples were taken from the tail tip into chilled capillaries coated with paraoxon to 
prevent ex vivo lipolysis. The tubes were placed on ice and centrifuged at 4°C. Plasma levels 
of TG, free fatty acids (FFA) and glucose were determined using commercially available kits 
and standards according to the instructions of the manufacturer (Instruchemie, Delfzijl, The 
Netherlands) in 96-wells plates (Greiner Bio-One, Alphen a/d Rijn, The Netherlands). Plasma 
insulin levels were measured using a mouse-specific insulin ELISA kit (Mercodia AB, Uppsala, 
Sweden) and plasma leptin levels using a rat/mouse-specific ELISA kit (Millipore, St Charles, 
USA). Lipids were extracted from plasma according to Bligh and Dyer (21). The lipid fraction 
was dried under nitrogen, dissolved into chloroform/methanol (5:1 [v/v]) and subjected to thin 
layer chromatography (TLC) (LK5D gel 150; Whatman, US) using hexane: diethylether: acetic 
acid (83:16:1) [v/v/v]) as mobile phase. Standards for TG and FA were included during the TLC 
procedure to locate spots of these lipids. Spots were scraped, lipids dissolved in hexane and 
radioactivity measured (22). 
tissue-specific fa retention analysis 
Tissues were dissolved in 5 M potassium hydroxide in 50% (v/v) ethanol. After overnight 
saponification, protein content was determined in the various organs using a bicinchoninic 
acid (BCA) protein assay kit (BCA Protein Assay Kit, Thermo Scientific Pierce Protein Research 
Products, Rockford, US). Retention of radioactivity in the saponified tissues was measured per 
mg protein and corrected for the corresponding plasma specific activities of [3H]TG and [14C]
FA (23;24). 
western blot analysis
Tissues were homogenized by Ultra-Turrax (22.000 rpm; 2x5 sec) in a 10:1 (v/w) ratio of ice-
cold buffer containing: 50 mM 4-(2-hydroxyethyl)-1-piperazineethanesulfonic acid (pH  7.6), 
50  mM sodium fluoride, 50 mM potassium chloride, 5 mM sodium pyrophosphate, 1  mM 
EDTA, 1 mM ethylene glycol tetraacetic acid, 5 mM β-glycerophosphate, 1 mM sodium 
vanadate, 1 mM dithiothreitol, 1% nonyl phenoxypolyethoxylethanol (Tergitol-type NP40) and 
protease inhibitors cocktail (Complete, Roche, Mijdrecht, The Netherlands). Homogenates 
were centrifuged (13.200 rpm; 15 min, 4°C) and the protein content of the supernatant was 
determined using the BCA protein assay kit. Proteins (10-30 μg) were separated by 7-10% SDS-
PAGE followed by transfer to a polyvinylidene fluoride transfer membrane. Membranes were 
blocked for 1 h at room temperature in tris-buffered saline tween-20 buffer with 5% non-fat dry 
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milk followed by an overnight incubation with phospho-specific or total antibodies (all from 
Cell Signaling Technology, Beverly, US). Blots were then incubated with horseradish peroxidase-
conjugated secondary antibodies for 1 h at room temperature. Bands were visualized by ECL 
and quantified using Image J (NIH, US).
statistical analysis
All data are presented as means ± SEM. Most data were analyzed using SPSS. A Kruskall-
Wallis test for several independent samples was used, followed by a Mann-Whitney test for 
independent samples. P-values less than 0.05 were considered statistically significant.
r e s u lt s
I.v. administration of insulin increases the retention of plasma 
tG-derived and albumin-bound fa by wat 
To establish to which extent tissue-specific FA uptake from plasma is stimulated by circulating 
insulin, we compared in various organs the retention of FA derived from both glycerol tri[3H]oleate-
labeled VLDL-like emulsion particles and albumin-bound [14C]oleic acid between mice during 
hyperinsulinemic-euglycemic clamp conditions and mice in basal conditions infused with vehicle 
(Fig. 1A). During the clamp study, insulin levels were significantly higher as compared to basal 
conditions (4.4 vs. 0.3 ng/mL, P < 0.01), whereas average plasma glucose levels remained similar (6.1 
vs. 5.4 mmol/L, ns). Plasma TG levels were similar (0.3 vs. 0.4 mmol/L, ns), whereas plasma free fatty 
acids (FFA) levels decreased upon insulin administration (0.3 vs. 0.7 mmol/L, P < 0.05). 
As shown in Fig. 1, hyperinsulinemia decreased the retention of plasma TG-derived FA and 
albumin-bound FA in liver (Fig. 1C), without affecting the retention in brown adipose tissue 
(Fig. 1B), heart (Fig. 1D) and skeletal muscle (Fig. 1E). Moreover, hyperinsulinemic-euglycemic 
clamp conditions increased albumin-bound FA retention by 68%, (P < 0.05) in visceral fat and TG-
derived FA and albumin-bound FA retention by 397% (P < 0.05) and 579% (P < 0.01), respectively, 
in subcutaneous fat and by 68% (ns) and 267% (P < 0.01), respectively, in epigonadal fat pads 
(Fig. 1F-H). 
I.c.v. administration of insulin increases the retention of plasma 
tG-derived and albumin-bound fa by wat
Subsequently, the dual-tracer method was used to determine tissue-specific FA retention after 
i.c.v. administration of insulin (0.5 mU/h for 2.5 h) (Fig. 2A). Although i.c.v. insulin administration 
did not alter circulating levels of glucose, TG, FFA, insulin and leptin, it decreased the plasma 
half-life of [3H]TG by 34% (P < 0.05) (Table 1). Central insulin administration did not affect the 
retention of TG-derived FA and albumin-bound FA in brown adipose tissue, liver, heart and 
skeletal muscles (Fig. 2B-E). In contrast, i.c.v. insulin administration significantly increased FA 
retention in the different WAT compartments (Fig. 2F-H): i.c.v. insulin increased the retention 
of TG-derived FA and albumin-bound FA by 145% (P = 0.07) and 71% (P < 0.05) in visceral fat, by 
72% (P = 0.06) and 111% (P < 0.05) in subcutaneous fat, and by 58% (P < 0.05) and 70% (P < 0.05) 
in epigonadal fat, respectively. 
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Fig. 1. Circulating insulin stimulates FA retention by WAT, while decreasing FA retention by liver. Postabsorptive, 
body weight-matched WT mice received continuous i.v. infusion of vehicle (white bars) or insulin/glucose 
(hyperinsulinemic-euglycemic clamp study, black bars) (A). Infusion of glycerol tri[3H]oleate within VLDL-like 
emulsion particles and albumin-bound [14C]oleic acid was started 30 minutes after the start of i.v. infusion of 
vehicle or glucose/insulin and maintained for 2 h. Subsequently, the mice were sacrificed and the retention of 
TG-derived FA and albumin-bound FA was determined in brown fat (B), liver (C), heart (D), skeletal muscle (E), 
visceral fat (F), subcutaneous fat (G) and epigonadal fat (H). Values are means ± SEM for at least 5 mice per group. 
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Fig. 2. I.c.v. insulin administration stimulates FA retention by WAT. Postabsorptive, body weight-matched WT 
mice received continuous i.c.v. infusion of vehicle (white bars) or insulin (black bars, 0.5 mU/h) (A). Thirty 
minutes after starting the i.c.v. infusion, the mice were infused for 2 h with glycerol tri[3H]oleate within VLDL-like 
emulsion particles and albumin-bound [14C]oleic acid. Subsequently, the mice were sacrificed and the retention 
of TG-derived FA and albumin-bound FA was determined in brown fat (B), liver (C), heart (D), skeletal muscle (E), 
visceral fat (F), subcutaneous fat (G) and epigonadal fat (H). Values are means ± SEM for at least 7 mice per group. 
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the effect of i.c.v. insulin administration on fa retention in wat 
is independent of modulation of insulin, leptin or caMP-depend-
ent signaling pathways in wat
To investigate the molecular mechanism(s) underlying the i.c.v. insulin-induced FA retention 
in WAT, we studied various signaling pathways involved in the regulation of FA metabolism in 
both epigonadal and visceral fat. In agreement with the absence of any effect on plasma insulin 
levels (Table 1), i.c.v. insulin administration did not affect peripheral insulin signaling pathways, 
as phosphorylation of PKB on Ser473 and Thr308 was not increased in WAT (Fig. 3A-D), nor of 
FOXO1 on Ser256 (data not shown). In addition, i.c.v. insulin administration did not induce any 
changes in STAT3 Tyr705 or CREB Ser133 phosphorylation in WAT, indicating that neither leptin 
nor PKA signaling pathways are modified by i.c.v. insulin administration.
the effect of i.c.v. insulin administration on fa retention by wat 
is dependent on the activation of central k
ATP
 channels
Part of the central effects of insulin on the regulation of food intake and hepatic glucose 
production are dependent on activation of hypothalamic K
ATP
 channels (25). Therefore, we 
investigated whether the stimulatory effect of i.c.v. insulin administration on FA retention in WAT 
could be blocked by i.c.v. co-administration of the K
ATP
 channel blocker tolbutamide (Fig. 4A). 
I.c.v. administration of insulin (0.5 mU/h) did not affect plasma levels of glucose, TG, FFA and 
insulin, irrespective of co-administration of tolbutamide (12 nmol/h) (Table 2). In accordance 
with the previous experiments, the plasma half-life of [3H]TG decreased by 29%, (P < 0.05) 
upon i.c.v. insulin administration compared to vehicle. However i.c.v. insulin, administered 
concurrently with i.c.v. tolbutamide, did not alter plasma TG and FA kinetics. I.c.v. administration 
of tolbutamide alone did not affect tissue-specific FA partitioning. Comparable to the previous 
study, FA retention in liver, heart and skeletal muscles was unaltered upon i.c.v. insulin 
administration and remained unaltered upon co-administration of tolbutamide (Fig.  4B-D). 
Table 1. I.c.v. insulin administration does not affect plasma parameters, except for [3H]TG half-life. Plasma pa-
rameters of mice that received i.c.v. infusion of vehicle or insulin obtained at baseline and 2 h after starting an i.v. 
infusion of glycerol tri[3H]oleate-labeled VLDL-like emulsion particles and albumin-bound [14C]oleic acid. Values 
are means ± SEM for at least 9 mice per group. TG, triglycerides; (F)FA, (free) fatty acids. * P < 0.05 vs. vehicle. 
Baseline 2 hours
I.c.v. vehicle I.c.v. insulin I.c.v. vehicle I.c.v. insulin
Glucose (mmol/L) 4.9 ± 0.2 5.5 ± 0.3 4.7 ± 0.2 4.8 ± 0.4
TG (mmol/L) 0.4 ± 0.1 0.3 ± 0.1 0.4 ± 0.1 0.4 ± 0.1
FFA (mmol/L) 0.7 ± 0.1 0.6 ± 0.1 0.7 ± 0.1 0.7 ± 0.1
Insulin (ng/mL) 0.4 ± 0.1 0.4 ± 0.1 0.4 ± 0.1 0.4 ± 0.1
Leptin (ng/mL) 1.0 ± 0.1 1.3 ± 0.4 1.3 ± 0.1 1.4 ± 0.3
Half-life [14C]FA (min) - - 0.6 ± 0.2 0.6 ± 0.1
Half-life [3H]TG (min) - - 3.5 ± 0.1  2.3 ± 0.1 *
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Fig. 3. I.c.v. insulin administration does not affect insulin, leptin and cAMP signaling pathways in WAT. The 
phosphorylation state of PKB, STAT3 and CREB was analyzed by western blot in both epigonadal fat (A) and visceral 
fat (B) from mice that received i.c.v. infusion of vehicle or insulin for 2.5 h. The corresponding quantification of 
the western blot data was normalized for total protein or actin and expressed as fold change compared to vehicle 
(C-D). Values represent means ± SEM for at least 5 mice per group. 
Table 2. I.c.v. tolbutamide administration does not affect plasma parameters. Plasma parameters of mice that 
received i.c.v. infusion of vehicle or tolbutamide at baseline or hyperinsulinemic conditions. Values are means 









6.4 ± 0.3 6.7 ± 0.1 6.1 ± 0.8 7.0 ± 0.7 5.5 ± 0.3 5.5 ± 0.1 5.6 ± 1.1 5.7 ± 1.6
TG 
(mmol/L)
0.7 ± 0.1 0.6 ± 0.1 0.7 ± 0.1 0.7 ± 0.1 0.7 ± 0.1 0.7 ± 0.1 0.7 ± 0.1 0.7 ± 0.1
FFA 
(mmol/L)
1.2 ± 0.1 1.1 ± 0.1 1.0 ± 0.1 1.0 ± 0.1 1.0 ± 0.1 1.0 ± 0.1 1.0 ± 0.1 0.8 ± 0.1
Insulin 
(ng/mL)








- - - - 2.8 ± 0.5 2.0 ± 0.2* 2.7 ± 0.3 2.8 ± 0.1
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Fig. 4. I.c.v. co-administration of the K
ATP
 channel blocker tolbutamide blocks the stimulation of FA retention in 
WAT by i.c.v. insulin. Postabsorptive, body weight-matched WT mice received continuous i.c.v. infusion of vehicle 
(white bars), tolbutamide (cross-hatched bars, 12 nmol/h), insulin (black bars) or insulin in combination with 
tolbutamide (hatched bars) (A). Thirty minutes after starting the i.c.v. infusion, the mice were infused for 2 h with 
glycerol tri[3H]oleate within VLDL-like emulsion particles and albumin-bound [14C]oleic acid. Subsequently, the 
mice were sacrificed and the retention of TG-derived FA and albumin-bound FA was determined in liver (B), heart 
(C), skeletal muscle (D), visceral fat (E), subcutaneous fat (F) and epigonadal fat (G). Values are means ± SEM for 







Interestingly, tolbutamide completely blocked the stimulation of both plasma TG-derived FA 
and albumin-bound FA retention in WAT induced by i.c.v. insulin administration (Fig. 4E-G).
the effect of circulating insulin on fa retention by wat is 
mediated through k
ATP
 channel activation in the Cns
In order to investigate the contribution of the CNS to the effect of circulating insulin on 
FA retention in WAT, we examined whether i.c.v. administration of the K
ATP
 channel blocker 
tolbutamide inhibits the insulin-stimulated FA retention in WAT during hyperinsulinemic-
euglycemic clamp conditions (Fig. 5A). In steady-state clamp conditions, plasma glucose, TG 
and insulin concentrations were similar in both groups, as shown in Table 2. Hyperinsulinemia 
suppressed FFA levels to a similar extent in i.c.v. tolbutamide- and i.c.v. vehicle-infused mice. The 
glucose infusion rates required to maintain euglycemia, however, were 22% lower in mice that 
received i.c.v. tolbutamide compared to i.c.v. vehicle (P < 0.05). This is consistent with previous 
findings showing that i.c.v. administration of the K
ATP
 channel blocker tolbutamide impair the 
inhibition of hepatic glucose production in response to hyperinsulinemia (4;26). The plasma 
half-life of [3H]TG decreased by 60% (P < 0.05) during hyperinsulinemic conditions, but was 
partly restored by i.c.v. tolbutamide (Table 3). FA retention in liver, heart and skeletal muscles 
was unaffected by i.c.v. tolbutamide (Fig. 5B-D). Remarkably, i.c.v. tolbutamide considerably 
decreased the stimulatory effect of circulating insulin during clamp conditions on FA retention 
in WAT (Fig. 5E-G).
the effect of i.c.v. insulin administration on fa retention in wat 
requires the presence of Cd36
As CD36 is one of the main long-chain FA transporters and insulin can upregulate translocation 
and protein expression of CD36 (27;28), we studied to which extent CD36 is involved in the i.c.v. 
insulin-stimulated FA retention by WAT. Therefore, we investigated the effects of i.c.v. insulin 
Table 3. I.c.v. administration of tolbutamide decreases glucose infusion rate during hyperinsulinemic-eugly-
cemic clamp conditions. Plasma parameters of mice that received i.c.v. infusion of vehicle or tolbutamide at 
baseline and during hyperinsulinemic conditions. Values are means ± SEM for at least 9 mice per group. TG, 










Glucose (mmol/L) 7.3 ± 1.3 7.3 ± 1.0 6.1 ± 0.4 6.7 ± 1.3
TG (mmol/L) 0.4 ± 0.1 0.4 ± 0.1 0.3 ± 0.1 0.3 ± 0.1
FFA (mmol/L) 0.9 ± 0.1 0.8 ± 0.1 0.3 ± 0.1 0.3 ± 0.1
Insulin (ng/mL) 0.3 ± 0.1 0.2 ± 0.1 4.4 ± 1.5 4.1 ± 0.8
GIR (umol/min/kg) - - 114 ± 5.7 89 ± 3.2 *
Hematocrit (%) 43 ± 2 42 ± 2 42 ± 2 41 ± 2
Half-life [14C]FA (min) - - 0.5 ± 0.1 0.7 ± 0.1
Half-life [3H]TG (min) - - 1.4 ± 0.1 1.7 ± 0.1
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Fig. 5. I.c.v. administration of tolbutamide impairs the stimulation of FA retention in WAT induced by 
hyperinsulinemic-euglycemic clamp conditions. Postabsorptive, body weight-matched mice received 
continuous i.c.v. infusion of vehicle (black bars) or tolbutamide (12 nmol/h, hatched bars) 30 minutes before the 
start of hyperinsulinemic-euglycemic clamp study (A). Infusion of glycerol tri[3H]oleate within VLDL-like emulsion 
particles and albumin-bound [14C]oleic acid was started 30 minutes after the start of the hyperinsulinemic-
euglycemic clamp study and maintained for 2 h. Subsequently, the mice were sacrificed and the retention of 
TG-derived FA and albumin-bound FA was determined in liver (B), heart (C), skeletal muscle (D), visceral fat (E), 
subcutaneous fat (F) and epigonadal fat (G). Values are means ± SEM for at least 5 mice per group. * P < 0.05 vs. 
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on tissue-specific FA retention in CD36-/- vs. WT mice (Fig. 6)A. In accordance with previous 
observations (29), basal plasma TG and FFA levels were increased in CD36-/- mice compared to 
WT mice by 28% and 26%, respectively (P < 0.05), but they remained unaltered, as did circulating 
glucose and insulin levels, following i.c.v. administration of insulin (data not shown). I.c.v. 
insulin decreased the half-lives of plasma [3H]TG and [14C]FA in WT mice, but not in CD36-/- mice 
(data not shown). Again, we confirmed in WT mice that i.c.v. insulin stimulated the retention of 
TG-derived FA and albumin-bound FA by 100% (P < 0.05) and 107% (P < 0.05) in visceral fat, by 
53% (P = 0.09) and 85% (P < 0.05) in subcutaneous fat and by 77% (P = 0.06) and 104% (P < 0.05) 
in epigonadal fat pads, respectively. In basal conditions, i.e. i.c.v. administration of vehicle, the 
retention of both FA by WAT was dramatically decreased in CD36-/- mice compared to wild-type 
mice (Fig. 6B-D). More importantly, i.c.v. insulin administration did not stimulate FA retention 
from plasma by WAT in CD36-/- mice. I.c.v. insulin administration did not affect FA retention 
in other organs of CD36-/- mice, in accordance with the observations made in WT mice (see 
above). Since i.c.v. insulin administration was unable to stimulate FA retention by WAT in CD36-/- 
mice, these data suggest that CD36 is the predominant FA transporter mediating i.c.v. insulin-
stimulated FA retention by WAT. 
the effect of i.c.v. insulin on fa retention in wat is lost in diet-
induced obesity
Subsequently, we examined the effect of i.c.v. insulin administration on FA retention in high-fat 
fed mice (Fig. 7A). Body weight of the diet-induced obese mice was 40% higher compared to 
chow fed mice (P < 0.01). I.c.v. insulin administration did not alter glucose, TG, FFA and insulin 
levels (Table 4). In contrast to chow fed mice, i.c.v. administration of insulin did not decrease 
the plasma half-life of [3H]TG in these diet-induced obese mice. I.c.v. insulin administration 
did not alter FA retention in liver, heart or skeletal muscles, but surprisingly also not in WAT 
(Fig. 7B-G). 
Table 4. I.c.v. insulin administration in diet-induced obese mice does not affect plasma parameters. Parameters 
of diet-induced obese mice that received i.c.v. infusion of vehicle or insulin obtained at baseline and 2 h after 
starting an i.v. infusion of glycerol tri[3H]oleate-labeled VLDL-like emulsion particles and albumin-bound [14C]
oleic acid. Values are means ± SEM for at least 9 mice per group. TG, triglycerides; (F)FA, (free) fatty acids. 
Baseline 2 hours
I.c.v. vehicle I.c.v. insulin I.c.v. vehicle I.c.v. insulin
Bodyweight (g) 32.5 ± 0.6 32.0 ± 0.4 32.5 ± 0.6 32.0 ± 0.4
Glucose (mmol/L) 7.7 ± 0.3 7.7 ± 0.2 6.0 ± 0.3 5.6 ± 0.2
TG (mmol/L) 1.0 ± 0.1 0.9 ± 0.1 1.0 ± 0.1 1.0 ± 0.1
FFA (mmol/L) 0.9 ± 0.1 0.8 ± 0.1 0.8 ± 0.1 0.8 ± 0.1
Insulin (ng/mL) 3.8 ± 0.3 4.0 ± 0.4 4.0 ± 0.4 3.8 ± 0.3
Half-life [14C]FA (min) - - 1.1 ± 0.1 1.2 ± 0.1
Half-life [3H]TG (min) - - 9.2 ± 1.1 9.4 ± 1.6
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FIG. 6
Fig. 6. The stimulation of FA 
retention in WAT by i.c.v. insulin 
administration is abrogated in CD36-
deficient mice. Postabsorptive, 
body weight-matched WT and 
CD36-deficient mice received 
continuous i.c.v. infusion of vehicle 
(white and hatched bars) or insulin 
(black and cross-hatched bars) 
(A). Thirty minutes after starting 
the i.c.v. infusion, the mice were 
infused for 2 h with glycerol tri[3H]
oleate within VLDL-like emulsion 
particles and albumin-bound [14C]
oleic acid. Subsequently, the mice 
were sacrificed and the retention of 
TG-derived FA and albumin-bound 
FA was determined in visceral 
fat (B), subcutaneous fat (C) and 
epigonadal fat (D). Values are means 
± SEM for at least 6 mice per group. 
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FIG. 7
Fig. 7. I.c.v. insulin administration in diet-induced obese mice does not stimulate FA retention by WAT. 
Postabsorptive, body weight-matched WT mice received continuous i.c.v. infusion of vehicle (white bars) or 
insulin (black bars, 0.5 mU/h) (A). Thirty minutes after starting the i.c.v. infusion, the mice were infused for 2 h 
with glycerol tri[3H]oleate within VLDL-like emulsion particles and albumin-bound [14C]oleic acid. Subsequently, 
the mice were sacrificed and the retention of TG-derived FA and albumin-bound FA was determined in liver (B), 
heart (C), skeletal muscle (D), visceral fat (E), subcutaneous fat (F) and epigonadal fat (G). Values are means ± SEM 
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k
ATP
 channel blockage does not affect circulating insulin-stimu-
lated fa retention by wat in diet-induced obese mice
Finally, we examined whether i.c.v. administration of the K
ATP
 channel blocker tolbutamide 
would still inhibit the insulin-stimulated FA retention in WAT during hyperinsulinemic-
euglycemic clamp conditions in high-fat fed mice (Fig. 8A). Therefore, we determined FA 
retention between mice during hyperinsulinemic-euglycemic clamp conditions infused 
i.c.v. either with tolbutamide or vehicle and mice in basal conditions infused i.c.v. with 
vehicle. Body weight of the high-fat fed mice was 65% higher compared to chow fed 
mice (P < 0.01). In steady-state clamp conditions, plasma glucose and TG concentrations 
were similar between tolbutamide- and vehicle-treated mice, as shown in Table 5. During 
hyperinsulinemic-euglycemic clamp conditions, circulating insulin levels were fourfold 
higher in both groups as compared to basal conditions, resulting in a decrease of ~50% 
in FFA levels. The rate of glucose infusion necessary to maintain euglycemia, was not 
different between tolbutamide- and vehicle-treated animals. The plasma half-life of [3H]
TG was similar in basal conditions as in hyperinsulinemic conditions, irrespective of i.c.v. 
tolbutamide administration. Similar to chow fed mice, hyperinsulinemia decreased the 
retention of plasma TG-derived FA and albumin-bound FA in liver, which was unaltered by 
i.c.v. tolbutamide administration (Fig. 8B). FA retention in liver, heart en skeletal muscles 
was similar in all groups (Fig. 8B-D). Unlike in chow fed mice, hyperinsulinemia did not 
stimulate FA retention in WAT and i.c.v. tolbutamide did not decrease FA retention in WAT 
(Fig. 8E-G). 
Table 5. I.c.v. administration of tolbutamide in diet-induced obese mice during hyperinsulinemic-euglycemic 
clamp conditions does not affect plasma parameters. Parameters of diet-induced obese mice that received 
i.c.v. infusion of vehicle or tolbutamide at baseline and during basal infusions or hyperinsulinemic conditions. 
Values are means ± SEM for at least 5 mice per group. TG, triglycerides; (F)FA, (free) fatty acids; GIR, glucose 
infusion rate.











Body mass (g) 38.6 ± 0.8 38.6 ± 0.4 38.6 ± 0.8 39.6 ± 0.3 38.6 ± 0.4
Glucose (mmol/L) 6.6 ± 0.2 6.0 ± 0.2 5.7 ± 0.2 7.0 ± 0.2 7.5 ± 0.2
TG (mmol/L) 0.8 ± 0.1 0.7 ± 0.1 0.7 ± 0.1 0.7 ± 0.1 0.6 ± 0.1
FFA (mmol/L) 0.9 ± 0.1 0.8 ± 0.1 0.9 ± 0.1 0.5 ± 0.1 0.4 ± 0.1
Insulin (ng/mL) 1.8 ± 0.3 1.4 ± 0.2 2.2 ± 0.3 7.7 ± 0.4 6.9 ± 0.1
GIR (umol/min/kg) - - - 52.4 ± 1.5 53.3 ± 2.7
Hematocrit (%) 44± 2 44 ± 1 42 ± 2 41 ± 2 41 ± 2
Half-life [14C]FA (min) - - 1.2 ± 0.1 1.5 ± 0.2 1.2 ± 0.1
Half-life [3H]TG (min) - - 14.6 ± 1.5 16.1 ± 0.5 17.0 ± 1.2
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Fig. 8. I.v. insulin administration in diet-induced obese mice does not stimulate FA retention by WAT. 
Postabsorptive, body weight-matched mice received continuous i.c.v. infusion of vehicle (white and black bars) 
or tolbutamide (12 nmol/h, hatched bars) in basal state (i.v. infusion of vehicle; white bars) or hyperinsulinemic-
euglycemic state (black and hatched bars) (A). Infusion of glycerol tri[3H]oleate within VLDL-like emulsion 
particles and albumin-bound [14C]oleic acid was started 30 minutes after initiating the i.v. infusion of vehicle or 
insulin/glucose, and maintained for 2 h. Subsequently, the mice were sacrificed and the retention of TG-derived 
FA and albumin-bound FA was determined in liver (B), heart (C), skeletal muscle (D), visceral fat (E), subcutaneous 






























































I.c.v. tolbutamide + 
i.v. insulin
I.c.v. vehicle + 
i.v. insulin
0 min 30 60 90 120 150
I.c.v. vehicle or tolbutamide
I.v. vehicle or insulin
I.v. vehicle or glucose










InsulIn stIMulates fa retentIon In wat vIa Cns
d I s C u s s I o n
This study addressed the effects of circulating insulin on tissue-specific TG-derived FA and 
albumin-bound FA retention, and the role of central insulin action in these effects. Circulating 
insulin, which activated insulin signaling in the brain, stimulated retention of both TG-derived 
FA and albumin-bound FA in WAT. Centrally administered insulin stimulated retention of both 
FA sources in a similar manner, but without activating insulin signaling in WAT. Tolbutamide, 
a K
ATP
 channel blocker, decreased this insulin-stimulated FA partitioning to WAT during 
peripheral insulin infusion, and even abolished this effect during i.c.v. co-administration with 
insulin. Taken together, we show that the central effects of circulating insulin contribute on 
average ~30% to TG-derived FA uptake in WAT and ~66% to albumin-derived FA uptake in WAT 
to the total effects of circulating insulin during hyperinsulinemic clamp conditions. In contrast, 
in diet-induced obese mice, centrally administered insulin was unable to stimulate FA retention 
in WAT. Furthermore, inhibition of central action of i.c.v. administered insulin or circulating 
insulin by tolbutamide did not affect FA retention in WAT. Collectively, these data indicate 
that circulating insulin stimulates FA partitioning from plasma to WAT to a considerable extent 
through indirect effects on central neural pathways and that insulin-stimulated FA partitioning 
through these central neural pathways is absent in mice with insulin resistance after 12 weeks 
of high-fat feeding.
First, we determined tissue-specific FA uptake during hyperinsulinemic-euglycemic clamp 
conditions compared to basal conditions. In agreement with the rise in plasma insulin levels, 
hypothalamic insulin signaling was activated during hyperinsulinemic-euglycemic clamp 
conditions as phosphorylation of PKB on Thr308 (1.24 ± 0.05 vs. 1.00 ± 0.10, P = 0.08) and its 
downstream target PRAS40 on Thr246 (1.51 ± 0.11 vs. 1.00 ± 0.06, P < 0.05) were increased 
compared to basal conditions (unpublished data). We observed that peripheral as well as i.c.v. 
insulin administration promotes FA storage specifically in WAT. By employing the dual tracer 
methods described by Teusink et al. (23), we made a distinction between FA derived from 
plasma TG and FA derived from plasma albumin. Both peripheral and i.c.v. administration of 
insulin stimulated the retention of both sources of plasma FA in WAT. This insulin-stimulated FA 
retention by WAT was accompanied by a decreased half-life of TG, reflecting increased turnover 
of plasma TG. Interestingly, these acute effects of i.c.v. insulin administration on plasma TG 
and FA fluxes towards WAT, together with recent data showing that brain insulin suppresses 
intracellular lipolysis and stimulates lipogenesis in adipocytes (14), provide an explanation for 
the finding that chronic i.c.v. insulin administration increases fat mass (13). 
In addition to stimulating FA retention by WAT, peripheral insulin infusion decreased FA 
storage by the liver. However, i.c.v. administration of insulin or blockage of central K
ATP
 channels 
did not affect FA retention by the liver. This suggests that the effect of peripheral insulin on liver 
FA retention is not mediated by the CNS, but, rather, seems to be a direct effect on the liver 
caused by an associated reduction in the availability of plasma FFA. 
Recently, Bartelt et al. described the fundamental role of BAT for TG and FA clearance (30). 
Exposure of mice to cold accelerated TG uptake by BAT, in a lipoprotein lipase (LPL) and CD36-
dependent manner. In the current study, we have also determined the effects of insulin on 
FA retention by BAT. However, peripheral nor central insulin administration increased FA 
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retention by BAT, indicating that insulin, in contrast to cold exposure, is not a major stimulator 
of TG and FA uptake by BAT.
The question arises how insulin exerts its indirect effects through the central nervous system 
on FA uptake in WAT. We used an i.c.v. dose of insulin, ascertained in a dose-finding study, which 
did not affect plasma insulin and glucose levels. Nonetheless, this i.c.v. dose of insulin stimulated 
FA uptake by WAT. Therefore, the stimulatory effect of i.c.v. insulin on retention of FA by WAT is 
not caused by i.c.v. insulin-induced changes in plasma levels of glucose and insulin. We cannot 
exclude the possibility of other neuroendocrine, insulin-potentiating effects induced by the 
effects of insulin on the central nervous system, like a decrease in plasma levels of the insulin 
antagonist  epinephrine or corticosterone. Furthermore, it is possible that the indirect effects 
of insulin through the CNS involve alterations in the activity of the autonomic nerves projecting 
towards WAT, i.e. in (para)sympathetic activity. In accordance with this concept, we documented 
in a model of suprarenal fat pads in rats that selective vagotomy (i.e. parasympathetic denervation 
of the suprarenal fat pads) reduced FA uptake in WAT by 36% during hyperinsulinemic clamp 
conditions (31). An increase in parasympathetic activity towards WAT might be involved in the 
indirect effects of circulating insulin through the CNS, although the existence of parasympathetic 
innervation of other fat compartments is at present uncertain. Alternatively, it might be 
hypothesized that a change in the activity of the sympathetic activity towards WAT may be 
involved in the indirect effects of insulin on FA uptake in WAT in vivo, as it has been shown that 
insulin administered in the mediabasal hypothalamus dampens the sympathetic activity (14).
We determined to which extent the stimulatory effects of circulating insulin on FA retention 
in WAT were mediated through the CNS by i.c.v. administration of tolbutamide. Tolbutamide, 
which belongs to the sulfonylurea family, inhibits K
ATP
 channels in the hypothalamus when 
administered i.c.v. (4). Sulfonylureas bind to the K
ATP
 channels on the cell membrane of certain 
hypothalamic neurons, where they inhibit the hyperpolarizing efflux of potassium (32). 
Insulin acts in central neurons by opening/activating K
ATP
 channels, and, consequently, i.c.v. 
administration of tolbutamide blocks central K
ATP
 channel-mediated insulin signaling (4). Our 
study shows that the rapid stimulatory effect of i.c.v. insulin administration on FA uptake in 
WAT is blocked by i.c.v. co-administration of tolbutamide. This indicates that tissue-specific 
stimulation of FA uptake by WAT induced by i.c.v. insulin administration is mediated by activation 
of K
ATP
 channels in the brain. By blocking central insulin signaling by i.c.v. administration of 
tolbutamide during hyperinsulinemic-euglycemic clamp conditions, we showed that insulin 
stimulates FA retention in WAT to a considerable extent via action in the CNS.
We also assessed the effects of high-fat diet on the central effects of circulating insulin on FA 
retention in WAT. The high-fat diet abolished the stimulating effect of i.c.v. administration of 
insulin on FA retention in WAT. Furthermore, peripheral administered insulin did not result in FA 
retention in WAT and blocking central insulin signaling by i.c.v. administration of tolbutamide 
did not affect the FA retention in WAT. The absence of insulin effects on FA retention in these 
diet-induced obese mice is probably the result of both high-fat-diet induced insulin resistance 
of WAT and central insulin resistance associated with blunted activation of hypothalamic K
ATP
 
channels (25;33-36). This present study indicates that in high-fat fed conditions, FA partitioning 
is no longer influenced by (central acting) insulin. 
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The present results showed that insulin stimulates FA retention in WAT to a considerable 
extent through action in the CNS. Since insulin stimulates FA transport by upregulating and 
translocating the long chain FA transporter CD36 in isolated skeletal muscles and cardiac 
myocytes (27;28), we hypothesize that the stimulating effect of centrally acting insulin on 
FA retention in WAT can be mediated by CD36 translocation. When administered in CD36-
deficient mice, i.c.v. insulin was unable to stimulate FA retention in WAT, suggesting a role of 
this FA transporter in i.c.v. insulin-stimulated FA retention in WAT. Accordingly, AMP-activated 
protein kinase (AMPK), which can stimulate FA retention by promoting translocation of CD36 
from intracellular pool to the plasma membrane (37), was activated in WAT upon i.c.v. insulin 
administration (Fig. 9). These preliminary data suggest that central insulin action can lead to 
CD36 translocation following AMPK activation, thereby resulting in FA retention in WAT. 
Recent observations have challenged the traditional notion that adipose tissue acquires FA 
from TG-rich lipoproteins mediated by the LPL system. Shadid et al. documented direct uptake 
of plasma FFA by adipose tissue in humans in the postabsorptive state (38). In accordance, we 
previously demonstrated considerable uptake of plasma FFA in adipose tissue in both fed and 
Fig. 9. I.c.v. insulin administration activates AMPK in WAT. The phosphorylation state of AMPK and its downstream 
target ACC was analyzed by Western blot in both epigonadal fat (A) and visceral fat (B) in mice that received i.c.v 
infusion of vehicle or insulin for 2.5 h. The corresponding quantification of the Western blot data was normalized 
for total protein and expressed as fold change compared to vehicle (C-D). Values represent means ± SEM for at 
least 5 mice per group. * P < 0.05 vs. vehicle.
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fasted mice (23). In older experiments the uptake of FA in adipose tissue from plasma FFA and 
plasma TG was assessed by quantification of the uptake as a percentage of the total administered 
radioactive dose (39). In the present study, we assessed tissue FA uptake from plasma FFA and 
plasma TG per mg protein after correction for the corresponding plasma specific activities of [14C]
FA and [3H]TG. This correction for precursor pool enrichment enabled to assess the absolute rate 
of FA uptake from the two plasma sources as compared to the assessment of the relative uptake of 
FA radio-isotopes in relation to the total administered radioactive doses in the older experiments. 
In addition, there are other methodological differences including labeling procedures of plasma 
TG, the use of the postabsorptive state vs. hyperinsulinemic-euglycemic clamp procedure, that 
limit a simple comparison of the results of our and those previous experiments.
I.c.v. administration of insulin did not stimulate FA retention by WAT to the same extent as 
peripherally administered insulin. However, the dose of insulin used in the i.c.v. experiments 
and the i.v. dose used in the hyperinsulinemic euglycemic clamp experiments cannot easily be 
compared. The i.c.v. dose of insulin used in the current study was ascertained in a dose-finding 
study to exclude hormone-sensitive lipase inactivation by i.c.v. insulin (as shown recently by 
Scherer et al.; (14)). Therefore, the change in FA retention by WAT upon i.c.v. insulin is the result 
of a net influx of FA, whereas FA retention upon peripheral insulin administration is the result of 
suppression of lipolysis and FA uptake, explaining the difference in the amount of FA retention 
by WAT between centrally and peripherally administered insulin.
In conclusion, we show that circulating insulin stimulates tissue-specific FA retention by 
WAT to a considerable extent by indirect pathways, involving activation of K
ATP
 channels in 
the brain, which is lost in diet-induced obese mice. These observations highlight a paradigm 
that circulating hormones can act on target tissues directly, as well as indirectly through the 
CNS and indicate that such a central pathway is disturbed in insulin resistance of WAT in diet-
induced obesity. 
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a b s t r aC t
The effects of thyroid hormone (TH) status on energy metabolism and tissue-specific substrate 
supply in vivo are incompletely understood. To study the effects of TH status on energy 
metabolism and tissue-specific fatty acid (FA) fluxes, we used metabolic cages as well as 
14C-labelled FA and 3H-labeled triglyceride (TG) infusion in rats treated with methimazole and 
either 0 (hypothyroidism), 1.5 (euthyroidism) or 16.0 (thyrotoxicosis) μg/100g*day of thyroxine 
for 11 days. 
Thyrotoxicosis increased total energy expenditure (TEE) by 38% (P < 0.05), resting energy 
expenditure (REE) by 61% (P < 0.01) and food intake by 18% (P < 0.01). Hypothyroidism tended to 
decrease TEE (10%; P = 0.064), and REE (12%; P < 0.05), but did not affect food intake. TH status did 
not affect spontaneous physical activity (SPA). Thyrotoxicosis increased fat oxidation (P < 0.01), 
whereas hypothyroidism decreased glucose oxidation (P < 0.05). Plasma FA concentration was 
increased in thyrotoxic, but not in hypothyroid rats. Thyrotoxicosis increased albumin-bound 
FA uptake in muscle and white adipose tissue (WAT), whereas hypothyroidism had no effect in 
any tissue studied, suggesting mass-driven albumin-bound FA uptake. During thyrotoxicosis, 
TG-derived FA uptake was increased in muscle and heart, unaffected in WAT, and decreased in 
brown adipose tissue. Conversely, during hypothyroidism TG-derived FA uptake was increased 
in WAT in association with increased lipoprotein lipase activity, but unaffected in oxidative 
tissues and decreased in liver. 
In conclusion, TH status determines EE independently of SPA. The changes in whole 
body lipid metabolism are accompanied by tissue-specific changes in TG-derived FA 





I n t r o d u C t I o n
Thyroid hormone (TH) is a primary denominator of energy homeostasis, reflected by the strong 
association between hyperthyroidism and increased energy expenditure (EE) in man. This 
is exemplified by the widespread clinical use of calorimetry in addition to the determination 





) RIAs became available in the 1970s (3). Whereas modulation of resting 
EE by thyroid hormone status is well established in humans and rodents, it has been difficult 
to assess TH effects on total EE (TEE) in vivo. In addition, the mechanism of the increased EE 
induced by THs has remained incompletely understood (4). For example, few studies have 
addressed how THs influence spontaneous physical activity (SPA) and if changes in SPA may 
contribute to the alterations in EE associated with thyrotoxicosis and hypothyroidism in freely 
moving organisms (5;6). 
We have previously studied glucose metabolism during thyrotoxicosis in rats and found 
increased endogenous glucose production and hepatic insulin resistance (7). Furthermore, 
thyrotoxicosis is associated with major changes in lipid metabolism. Fatty acids (FA) are a 
preferential fuel source during thyrotoxicosis (8;9), especially during the first days after 
the induction of thyrotoxicosis (10). These FA are provided to tissues mostly by hydrolysis 
(i.e. lipolysis) of circulating triglyceride (TG)-rich lipoprotein particles by the enzyme lipoprotein 
lipase (LPL), located in the capillary lumen. In addition, albumin-bound FA are provided to the 
tissues from the plasma, a process which is independent of LPL. Although there is evidence 
suggesting that LPL is regulated by TH (11), it is unknown at present how FA fluxes via these two 
pathways are modulated by TH in metabolically relevant tissues in vivo.
The aim of the present study was to examine the effects of thyrotoxicosis and hypothyroidism 
on whole body energy metabolism and SPA in rats. To delineate how the effects of thyroid status 
on whole body energy homeostasis are reflected in substrate (i.e. lipid) supply on the tissue 
level in vivo, we additionally studied the rates of disappearance and tissue-specific partitioning 
of both TG-derived and albumin-bound FA. We report effects of thyroid hormone status on 
TEE, resting energy expenditure (REE), SPA and substrate (i.e. glucose and lipid) oxidation, that 
are paralleled by complex and tissue-specific effects of TH on FA uptake. 
M at e r I a l s  a n d  M e t h o d s 
In the first experiment, 3 groups of rats were studied, i.e. hypothyroid (Hypo, n = 7), euthyroid 
(Eu, n = 7) and thyrotoxic rats (Tox, n = 7). All groups were treated with methimazol (MMI) in 
drinking water. After 7 days, all groups were implanted with subcutaneous osmotic mini-pumps 
(day (D) 0), delivering either vehicle (Hypo group), or thyroxine (T
4
) at a dose of 1.5 (Eu group) 
or 16.0 μg/100 g BW*day (Tox group) (7). Rats were subsequently placed in metabolic cages 
for determining TEE, REE, food intake, respiratory exchange ratio (RER), and fat and glucose 
oxidation during a 48 h period (D9 and D10). 
In the second experiment (D11), hypothyroid (Hypo, n = 9), euthyroid (Eu, n = 8) and 
thyrotoxic rats (Tox, n = 7) were i.v. infused with albumin-bound 14C-oleate (FA) and VLDL-like 
effeCts of thyroId status on enerGy hoMeostasIs and fa uPtake
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emulsion-incorporated glycerol tri[3H]oleate (TG). This method enables measurement of FA 
turnover, tissue-specific FA partitioning and differentiation between albumin-bound and TG-
derived FA uptake on the tissue level (12).
animals
Male Wistar rats (Harlan, Horst, the Netherlands) were housed under constant conditions 
of temperature (21 ± 1°C) and humidity (60 ± 2%) with a 12 h/12 h light/dark (L/D) schedule 
(lights on 7:00 am). Animals were allowed to adapt for 6 days before the first experimental 
manipulations. Body weight (BW) was between 320 and 360 g. Food and drinking water was 
available ad libitum. All of the following experiments were conducted with the approval of the 
Animal Care Committee of the Leiden University Medical Center.
hormonal treatment; block and replacement
At D0 of the protocol animals were placed in individual cages and treated with methimazole 
0.025% (MMI, Sigma, the Netherlands) in drinking water containing 0.3% saccharin. At D7, 
osmotic minipumps (OMP, Alzet 2ml2, Durect Corp., Cupertino, USA) loaded with L-thyroxine 
(T
4
, Sigma, the Netherlands) solved in 6.5 mM NaOH and 50% propylene glycol, were implanted 
under the dorsal skin during the surgical procedure. OMPs delivered either vehicle (hypothyroid 
rats), or T
4
 at a dose of 1.5 μg (replacement dose; euthyroid group) or 16.0 μg (thyrotoxic group) 
/100 g BW*day, as described previously (7).
surgery
In all animals an intra-atrial silicone cannula was implanted through the right jugular vein 
for infusion and sampling (13) during anesthesia (7). The cannula was tunneled to the head 
subcutaneously, fixed with dental cement to 4 stainless-steel screws inserted into the skull. 
A mixture of 60% amoxicillin, 20% heparin and 20% saline in polyvinylpyrrolidone (Sigma, the 
Netherlands) was used to fill the cannula and prevent inflammation and occlusion.
energy expenditure, fat oxidation, spontaneous physical activity 
and food intake
At D7, animals were placed into an 8-cage combined, open circuit indirect calorimetry 
system (LabMaster system, TSE Systems, Bad Homburg, Germany, for the remainder of this 





 production, as well as SPA. Although the cages including bedding were identical to 
the cages in which the rats were housed the first 7 days (only the cover of the metabolic cage 
differs), animals were adapted to this environment before the start of the actual measuring 
periods (D9 and D10) for approximately 48 h. EE, RER and fat oxidation were calculated from 
the O
2
 uptake and CO
2
 production relative to individual body weights (14). O
2
 uptake and 
CO
2
 production were measured with 10 min intervals. Food and water intake and physical 
activity were measured continuously. Activity monitoring and detection of animal location 
was performed with infrared sensor pairs arranged in strips for horizontal (X level) and vertical 
(Z level) activity, detecting every ambulatory movement. Spontaneous physical activity (SPA 
or XA), high-frequent activity (XF; equivalent of breathing activity), total activity (XT=XA+XF) 
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and rearing (Z) were monitored. The infrared sensors for detection of movement allowed 
continuous recording in both light and dark phases. 
radiolabeled fa infusion
At D11, rats were restrained from access to food from 5h prior to the labelled lipid infusion 
(i.e. from 9:00 am onwards). Rats were connected to a metal collar attached to polyethylene 
tubing (for blood-sampling and isotope infusion) which was kept out of reach of the animals 
by a counterbalanced beam. This allowed all subsequent manipulations to be performed 
outside the cages without handling the freely moving animals. After obtaining a blood sample 
for measurement of plasma TH, FA, and TG concentrations (800 μL), rats received a primed 
(500 μl in 5 min), continuous (500 μl/h) infusion of albumin-bound 14C-oleate (FA) and VLDL-
like emulsion-incorporated glycerol tri[3H]oleate (TG) i.v. for 2 h. At the end of the 2 h infusion 
period we obtained another blood sample (800 μL) for measurement of plasma [3H]-FA and 
[14C]-FA radioactivity. Rats were sacrificed and striated muscle (M triceps brachii), heart, liver, 
three white adipose tissue (WAT) depots (gonadal (epididymal), subcutaneous, visceral) and 
infrascapular brown adipose tissue (BAT) were harvested, snap frozen and stored at -20°C for 
subsequent analysis. 
Preparation of radiolabeled emulsion particles
Protein-free VLDL-like TG-rich emulsion particles were prepared from 100 mg total lipid at 
a weight ratio of triolein (Sigma, St. Louis, MA, US): egg yolk phosphatidylcholine (Lipoid, 
Ludwigshafen, Germany): lyso phosphatidylcholine (Sigma, St. Louis, MA, US): cholesteryl 
oleate (Janssen, Beersse, Belgium): cholesterol (Sigma, St. Louis, MA, US) of 70: 22.7: 2.3: 3.0: 
2.0 in the presence of 800 μCi of glycerol tri[9, 10(n)-3H]oleate ([3H]TG) (Amersham, Little 
Chalfont, UK), as reported previously (15). Lipids were hydrated in 10 mL of 2.4M NaCl, 10 mM 
Hepes, 1 mM EDTA, pH 7.4, and sonicated for 30 min at 10 μm output using a Soniprep 150 (MSE 
Scientific Instruments, UK) equipped with a water bath for temperature (54°C) maintenance. 
The emulsion was separated into fractions with a different average size by density gradient 
ultracentrifugation. Intermediate (80 nm) [3H]-TG particles were mixed with a trace amount 
of [14C]-oleic acid (Amersham, Little Chalfont, UK) complexed to bovine serum albumin (BSA). 
tissue uptake analysis
Tissues were dissolved in 5 mol/l KOH in 50% (vol/vol) ethanol. After overnight saponification, 
protein content was determined in the various organs using BCA kit (BCA Protein Assay Kit, 
Thermo Scientific). Radioactivity was measured in the saponified organs and corrected for 
the corresponding protein concentration and plasma specific activities of [3H]-FA and [14C]-
FA. Calculations of tissue FA uptake and rate of disappearance were performed as described 
previously (12).
analysis of lipoprotein lipase (lPl) and hepatic lipase (hl) activity
Striated muscle, heart, liver and three WAT depots were cut into small pieces and put in 1 mL 
2% BSA-containing DMEM medium. Heparin (2 units) was added and samples were incubated 
at 37°C for 60 minutes. After centrifugation (10 min at 13.000 rpm), the supernatants were 
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taken and snap-frozen until analysis. Total LPL and HL activity was determined as modified 
from Zechner et al. (16). In short, the lipolytic activity of tissue supernatant was assessed by 
determination of [3H]oleate production upon incubation of tissue supernatant with a mix 
containing an excess of both [3H]triolein, heat-inactivated human plasma as sources of the 
hydrolase coactivator apoC2 and FA-free BSA as FFA acceptor. 
Plasma analysis




 were determined by an in-house 
RIA, with inter- and intra-assay CV of 7-8% and 3-4% (T
3
), and 3-6 and 2-4% (T
4
), respectively. 




 were 0.3 nmol/l and 5 nmol/l, respectively. Plasma TSH 
concentrations were determined by a chemiluminescent immunoassay (Immulite 2000, 
Diagnostic Products Corp., Los Angeles, CA), using a rat-specific standard (17). The inter- and 
intra-assay CV for TSH were less than 4% and 2% at ± 3.5 mU/l, respectively, and the detection 
limit was 0.2 mU/l. Blood samples were kept in chilled paraoxon-coated Eppendorf tubes to 
prevent ex vivo lipolysis. The tubes were placed on ice and immediately centrifuged at 4°C. 
Plasma levels of TG and FA were determined using commercially available kits and standards 
according to the manufacturer’s instructions (Instruchemie, Delfzijl, The Netherlands) in 96-
wells plates (Greiner Bio-One, Alphen a/d Rijn, The Netherlands). Lipids were extracted from 
plasma according to Bligh and Dyer (18). The lipid fraction was dried under nitrogen, dissolved 
into chloroform/methanol (5:1 [vol/vol]) and subjected to TLC (LK5D gel 150; Whatman) using 
hexane:diethylether:acetic acid (83:16:1) [vol/vol/vol]) as mobile phase. Standards for FA and 
TG were included during the TLC procedure to locate spots of these lipids. Spots were scraped, 
lipids dissolved in hexane and radioactivity measured. 
statistics
Both energy homeostasis and FA uptake data were analysed by non-parametric Kruskall-Wallis 
(KW) test, and a Mann Whitney U post hoc test was performed if KW revealed significance to 
determine which experimental groups differed from each other. Cosinor analysis was performed 
on the metabolic cage data of individual animals (48 h). Curve fitting was performed using 
constrained nonlinear regression analysis (SPSS 16.0). Subsequently, only if the significance level 
(P value) of the fitted curve was less than 0.05, data were used to calculate mesor, amplitude 
and acrophase of the individual curve. Significance was defined at P ≤ 0.05. Data are presented 
as mean ± SEM.
r e s u lt s
effects of thyroid status on energy homeostasis
Body weight and eating behaviour
At the time of starting hormonal (T
4
) treatment (osmotic mini-pump implantation; day 0), 
there were no differences in bodyweight (BW) between groups (Hypo 339 ± 13, Eu 340 ± 5, Tox 
345 ± 4 g, ns). At the time of placement in the metabolic cages (day 7), BW was decreased by 
13 ± 3 g in thyrotoxic rats, compared with an increase of 2 ± 5 g and 13 ± 9 g in euthyroid and 
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hypothyroid rats, respectively (Hypo vs. Eu ns, Eu vs. Tox P < 0.05, Hypo vs. Tox P = 0.053). 
However, during the whole period in the metabolic cages (day 7-10), BW increased to a similar 
extent in all groups (Hypo 12 ± 1, Eu 14 ± 3, Tox 12 ± 1 g, ns). 
After placement in the metabolic cages animals were allowed to adapt to this new 
environment for 48 h (day 7-8). Subsequently, we gathered energy homeostasis data for 48 h 
(day 9-10). During this time period, thyrotoxic rats showed increased cumulative food intake by 
18% as compared with euthyroid rats. Hypothyroid rats ate less than euthyroid rats, although 
this did not reach statistical significance (Hypo 44 ± 2 g, Eu 48 ± 2 g, Tox 57 ± 2 g, Eu vs Tox 
P < 0, 01, Hypo vs. Eu P = 0.128). 
Plasma thyroid hormones




 and TSH following the 48 h measurement of energy homeostasis 




 concentrations were 163% and 30% higher, respectively, 





concentrations were decreased to 44% and 15%, respectively, of euthyroid levels. Plasma TSH 
was 12.9 ± 2.2 mU/l in hypothyroid rats, and showed similar values in euthyroid and thyrotoxic 
rats (0.3 ± 0.1 and 0.2 ± 0.0 mU/l, ns, respectively). 
Table 1. Plasma thyroid hormone concentrations after 48 h measurement of energy homeostasis (day 11) in 









 (nmol/l) 0.50 ± 0.11 * 1.14 ± 0.07 3.00 ± 0.27 *
T
4
 (nmol/l) 20 ± 2 * 136 ± 8 177 ± 8 *
TSH (mU/l) 12.9 ± 2.2 * 0.3 ± 0.1 0.2 ± 0.0
Total EE, physical activity and resting EE
Total EE (TEE) showed a clear diurnal rhythm in all treatment groups, with a rise in the dark 
(i.e. active) period (Fig. 1A). As expected, this was paralleled by a similar rhythm in SPA in all 
groups (Fig. 1B). There was a marked, 37% increase in mean TEE/kg in thyrotoxic relative to 
euthyroid rats (P < 0.05). This increase persisted when mean TEE was not corrected for BW 
(P < 0.05, data not shown). Hypothyroid rats showed a trend (P = 0.064) towards decreased 
(-10%) mean TEE relative to euthyroid rats. Cosinor analysis revealed similar changes in the 
mesor of the fitted curves. In addition, there was a decrease in the amplitude of the rhythm in 
EE by 46% in hypothyroid relative to euthyroid rats (P < 0.05) as well as a ~1 h phase-advance 
of the acrophase relative to euthyroid and thyrotoxic rats (P < 0.05). There were no differences 
in the mean levels of SPA between groups (Kruskall-Wallis, ns). Also mesor, amplitude and 
acrophase of the fitted curves of SPA exhibited no differences between thyrotoxic, hypothyroid 
and euthyroid rats (Table 2). Likewise, there were no differences in high-frequency activity 
(equivalent of breathing; XF), rearing (Z) or total activity (XT) between groups, nor in mesor, 
amplitude or acrophase of the fitted curves (data not shown). 




























































Fig. 1. Forty-eight-hour total energy expenditure (TEE, A) and spontaneous activity (SPA, B) in hypothyroid 
(Hypo), euthyroid (Eu) and thyrotoxic (Tox) rats entrained to a regular 12/12-h L/D cycle. Horizontal black 
bars indicate the dark phase of the L/D cycle. Data are mean of 7 animals per group at each time point and the 
interval between time points was 10 min. Cosinor data and statistical analysis are given in Table 2. Resting energy 
expenditure (REE, defined as the mean energy expenditure during 10 min intervals of inactivity (see text) in each 
individual animal, C) in hypothyroid (Hypo), euthyroid (Eu) and thyrotoxic (Tox) rats. Note the increase of REE 
in Tox vs. Eu rats (** P < 0.01) that was more pronounced than the decrease of REE in Hypo vs. Eu rats (* P < 0.05). 
Data are mean ± SEM of 7 animals per group.





























































































In each animal we determined the total number of 10 min intervals in which the activity 
sensors did not detect any activity (activity units (AU) = 0). Hypothyroid rats tended to spend 
more time inactive than euthyroid rats (533 ± 72 vs. 359 ± 40 min, P = 0.064), whereas thyrotoxic 
rats showed a trend towards less inactivity time compared to euthyroid rats (256 ± 33 min, 
P = 0.073). During these periods of inactivity, mean EE, termed resting EE (REE), was markedly 
higher in thyrotoxic as compared with euthyroid rats (P < 0.01), and lower in hypothyroid rats 
(P < 0.05 vs. Eu, Fig. 1C). REE/TEE ratios showed no differences between groups (Hypo 0.83 ± 
0.02, Eu 0.85 ± 0.02, Tox 0.82 ± 0.01, KW, ns). 
RER and substrate oxidation
Euthyroid rats showed a diurnal rhythm in RER (Fig. 2A), although less evident than the 
rhythm in TEE and SPA. The nocturnal acrophase fits with a relative increase in glucose 
oxidation in the dark (i.e. feeding) period. Both thyrotoxic and -although to a lesser extent- 
hypothyroid rats showed a decrease in mean RER levels relative to euthyroid rats (Tox: 94% 
of Eu levels, P < 0.01, Hypo: 96% of Eu levels, P < 0.05). In addition, cosinor analysis revealed 
that the amplitude of the day-night rhythm in RER was markedly increased in thyrotoxic rats 
(155%, P < 0.01). Although the RER phase difference between the euthyroid and thyrotoxic 
groups did not reach statistical significance (P = 0.128), there appeared to be an inverse 
rhythm in thyrotoxic relative to hypothyroid rats (P < 0.05). Hypothyroid animals showed 
Table 2. Data derived from cosinor curve-fit of all individual animals with statistical analysis. * P < 0.05 vs. Eu, 
“ P = 0.073 vs. Eu, ^ P < 0.05 vs. Tox.
Energy Expenditure (kcal/h*kg)
Mesor Amplitude Acrophase (h) n
Hypo 6.52 ± 0.26 “^ 0.64 ± 0.15 *^ 23.15 ± 0.16 *^ 7
Eu 7.24 ± 0.21 1.19 ± 0.09 00.23 ± 0.18 7
Tox 10.16 ± 0.67 * 1.70 ± 0.32 00.39 ± 0.22 7
P = 0.001 P = 0.009 P = 0.015
Spontaneous physical activity (AU)
Mesor Amplitude Acrophase (h) n
Hypo 63 ± 6 37 ± 8 00.26 ± 0.15 7
Eu 62 ± 5 38 ± 5 01.09 ± 0.35 7
Tox 60 ± 7 33 ± 6 00.13 ± 2.25 7
P = 0.901 P = 0.780 P = 0.248
Respiratory exchange ratio
Mesor Amplitude Acrophase (h) n
Hypo 0.94 ± 0.01 * 0.0123 ± 0.0014 ^ 20.44 ± 0.30 *^ 7
Eu 0.97 ± 0.01 0.0120 ± 0.0010 22.27 ± 0.24 7
Tox 0.91 ± 0.01* 0.0306 ± 0.0110 * 03.35 ± 2.48 7
P = 0.014 P = 0.032 P = 0.018
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a RER increase in the early part of the dark period, whereas thyrotoxic rats showed a 
pronounced trough in RER during the feeding periods at the beginning and end of the dark 
period. Cosinor analysis confirmed that hypothyroid rats exhibit a decrease (P = 0.053) in the 
mesor of their RER day-night rhythm relative to euthyroid rats, but less pronounced than in 
thyrotoxic animals (P < 0.01). The acrophase of the RER rhythm in hypothyroid animals was 
~2 h phase-advanced relative to euthyroid (P < 0.05), and almost 7 h relative to thyrotoxic 
animals (P < 0.05).
Substrate oxidation is depicted in Fig. 2B-C. In euthyroid animals, mean levels of glucose 
oxidation were ~30-fold higher than fat oxidation, in line with ad libitum access to carbohydrate-
rich chow. Thyrotoxic animals showed no difference in glucose oxidation relative to euthyroid 
rats, whereas hypothyroid rats showed a mild decrease in mean level of glucose oxidation 
relative to euthyroid (19%, P < 0.05) and thyrotoxic animals (23%, P < 0.05, Fig. 2B). Mean levels of 
fat oxidation were markedly (479%) increased in thyrotoxic relative to euthyroid rats (P < 0.01), 
but there was no difference in fat oxidation between hypothyroid and euthyroid rats (ns, 
Fig. 2C). Thus, RER showed a decrease in both thyrotoxic and (to a lesser extent) hypothyroid 
animals relative to euthyroid rats. However, the mechanism of this decrease was different 
between groups, i.e. a decrease of glucose oxidation in hypothyroid animals, and a pronounced 
increase in fat oxidation in thyrotoxic animals.
effects of thyroid status on lipid turnover, uptake and partitioning
In order to determine how whole body alterations in fat oxidation induced by thyrotoxicosis 
and hypothyroidism translated into substrate (i.e. FA) uptake at the tissue level, we applied 
a dual FA-isotope infusion technique that permits differentiation between plasma TG-derived 






 and TSH concentrations in thyrotoxic, euthyroid and hypothyroid rats are shown 
in Table 3.
FA and TG plasma concentrations and rate of disappearance
Plasma FA concentrations were 118% higher in thyrotoxic relative to euthyroid rats (P < 0.01). 
Plasma TG concentrations tended to increase in thyrotoxic (P = 0.059) rats, and showed a 
significant decrease in hypothyroid (P < 0.05) compared with euthyroid rats (Table 3). 
Rate of disappearance (Rd) of 14C-FA was 59% increased in thyrotoxic relative to euthyroid 
rats (P = 0.054). There were no differences in Rd of 3H-TG between groups (Table 3).
Table 3. Plasma thyroid hormone concentrations before radio-labeled FA infusion (day 11) in hypothyroid 









 (nmol/l) 0.41 ± 0.08 * 1.21 ± 0.09 2.78 ± 0.27 *
T
4
 (nmol/l) 19 ± 2 * 139 ± 7 187 ± 5 *
TSH (mU/l) 10.9 ± 1.8 * 0.2 ± 0.0 0.2 ± 0.0
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Tissue-specific TG-derived FA uptake, lipoprotein lipase, hepatic lipase 
activity and albumin-bound FA uptake
Thyrotoxicosis induced an increase of TG-derived FA uptake in striated muscle (58%, P < 0.05, 
Fig. 3A), and tended to increase TG-derived FA uptake in heart (78%, P = 0.059) relative 
to euthyroid rats, but did not induce alterations in muscle or heart LPL activity (Fig. 3B). 
Thyrotoxicosis induced a pronounced decrease in TG-derived FA uptake to 21% of euthyroid 
levels in BAT (P < 0.01). It should be noted that FA uptake was approximately 30-fold higher in 
BAT as compared to oxidative striated muscle, in line with the high mitochondrial density and 
high FA oxidative capacity of brown adipocytes. Thyrotoxicosis had no effect on TG-derived 
FA uptake in any of the WAT depots, although it induced a modest decrease in LPL activity in 
gonadal WAT (48%, P < 0.05). In contrast, hypothyroid rats showed a pronounced increase of 
Fig. 2. Forty-eight-hour respiratory exchange ratio (RER, A) in hypothyroid (Hypo), euthyroid (Eu) and thyrotoxic 
(Tox) rats entrained to a regular 12/12-h L/D cycle. Horizontal black bars indicate the dark phase of the L/D cycle. 
Data are mean of 7 animals per group at each time point, and the interval between time points was 10 min. 
Cosinor data and statistical analysis are given in Table 2. Mean 48 h glucose oxidation (B) in hypothyroid (Hypo), 
euthyroid (Eu) and thyrotoxic (Tox) rats. Note that Hypo rats exhibit decreased glucose oxidation as compared 
with Eu animals (* P < 0.05). Mean 48 h fat oxidation (C) in hypothyroid (Hypo), euthyroid (Eu) and thyrotoxic 
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Fig. 3. Triglyceride (TG)-derived fatty acid (FA) uptake (A), lipoprotein lipase activity (B) and albumin-bound 
FA uptake (C) in striated muscle, heart, liver, three white adipose tissue (WAT) depots (gonadal, subcutaneous, 
visceral) and brown adipose tissue (BAT) of hypothyroid (Hypo, white bars), euthyroid (Eu, grey bars) and 
thyrotoxic (Tox, black bars) rats. ^ 0.05 < P < 0.10, * P ≤ 0.05, ** P < 0.01 vs. Eu.
TG-derived FA uptake in gonadal and visceral WAT (184%, P < 0.01 and 75%, P < 0.05, respectively, 
Fig. 3A), associated with an increase in LPL activity both in gonadal and visceral WAT (234%, 
P < 0.01 and 306%, P < 0.05, respectively, Fig. 3B). In liver, hypothyroid rats showed decreased 
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TG-derived FA uptake relative to euthyroid rats (37%, P < 0.05), but no change in HL activity. 
Conversely, thyrotoxic rats showed no effect on TG-derived FA uptake but an increase in HL 
activity (52%, P < 0.01). 
Thyrotoxicosis induced an increase in albumin-bound FA uptake in striated muscle (71%, 
P = 0.054, Fig. 3C), a 97% increase of albumin-bound FA uptake in gonadal WAT (P < 0.05), and 
it similarly tended to increase albumin-bound FA uptake in subcutaneous and visceral WAT 
(71%, P = 0.059 and 129%, P = 0.059, respectively). There was no difference in albumin-bound FA 
uptake between hypothyroid and euthyroid rats in any of the tissues studied.
d I s C u s s I o n
We studied the changes in whole body energy metabolism associated with thyroid hormone 
status and we delineated how these changes translate into substrate (i.e. FA) uptake at the 
tissue level. Our main findings are that thyrotoxicosis induces a hypermetabolic phenotype 
(increased TEE, REE, and fat oxidation) as well as increased food intake favouring substrate 
replenishment. Interestingly, thyrotoxicosis did not increase SPA, indicating that changes in SPA 
do not contribute to increased TEE. Moreover, hypermetabolism was associated with increased 
TG-derived FA uptake in most oxidative tissues, whereas TG-derived FA uptake was unaltered 
in WAT. Conversely, hypothyroidism induced a hypometabolic phenotype with a mild decrease 
in REE, a trend towards decreased TEE, and a decrease of glucose oxidation. In addition, TG-
derived FA uptake was increased in lipid storing WAT, concomitantly with increased LPL activity. 
However, during hypothyroidism TG-derived FA uptake in oxidative tissues was unaltered. 
These alterations in TG-derived FA uptake during thyrotoxicosis and hypothyroidism indicate 
that FA uptake from TG-rich lipoproteins is differentially regulated by thyroid hormones in a 
tissue-specific manner.
The mechanism of the increase of TEE induced by thyrotoxicosis is incompletely understood. 
It has been known for many years that REE is highly responsive to thyroid hormones (1). In 
addition, many thyrotoxic patients show a characteristic resting tremor and self-reported 
increased physical activity. Conversely, many hypothyroid patients complain of slowness 
(19). However, there is little experimental evidence indicating that thyroid status modulates 
locomotor behaviour or SPA, and it is unclear how this relates to the alterations in energy 
homeostasis induced by hypothyroidism and thyrotoxicosis. This is of particular interest, 
since accumulating evidence suggests that EE associated with SPA, termed non-exercise 
activity thermogenesis (NEAT), is an independent (negative) determinant of (development 
of) obesity in humans and rodents. As thyroid hormone is a principal regulator of energy 
metabolism, it may also be involved in the regulation of NEAT. The present study shows that 
although moderate hyperthyroidism increases TEE by 37%, it induces no alterations in SPA. In 
contrast, resting REE, defined as the energy expended during time periods when no activity 
was detected, is increased by 61% in thyrotoxic rats. Moreover, hypothyroidism induces 
a significant 12% decrease of REE, but it does not affect SPA either, and REE/TEE ratios are 
unaffected by both hypothyroidism and thyrotoxicosis. Together, our data strongly suggest 
that the increased energy requirements of SPA are not determined by thyroid hormone status 
effeCts of thyroId status on enerGy hoMeostasIs and fa uPtake
141
and do not explain increased TEE associated with thyrotoxicosisOur data are in contrast with 
those of Levine et al. (5) who reported increased SPA during thyrotoxicosis in rats, suggesting 
that NEAT was a significant component of the increase in TEE. This discrepancy is most likely 
explained by the pharmacological dose of T
3
 used by Levine et al. to induce thyrotoxicosis, 
resulting in a ~13-fold increase in plasma T
3
. In the present study serum T
3
 was increased only 
2.5-fold, which is within the range of plasma T
3
 often found in patients with thyrotoxicosis. 
Interestingly, this was paralleled by a relatively mild, 30% increase in plasma T
4
 concentrations. 
In thyrotoxic patients, a relative overproduction of T
3





ratios may be observed (20). Deiodinase type 1 (D1), which is mainly expressed in liver and 
kidney, is positively regulated by T
3 
(21). Therefore, D1-mediated T
3
 production is thought to be 
a major source of extra-thyroidal T
3 





ratio in our rat model of thyrotoxicosis is paralleled by an induction of hepatic D1 expression 
(7), which may underlie the relatively mild increase of plasma T
4
 relative to T
3
.
Our experimental approach does not allow for measurement of other components of 
TEE, such as diet-induced thermogenesis (absorption, digestion and metabolism of food) 
and facultative thermogenesis (energy expended to maintain body temperature during 
cold exposure in homeothermic species). However, it is reasonable to assume that the 18% 
increase in 48 h cumulative food intake led to an increase of diet induced thermogenesis in 
thyrotoxic rats, although this component generally comprises only a minor part (~10-15%) of 
TEE. Facultative thermogenesis is unlikely to have played a role in our study, as it is generally 
negligible under thermo-neutral circumstances. 
TH is known to play a role in regulating seasonal adaptations in several species, for 
example reproduction and maintenance of body weight (23;24), but its possible involvement 
in modulating rhythms of shorter phase, i.e. circadian rhythms, has received less attention. 
This possibility is theoretically supported by thyroid hormone receptor α1 mRNA expression 
in the region of the main circadian oscillator, i.e. the suprachiasmatic nuclei (SCN) (25), 
although this has not been confirmed at the protein-level (26;27). Previous studies have 
shown lack of an effect of hypothyroidism on rhythms of locomotor (wheel running) 
activity (28). Therefore, the subtle effects of hypothyroidism on the acrophase of the daily 
TEE and RER rhythms we did observe, are most likely occurring downstream of the SCN. 
Euthyroid rats exhibited a through in RER during the light period, fitting with relatively high 
fat oxidation during the inactive period when little food is consumed. The shift in acrophase 
of RER in thyrotoxic rats appears to be mainly due to increased fat oxidation during the 
nightly feeding periods (data not shown), suggesting that during thyrotoxicosis, high energy 
demands require mobilization of energy stores on top of the nutrients supplied by increased 
food intake during the active period.
Lipoprotein lipase (LPL) is the key enzyme regulating tissue-specific FA disposal by 
hydrolyzing triglycerides (TG) in circulating TG-rich lipoprotein particles. LPL has been 
proposed as a metabolic “gatekeeper” (29), directing substrate to tissues dependent on the 
body’s metabolic status (30;31). In the present study, we explored TH effects on tissue FA uptake, 
and we were able to differentiate between TH effects on TG-derived (i.e. LPL-dependent) and 
albumin-bound (i.e. LPL-independent) FA uptake on the tissue level. In addition, we measured 
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tissue-specific LPL activity. In keeping with the observed hypermetabolic state associated 
with thyrotoxicosis, we found that thyrotoxicosis increases TG-derived FA uptake in major 
oxidative tissues such as striated muscle and the heart, without affecting TG-derived FA 
uptake in lipid-storing WAT depots. This increase in TG-derived FA uptake in oxidative tissues 
was not paralleled by increased local LPL activity. It has been previously reported that the 
linear relationship between muscle TG-derived FA uptake and LPL activity in euthyroid animals 
is lost after experimental alterations in thyroid status (32). This may be explained by TH effects 
on additional determinants of the process of TG-derived FA-uptake. In addition, TH induced 
stimulation of local blood flow (33;34) may have interfered with FA-uptake, independently of 
LPL activity. 
Conversely, hypothyroidism increased TG-derived FA uptake in WAT. Indeed, earlier studies 
in rats have also reported increased LPL activity in WAT during hypothyroidism (35) that could 
be reversed by tri-iodothyronine (T
3
) administration (36;37). However, hypothyroidism had 
no effect on TG-derived FA uptake in oxidative tissues. In the liver, hypothyroidism decreased 
TG-derived FA uptake but not hepatic lipase (HL) activity, whereas thyrotoxicosis increased 
HL activity, but not TG-derived FA uptake. Taken together, the present evidence suggests 
that during thyrotoxicosis, hypermetabolism and increased FA oxidation are facilitated by 
preferential shuttling of TG-derived FA’s to oxidative tissues. Conversely, during hypothyroidism 
TG-derived FA’s are shuttled to lipid storing WAT, away from the liver and oxidative tissues, via 
increased tissue-specific LPL activity. 
Circulating FA that are not incorporated in TG-rich lipoprotein particles are bound to albumin 
in plasma. We found that thyrotoxicosis increases albumin-bound FA uptake in muscle as well 
as in the WAT depots, whereas hypothyroidism had no effect on albumin-bound FA uptake 
in any of the tissues studied. Plasma FA concentration were increased in thyrotoxic, but not 
in hypothyroid relative to euthyroid animals. This is in line with the notion that tissue uptake 
of albumin-bound FA is mainly driven by the concentration gradient between the capillary 
lumen and the intracellular space (30). Interestingly, in contrast to the increase in FA-uptake in 
oxidative tissues like striated muscle and heart, thyrotoxicosis induced a pronounced decrease 
of TG-derived FA uptake in BAT. BAT is the main site for adaptive thermogenesis in rodents. 





thereby generating heat via induction of mitochondrial uncoupling (38). Simultaneously, LPL 
is markedly induced via a β-adrenergic mechanism, enabling replenishment of the FA used 
for mitochondrial oxidation (39). During thyrotoxicosis, increased thermogenesis has been 
proposed to evoke a compensatory decrease in sympathetic tone to BAT (40;41). We now 
speculate that such a decrease in sympathetic tone may explain the marked decrease in TG-
derived FA uptake in the present study, possibly via decreased LPL activity. 
In conclusion, our data indicate that FA uptake from TG-rich lipoproteins is regulated by 
TH in a tissue-specific manner. Thyrotoxicosis increases TG-derived FA uptake in all oxidative 
tissues except BAT, whereas hypothyroidism increases TG-derived FA uptake in lipid storing 
WAT via increased LPL activity, and decreases uptake in liver. In contrast, albumin bound FA 
uptake during hypothyroidism and thyrotoxicosis appears to be merely mass, i.e. concentration 
gradient, driven.
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The prevalence of type 2 diabetes mellitus (T2DM) is rising steadily. The world health 
organization estimates that by the year 2030 more than 5% of the adult population worldwide is 
suffering from T2DM, as a consequence of the growing obesity epidemic (1). The development 
of T2DM is the result of both a deficient insulin secretion by pancreatic ß-cells and insulin 
resistance, finally resulting in hyperglycemia. In addition to glucose metabolism, fatty acid (FA) 
metabolism is disturbed in T2DM. Even though the first evidence that the brain is involved in 
the control of peripheral glucose homeostasis already dates back from 1855, the role of the 
brain in the regulation of glucose metabolism has since then been virtually overlooked. Only 
recently it has been shown that insulin as produced by the pancreas in response to a meal, 
normalizes plasma glucose levels in part via action in the brain (2;3), suggesting that insulin 
affects peripheral processes in part via action in the brain. The suprachiasmatic nucleus (SCN) 
located in the anterior hypothalamus of the brain generates 24 h cycles, so called circadian 
rhythms, and disturbance of the circadian rhythm, for instance by shift work, has been 
associated with the development of T2DM (4). 
The research described in this thesis was performed to elucidate the role of disturbed 
circadian rhythm in the development of insulin resistance, to ascertain the role of insulin 
signaling in the brain on peripheral FA and glucose utilization, and to evaluate an experimental 
therapy with potential brain action in the treatment of T2DM. The major conclusions and 
implications of our findings and future perspectives will be discussed here. 
C I r C a d I a n  r h y t h M  d I s t u r b a n C e s  a n d  I n s u l I n 
r e s I s ta n C e
The rotation of the earth around its axis imparts light-dark cycles of 24 h and by developing 
an endogenous circadian (circa-about and dies-day) clock, animals and plants ensured that 
physiological processes are carried out at the appropriate time of day (5). Many hormones 
involved in metabolism, such as insulin (6), glucagon (7), adiponectin (8), corticosterone (9), 
leptin and ghrelin (10) exhibit circadian oscillation. In addition, the circadian clock regulates 
metabolism and energy homeostasis in liver and other peripheral tissues, by mediating 
the expression and/or activity of metabolic enzymes and transport systems involved in 
cholesterol metabolism, amino acid regulation, drug and toxin metabolism, citric acid cycle 
and glycogen and glucose metabolism (6;11;12). The rhythmic expression and activity of 
metabolic pathways is mainly the result of coordinated expression of clock genes (Clock, 
Bmal1, Per1, Per2, Per3, Cry1 and Cry2) in liver and adipose tissue (13-15). Although each cell in 
the body harbors its own endogenous clock system, the central circadian clock in mammals 
that coordinates the peripheral clocks is located in the suprachiasmatic nucleus (SCN) of 
the anterior hypothalamus in the brain (16). The SCN clock is composed of multiple, single-
cell oscillators, which generate coordinated circadian outputs that regulate rhythms when 
synchronized (17). Since the SCN oscillation is not exactly 24 h, the circadian pacemaker 
must be entrained to the external light-dark cycle to prevent drifting out of phase. Light, 
as perceived by the retina and transmitted to the SCN via the retinohypothalamic tract, is 
the most potent synchronizer for the SCN (16;18). The SCN transmits its rhythmic signal to 
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the peripheral oscillators via hormones and the autonomic nervous system (19-21), thereby 
influencing nearly all aspects of physiology and behavior, including sleep-wake cycles, 
cardiovascular activity, endocrine system, body temperature, renal activity, physiology of 
the gastrointestinal tract and hepatic metabolism (16;22). Complete ablation of the SCN 
abolishes circadian rhythmicity in the periphery as it leads to a loss of synchrony among 
individual cells and dampening of the rhythm at the population level (23;24). As a result, SCN 
lesioned (SCNx) rats do not show a circadian rhythm in, for example, glucose plasma levels 
and glucose uptake (6) or leptin regulation (25).
In chapter 2 we disrupted circadian rhythmicity by constant light exposure, which resulted 
in decreased (~50%) SCN output. The relatively mild decrease in SCN rhythm amplitude 
completely abolished peripheral circadian rhythms in energy metabolism and insulin sensitivity. 
Determining the oscillatory expression of glycoregulatory genes in liver and muscle could 
shed more light into how the decrease in SCN output results in complete loss of rhythmicity 
in peripheral processes. Disruption of circadian rhythm by constant light had an immediate 
effect on SCN output as well as on energy metabolism. As a result of increased food intake 
and decreased energy expenditure, constant light exposure stimulated body weight gain 
instantaneously. This suggests that short term alterations in circadian rhythm, for instance 
caused by (social) jetlag and disrupted sleep in humans, can have immediate effects on 
homeostasis, thereby contributing to development of secondary metabolic pathophysiology. 
Indeed, a single night of partial sleep deprivation acutely reduces energy expenditure in healthy 
men (26) and induces insulin resistance in type 1 diabetic patients (27), as well as in healthy 
subjects (28). It should be explored whether interventions aimed at optimizing sleep duration 
can be beneficial for stabilizing glucose levels in patients with diabetes. As disturbances in 
circadian rhythms in humans are also associated with dyslipidemia and cardiovascular morbidity 
and mortality (29-31), and mice mutant for certain clock genes develop hyperlipidemia and 
increased vascular injury (32-34), it will be of interest to elucidate the involvement of the 
circadian clock in lipid metabolism and to determine the effect of disturbed circadian rhythm 
in the development of dyslipidemia and atherosclerosis. 
In chapter 3 we investigated the role of the SCN in more detail, by studying the effect of 
SCN lesions on energy metabolism and insulin sensitivity. Thermic ablation of the SCN (SCNx) 
completely disrupted the circadian pattern in energy metabolism, resulting in a higher 
percentage of food intake during the day. In line with previous studies showing that a shift 
in energy intake from the nocturnal part of the day to the diurnal part of the day results in 
adiposity (35-37), the SCNx mice showed a mild increase in body weight, due to increased fat 
mass. Even though the SCNx mice were only marginally overweight, hepatic insulin sensitivity 
was severely impaired. The hepatic insulin resistance in these SCNx mice could be the result of 
disrupted SCN mediated control of glucose production, as the SCN has been shown to directly 
control glucose production by the liver via innervation (38). 
Both chapter 2 and 3 indicate that disturbances in circadian rhythm can contribute to 
the development of T2DM. The set-up in the two studies was similar: insulin sensitivity was 
determined by hyperinsulinemic-euglycemic clamp technique in C57Bl/6J male mice five 
weeks after the intervention, either constant light exposure or ablation of the SCN, was 
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started. The chow fed control mice from both studies had a similar body weight and also similar 
insulin sensitivity. The reduced SCN output, induced by constant light exposure, immediately 
stimulated weight gain by increasing food intake during the subjective day. Later on, the food 
intake in constant light was decreased and the weight gain induced by the light intervention 
stabilized. SCN ablation resulted in complete arrhythmia almost immediately, but this was 
not reflected in an immediate body weight gain. The body weight development did not differ 
between SCNx and control mice for the first three weeks after the operation, but when the 
hyperinsulinemic clamp was performed, SCNx mice were slightly, but significantly heavier. 
Even though the SCNx mice had a similar body weight compared to mice in constant light on a 
high-fat diet, the SCNx mice were very insulin resistant, whereas the mice in constant light on 
a high-fat diet had only lost their circadian variation in insulin sensitivity. Therefore, it will be 
interesting to determine how much input from the SCN is needed to prevent the development 
of insulin resistance. As it is now established that disturbances in circadian rhythmicity can 
contribute to the development of obesity and T2DM, patients with mild rhythm disturbances, 
such as elderly and shift workers, can benefit from prevention and treatment programs to 
synchronize behavior and endogenous phase.
Patients treated for large pituitary tumors have disturbed sleep duration and quality, and 
disturbed circadian movement rhythm (39). These patients also have a higher prevalence 
of metabolic risk factors, such as dyslipidemia and insulin resistance, as compared to the 
general population, despite optimal replacement therapy of hypopituitarism (40-43). The 
sleep disorders as well as the metabolic abnormalities in these patients could be the result 
of damage to the SCN by the initial tumor, as we show in chapter 3 that lesions of the SCN 
completely disrupts circadian rhythm and severely impairs hepatic insulin sensitivity. It needs 
to be established whether normalization of sleeping patterns in these patients (for example 
by maintaining a regular schedule for going to bed and waking up and engaging in stimulating 
activities and light exposure immediately after waking up (44)), can also reverse the metabolic 
abnormalities. 
t h e  r o l e  o f  I n s u l I n  s I G n a l I n G  I n  t h e  b r a I n
Insulin is secreted by pancreatic β-cells after a meal to normalize glucose levels by inhibiting 
endogenous glucose production (EGP) and stimulating glucose disposal by peripheral tissues. 
In part, the effects of circulating insulin are mediated by the brain, as neuron-specific insulin 
receptor knock-out (NIRKO) mice develop mild insulin resistance and elevated plasma insulin 
levels in association with obesity (45). Consistent with these data, decreased hypothalamic 
expression of the insulin receptor (IR) elicits insulin resistance in rats (2). A large body of work 
has addressed the effect of central insulin administration on EGP. For example, central infusion 
of insulin has been shown to suppress endogenous glucose production (3) and antagonism 
of insulin signaling in the brain impairs the ability of circulating insulin to suppress EGP (3). 
However, much less is known on the central regulation and the downstream mechanism by 
which central insulin affects peripheral glucose disposal and how this is regulated in an insulin 
resistant model.
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In chapter 4, we show that insulin-stimulated glucose uptake during hyperinsulinemic clamp 
conditions is dependent on insulin signaling in the brain. Blocking insulin signaling in the brain 
by intracerebroventricular (i.c.v.) administration of the ATP-sensitive potassium (K
ATP
) channel 
blocker, tolbutamide, inhibited insulin-stimulated glucose uptake by skeletal muscle, but 
not heart or adipose tissue. Previously, it was shown that i.c.v. administered insulin increases 
glucose storage in muscle as glycogen (46). Together with the results obtained in chapter 4, a 
concept emerges of an insulin-dependent central pathway targeted at skeletal muscle. 
In the brain, K
ATP
 channels with different properties are found in various cell types: glial 
cells (47) and dorsal vagal (48), hippocampal (49), and hypothalamic neurons, including 
proopiomelanocortin (POMC)- and agouti-related peptide (AgRP)/neuropeptide Y (NPY)-
expressing neurons of the ARC (50;51). In previous studies, it has been shown that K
ATP
 channels 
are activated downstream of the insulin receptor. I.c.v. administration of K
ATP
 channel blockers 
abolish the central effects of insulin on EGP and prevent in part the suppression of EGP by 
circulating insulin (3). Moreover, activation of K
ATP
 channels in the ARC is sufficient to lower 
blood glucose by inhibition of hepatic glucose production and gluconeogenesis (52;53). K
ATP
 
channels are heterooctameric proteins composed of inwardly rectifying K+ channel subunits 
(KIR6.1 or KIR6.2) and regulatory sulfonylurea receptor (SUR) subunits (54;55). Interestingly, 
mice lacking the SUR1 subunit of the SUR1/Kir6.2 K
ATP
 channel show impaired suppression of 
hepatic gluconeogenesis and EGP by insulin (52). It remains to be determined how the insulin-
signaling cascade leads to the activation of K
ATP
 channels. A possible mechanism could be via 
the regulation of the intracellular ATP/ADP ratio, either by increasing levels of glucose or AMP-
activated kinase (AMPK). A reduction of the ATP/ADP ratio results in closure of K
ATP
 channels, 
consecutive depolarization, and increased neuronal firing, thereby exerting their effects on 
second-order neurons. 
The orexigenic AgRP/NPY neurons and the anorexigenic POMC-neurons both express 
insulin receptors and are targeted by insulin (45;56). Interestingly, i.c.v. NPY or AgRP do not 
stimulate muscle glucose uptake from blood (57), whereas acute and chronic i.c.v. infusion of a 
POMC agonist enhances insulin-stimulated muscle glucose uptake (58-60). Therefore, insulin 
may signal through POMC, and not AgRP/NPY, to regulate muscle glucose uptake. As glucose 
utilization in skeletal muscle can be stimulated by sympathetic activity and i.c.v. insulin in rats 
increases sympathetic activity to the hind limb (24), it will be of interest to determine whether 
insulin action in POMC neurons regulates sympathetic activity, thereby stimulating glucose 
uptake by muscle. It will also be of interest to determine whether activation of K
ATP
 channels is 
sufficient to stimulate glucose uptake by muscle. 
Upon neural stimulation, skeletal muscles are stimulated to take up glucose. This uptake of 
glucose most probably involves the glucose transporter 4 (GLUT4). GLUT4 is a 12-transmembrane 
protein expressed in muscle and adipose tissues that catalyzes the transport of glucose across the 
plasma membrane via an ATP-independent, facilitative diffusion mechanism. Upon stimulation, 
GLUT4 is recruited to the plasma membrane, resulting in 2-10-fold increase in the surface level 
of GLUT4. The translocation of GLUT4 to the plasma membrane is responsive to hormones 
such as insulin and by energy-demanding conditions such as exercise and hypoxia. The insulin-
stimulated glucose uptake by muscle involves the phosphatidylinositol 3-kinase (PI3K) pathway, 
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whereas glucose uptake in response to exercise and hypoxia is PI3K-independent, but involves 
AMPK activation. In chapter 4, we show that under hyperinsulinemic conditions glucose 
uptake by skeletal muscle is stimulated, which coincides with an increase in insulin signaling in 
muscle. Blocking insulin signaling in the brain by i.c.v. administration of the K
ATP
 channel blocker 
tolbutamide inhibited insulin-stimulated glucose uptake by muscle. This inhibition of insulin-
stimulated glucose uptake occurred independent of a change in insulin signaling in muscle, 
but also independent of a change in AMPK activation. So, the brain-mediated glucose uptake 
by muscle does not involve the PI3K pathway or the “alternative pathway” (involving AMPK). 
Therefore, more research is needed to determine how insulin signaling in the brain can affect 
insulin-stimulated glucose uptake by muscle.
Insulin not only regulates glucose metabolism, but also stimulates fat storage in adipose 
tissue. In chapter 6, we show that insulin-stimulated uptake of FA by white adipose tissue (WAT) 
is also in part dependent on central insulin signaling. I.c.v. administration of the K
ATP
 channel 
blocker tolbutamide abolished the central effects of insulin on FA uptake by WAT and prevented, 
in part, the circulating insulin-stimulated FA uptake by WAT. By employing the dual tracer 
methods described previously (61), we made a distinction between FA derived from plasma 
triglyceride (TG) and FA derived from plasma albumin. Both peripheral and i.c.v. administrered 
insulin stimulated the retention of both sources of plasma FA in WAT. This insulin-stimulated FA 
uptake by WAT was accompanied by a decreased half-life of TG, reflecting increased turnover 
of plasma TG. Interestingly, these acute effects of i.c.v. insulin administration on plasma TG 
and FA fluxes towards WAT, together with recent data showing that brain insulin suppresses 
intracellular lipolysis and stimulates lipogenesis in adipocytes (62), provide an explanation for 
the finding that chronic i.c.v. insulin administration increases fat mass (63). The indirect effect 
of insulin on fat storage via the brain might involve alterations in the activity of the autonomic 
nerves projecting towards WAT. Parasympathetic denervation of WAT reduced FA uptake in 
WAT by 36% during hyperinsulinemic clamp conditions in rats (64), suggesting that an increase 
in parasympathetic activity towards WAT might be involved in insulin-stimulated fat storage. 
In chapter 6 we show that in CD36-deficient mice, i.c.v. insulin was unable to stimulate fat 
storage, suggesting a role for the long-chain FA transporter CD36 in i.c.v. insulin stimulated 
FA uptake. Accordingly, AMPK, which can stimulate FA uptake by promoting translocation of 
CD36 from intracellular pool to the plasma membrane (65), was activated in WAT upon i.c.v. 
insulin administration. A concept emerges of an insulin-dependent central pathway, leading 
to parasympathetic innervation of WAT and via CD36 translocation following AMPK activation 
resulting in FA uptake by WAT. Insulin also affects FA metabolism by acutely decreasing VLDL 
secretion by the liver (66;67). Therefore it will be interesting to determine whether this effect is 
also mediated by insulin action in the brain.
Combining data obtained in chapter 4 and chapter 6 indicates that circulating insulin 
affects glucose and FA metabolism in part via action in the brain. These effects via the brain 
are organ specific: central insulin signaling is involved in glucose uptake by skeletal muscle, 
but not heart or WAT, and central insulin signaling is involved in FA uptake by WAT, but not 
heart, muscle, liver or brown adipose tissue (BAT). The contrasting effects of central insulin 
suggest a branched-pathway model of hypothalamic insulin signaling in which insulin (in POMC 
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neurons, via sympathetic activity?) stimulates glucose uptake by muscle, whereas insulin (via 
parasympathetic activity?) promotes FA uptake in WAT. A tentative model of central insulin 




















Fig. 1. Tentative model of central insulin signaling. See text for explanation.
The observations in chapter 4 and chapter 6 stress the role of central insulin signaling in 
normal physiological conditions in maintaining glucose and lipid homeostasis. However, high-
fat feeding abolished the inhibitory effect of i.c.v. tolbutamide, suggesting central insulin 
resistance. Our in vivo observations in diet-induced obese mice extend in vitro observations, 
showing that insulin activates K
ATP
 channels in glucose responsive neurons of lean, but not of 
obese rats, suggesting that K
ATP
 channels are already inhibited in the insulin resistant state (68-
71). The ability of the brain to sense peripheral inputs and maintain metabolic homeostasis is 
impaired upon increased caloric intake, thereby contributing to the pathophysiology of obesity 
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and T2DM. New therapeutic interventions restoring brain insulin action in the hypothalamus of 
obese individuals could improve peripheral insulin sensitivity and plasma glucose levels.
It is now shown that circulating insulin affects peripheral processes, such as glucose and FA 
metabolism, in part via action in the brain. The fact that part of insulin’s effects are controlled 
by the brain could reflect a similar situation for other hormones, for instance thyroid hormones 
(TH). Thyroid hormones (TH) are crucial regulators of metabolism. In chapter 7 we show 
that TH status determines energy expenditure and tissue-specific changes in TG-derived 
FA uptake. TH status also affects glucose homeostasis: endogenous glucose production is 
increased upon high TH levels and reduced upon decreased TH levels (72-75). Recently it has 
been shown that TH administration directly in the brain mimics the effect of peripheral TH on 
glucose metabolism (76;77) and that both peripheral as well as central effects of TH on glucose 
production depend on sympathetic projections to the liver (77;78). This suggests that TH may 
affect glucose production in part via action in the brain. At this stage, however, it is unknown 
how these results reflect the human situation and whether hypothalamic bioavailability of TH 
is altered in diabetic patients. 
P h a r M aC o lo G I o C a l  I n t e rv e n t I o n  I n  t h e  b r a I n
The question arises whether the loss of insulin’s actions in the brain induced by high-fat 
feeding are amendable to pharmacological intervention. In chapter 5 we studied the effects 
of topiramate on insulin sensitivity as assessed by hyperinsulinemic-euglycemic clamp analysis. 
Topiramate, a sulfamate-substituted derivative of the monosaccharide D-fructose (79), is a 
broad-spectrum antiepileptic drug with potentially additional neurotherapeutic applications 
such as bipolar disorder and migraine (80;81). Its precise mechanism of action is unknown, 
although the antiepileptic effects of topiramate are mediated through at least six mechanisms 
of action within the central nervous system: (i) enhancement of GABA-ergic activity (82;83), (ii) 
inhibition of kainite/AMPA receptors (84), (iii) inhibition of voltage-dependent sodium channels 
(85), (iv) inhibition of high-voltage-activated calcium channels (86), (v) increase in potassium 
conductance (87) and (vi) inhibition of carbonic anhydrase (88). Besides its antiepileptic action, 
topiramate usage is associated with decreases in body weight. The reduction in body weight by 
topiramate treatment has been shown in epileptic patients as well as in obese, non-epileptic, 
persons (89-91). Although loss of appetite resulting in reduced caloric intake can account for 
initial reductions in body weight, other mechanisms might be involved in the long-term effects 
of topiramate on weight, as weight loss continued after caloric intake returned to baseline levels 
(91). Even though the half-life of topiramate is lower in rodents than in humans (~1-2 h), several 
studies have confirmed that topiramate also reduces food intake and body weight in lean as 
well as in obese mouse and rat models (92;93). Studies in obese, diabetic rats demonstrate 
that topiramate treatment reduces plasma glucose levels and improves insulin sensitivity 
independent of weight loss (94;95). In line with this, we document improved insulin sensitivity 
in our mice in absence of a reduction in body weight. This improvement in insulin sensitivity was 
present in (cardiac and skeletal) muscle and adipose tissue, but not in liver. As the concentration 
of topiramate in plasma correlates with that in cerebral spinal fluid (CSF) (96) and topiramate’s 
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effects on body weight, body composition and energy metabolism are associated with altered 
neuropeptide expression in the hypothalamus (97), whereas topiramate does not have a direct 
effect on insulin sensitivity in muscle cells, we hypothesized that the brain mediates the insulin 
sensitizing effects of topiramate. Since tolbutamide inhibits activation of neuronal K
ATP 
channels 
by insulin in insulin sensitive subjects, tolbutamide was used to demonstrate the involvement of 
the brain in the insulin sensitizing effect of topiramate. Central administration of tolbutamide 
in our mice had no effect on insulin sensitivity during hyperinsulinemic-euglycemic clamp, 
suggesting insulin resistance in the brain induced by high-fat feeding. I.c.v. tolbutamide in 
topiramate treated mice inhibited the insulin sensitizing effect of topiramate, suggesting that 
the improved insulin sensitivity by topiramate originates from an insulin sensitizing effect in 
the brain directed at muscle and adipose tissue but not liver. This improved insulin sensitivity 
in muscle and adipose tissue, but not in liver, has previously been associated with enhanced 
AMPK phosphorylation in muscle but not in liver (92). As α-adrenergic stimulation enhances 
AMPK phosphorylation, the increased glucose uptake by peripheral organs might be related to 
increased sympathetic nervous system (SNS) activity (98). 
Topiramate treatment has some negative side-effects that need to be overcome before it 
can be widely used in the clinics as an antidiabetic drug. Drowsiness, dizziness, fatigue and 
nervousness are common side-effects. Furthermore, determination of body composition by 
dual-energy X-ray absorptiometry in our mice showed a significant reduction in bone mineral 
density, in line with reports that topiramate treatment in epileptic children and young women 
results in hypocalcaemia, increased bone turnover and reduced bone mineral density (99;100), 
suggesting that topiramate has negative long-term effects on bone development. Taken 
together, topiramate improves insulin resistance by restoring insulin sensitivity in the brain 
and this feature renders topiramate as an exciting new drug when negative side effects are 
overcome, to treat diabetes by itself or in combination with classic antidiabetic drugs.
Other drugs that improve insulin sensitivity probably in part via action in the brain are GLP-1 
analogues. GLP-1 is a gut hormone, secreted in response to food. GLP-1 has many beneficial 
actions: it enhances glucose-stimulated insulin secretion, improves blood glucose profiles 
in type 2 diabetes patients, reduces body weight and food intake and slows gastric emptying. 
However, the half-life of native GLP-1 is only a few minutes in humans. Therefore, pharmaceutical 
companies are developing GLP-1 analogues that have the same beneficial qualities, but with a 
longer half-life. GLP-1 improves insulin sensitivity in part via activation of GLP-1 receptors in the 
brain (101;102). The neuronal circuits that are activated by peripheral administered GLP-1 (or its 
analogues) remain to be identified. One mode of action of GLP-1 could be a modulation of the 
NPY pathway in the hypothalamus, as i.c.v. GLP-1 completely prevents the orexigenic effects of 
NPY (103). Furthermore, GLP-1 has been reported to reduce NPY neuronal activity (104). Since NPY 
has been linked to insulin resistance, chronic administration of GLP-1 or any of its analogues may 
antagonize NPY-induced insulin resistance. GLP-1 can also improve insulin sensitivity by acting 
in the brainstem. Located in the brainstem, the nucleus of the solitary tract (NTS) receives vagal 
afferent input from the gastrointestinal tract. GLP-1 (or its analogues) can activate neurons in the 
NTS via afferent vagal input (105;106). Elucidating the precise molecular events in the brain that 
underlie the effects of GLP-1 (and its analogues) will lead to new or improved therapeutic agents. 
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C o n C l u d I n G  r e M a r k s
As the brain is clearly involved in maintaining peripheral homeostasis, experimental therapies 
with action in the brain should be considered as promising strategies for the treatment of T2DM 
and T2DM-associated complications. Disruptions in circadian rhythm, resulting in altered 
output by the SCN, have an immediate effect on energy metabolism and insulin sensitivity. It 
has become clear that the brain is able to directly sense circulating hormones and nutrients 
that provide the brain with information regarding the metabolic status of the body. Thyroid 
hormones affect glucose metabolism, and possible other processes as well, possibly via action 
in the brain. Insulin’s action in glucose and FA metabolism results in part via central mechanisms. 
High-fat diet induces not only peripheral insulin resistance, but also central insulin resistance, 
which can contribute to the pathophysiology of T2DM. Restoring insulin sensitivity in the brain, 
as we have observed with topiramate, may be a promising new target for T2DM therapies or can 
extend the action of current therapies. 
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The prevalence of type 2 diabetes mellitus (T2DM) is rising steadily as a consequence of 
the growing obesity epidemic. The pathophysiology of T2DM comprises of a combination 
of insulin resistance and impaired insulin secretion by pancreatic ß-cells, finally resulting in 
hyperglycemia. In addition to disturbed glucose metabolism, T2DM patients have disturbed 
lipid metabolism, resulting in concomitant dyslipidemia. Accumulating evidence suggests that 
the brain is a key player in metabolic regulation and maintenance ofmetabolic homeostasis. The 
aim of this thesis was to elucidate the role of the brain in the development of insulin resistance.
The first part of this thesis focused on the role of circadian regulation of insulin sensitivity. 
Disturbances in circadian rhythms are associated with increased incidence of obesity and T2DM. 
These disturbances in circadian rhythms can be caused by altered environmental cues, including 
shift work, jet lag, aging, depression and sleep disorders. In chapter 2 we examined the effects 
of a disturbed circadian rhythm on energy metabolism and insulin sensitivity by exposingmale 
C57Bl/6J mice on chow or high-fat diet to constant light. In vivo electrophysiological recordings 
of the central circadian pacemaker, the suprachiasmatic nucleus (SCN), showed that constant 
light exposure immediately reduces the circadian amplitudes of the SCN neuronal activity 
pattern and rhythm strength. Constant light exposureimmediately resulted in body weight 
gain, even before high-fat diet feeding resulted in weight gain. The circadian pattern in 
energy metabolism was completely lost after 5 weeks of constant light exposure. Furthermore, 
constant lightexposure neutralized the normal circadian variation in insulin sensitivity of the 
liver as well as of peripheral tissues. We concluded that constant light exposure reduces SCN 
rhythm strength and results in a complete absence of rhythm in energy metabolism and 
insulin sensitivity. 
In chapter 3 we studied the role of the SCN in the circadian regulation of energy homeostasis 
and insulin sensitivity. In male, chow fed C57Bl/6J mice, the SCN was bilaterally destroyed 
by thermic ablation. SCN lesions resulted in loss of circadian rhythm as determined by 
periodogram analysis. The circadian rhythm in energy metabolism was also completely lost, 
whereas total energy intake or expenditure was not different between sham and SCN lesioned 
mice. Nonetheless, deletion of the SCN resulted in a small, but significant increase in body 
weight, which was accounted for by an increase in fat mass. Furthermore, SCN lesions resulted 
in hyperglycemia, hyperinsulinemia and severe hepatic insulin resistance. We concluded that 
bilateral lesions of the SCN resulted in mild overweight and in severe hepatic insulin resistance, 
again suggesting that malfunctioning of the SCN could be involved in the development 
of T2DM. Apparently, a reduction in SCN output, as studied in chapter 2, resulted in loss of 
circadian variation in insulin sensitivity, whereas a complete loss in SCN function, as studied in 
chapter 3, caused severe insulin resistance. 
The second part of this thesis focused on the role of insulin signaling in the brain. Insulin 
normalizes plasma glucose levels after a meal by inhibitingthe endogenous glucose production 
(EGP) as well as by stimulating glucose uptake in peripheral tissues, and hypothalamic insulin 
signaling is required for the inhibitory effects of insulin on EGP. In chapter 4 we examined the 
role of the brain in insulin-stimulated tissue-specific glucose uptake. Tolbutamide, an inhibitor of 
ATP-sensitive potassium (K
ATP
) channels, or vehicle, was infused intracerebroventricular (i.c.v.) 
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in the basal state and during hyperinsulinemic-euglycemic conditions in male C57Bl/6J mice on 
chow or on high-fat diet. On chow diet, i.c.v. administration of tolbutamide impaired the ability 
of insulin to inhibit EGP during hyperinsulinemicclamp conditions. In addition, i.c.v. tolbutamide 
diminished insulin-stimulated glucose uptake in muscle, but not in heart or adipose tissue. In 
contrast, in high-fat fed, insulin resistant mice, i.c.v. administration of tolbutamide did not 
inhibit the effects of insulin during clamp conditions on EGP or glucose uptake by muscle. 
We concluded that insulin stimulates glucose uptake in muscle in part through effects via K
ATP
 
channels in the brain, in analogy with the inhibitory effects of insulin on EGP and that high-fat 
diet-induced obesity abolished these central effects of circulating insulin on liver and muscle. 
Topiramate is associated with improvement in insulin sensitivity, in addition to its antiepileptic 
action. The mechanisms underlying the insulin sensitizing effects oftopiramate are unknown. 
However, these effects could be mediated through the brain as the insulin sensitizing effects 
of topiramate occur independently of weight loss. In chapter 5 we investigated the role of the 
brain in the insulin-sensitizing effects of topiramate both in vivo and in vitro. Male C57Bl/6J mice 
were fed a high-fat diet for 6 weeks, to induce insulin resistance, before receiving topiramate or 
vehicle mixed in high-fat diet for 6 weeks. Therapeutic concentrations of topiramate improved 
insulin sensitivity, which was the result of improved insulin-mediated glucose uptake by heart, 
muscle and adipose tissue. Upon i.c.v. infusion of tolbutamide, these insulin sensitizing effects 
of topiramate were completely abrogated in hyperinsulinemic-euglycemic clamp conditions. 
Topiramate did not alter glucose uptake or insulin signaling in normal and insulin-resistant 
C2C12 muscle cells. We concluded that topiramate stimulates insulin-mediated glucose uptake 
in vivo through action in the brain. 
Insulin is not only involved in glucose metabolism, but also stimulates fat storage in adipose 
tissue. In chapter 6, we examined the role of the brain in the stimulatory effect of circulating 
insulin on the tissue-specific retention of fatty acids (FA) from plasma. In male, chow fed C57Bl/6J 
mice, hyperinsulinemic-euglycemic clamp conditions stimulated the retention of both plasma 
triglyceride (TG)-derived FA and plasma albumin-bound FA in the various white adipose tissues 
(WAT), but not in other tissues including brown adipose tissue (BAT). I.c.v. administration of 
insulin induced a similar pattern of tissue-specific FA partitioning. This effect of i.c.v. insulin 
administration was not associated with activation of the insulin signaling pathways in adipose 
tissue. I.c.v. administration of tolbutamideconsiderably reduced (during hyperinsulinemic-
euglycemic clamp conditions) and even completely blocked (during i.c.v. administration of 
insulin) WAT-specific retention of FA from plasma. This central effect of insulin was absent 
in CD36 deficient mice, indicating that CD36 is the predominant FA transporter in insulin-
stimulated FA retention by WAT. In high-fat fed, insulin resistant mice, these stimulating effects 
of insulin (circulating or i.c.v. administered) on FA retention in WAT were lost. We concluded 
that, in insulin-sensitive mice, circulating insulin stimulates tissue-specific partitioning of 
plasma-derived FA in WAT in part through activation of K
ATP
 channels in the brain and that high-
fat diet obesity abolished these central effects of circulating insulin on WAT. 
Thyroid hormones (TH) are crucial regulators of metabolism that exert their effects probably 
in part via action in the brain. In chapter 7 we studied the effects of TH status on whole body 
energy metabolism. Hyperthyroid rats exhibited markedly increased energy expenditure and 
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fat oxidation without alterations in spontaneous physical activity. Hypothyroid rats showed 
a mild decrease in energy expenditure and carbohydrate oxidation. In addition, we studied 
how these alterations in energy metabolism were associated with tissue-specific FA uptake. 
The hypermetabolic phenotype of hyperthyroidism was characterized by increased uptake 
of TG-derived FA in oxidative-tissues, but not in WAT. Conversely, during hypothyroidism 
TG-derived FA uptake was unaltered in oxidative-tissues, but increased in WAT, which was 
accompanied by an increased activity in lipoprotein lipase activity. We concluded that TH 
status determines energy expenditure independently of spontaneous physical activity and that 
the changes in energy metabolism induced by TH status are accompanied by tissue-specific 
changes in TG-derived FA uptake.
Taken together, the studies in this thesis contribute to the understanding of the role of the 
brain in insulin sensitivity. We demonstrated that disturbances in circadian rhythm resulting in 
alterations in SCN output, can contribute to the development of insulin resistance. We have 
also shown that insulin-stimulated glucose uptake by muscle and insulin-stimulated FA uptake 
by WAT is in part dependent on insulin action in the brain. These effects of circulating insulin on 
peripheral organs via the brain are abrogated by high-fat diet. These brain-dependent effects 
of insulin could reflect a similar situation for other hormones, for instance thyroid hormones. 
Furthermore, we demonstrated that topiramateimproves insulin resistance by restoring insulin 
sensitivity in the brain, suggesting that therapeutical targets in the brain may offer challenging 




s a M e n vat t I n G
Zwaarlijvigheid (obesitas) is het overmatig opslaan van vet in ons lichaam en wordt veroorzaakt 
door te veel en te calorierijk eten en te weinig bewegen. Inmiddels heeft de incidentie van 
obesitas epidemische proporties aangenomen. Als consequentie hiervan lijden ook steeds 
meer mensen aan suikerziekte (diabetes mellitus type 2). In gezonde mensen wordt de 
bloedsuikerspiegel (glucose spiegel) strikt gereguleerd om enerzijds te voorkomen dat organen 
beschadigd worden door een te hoge bloedsuikerspiegel (hyperglycemie) en anderzijds om 
te voorkomen dat de bloedsuikerspiegel te laag wordt (hypoglycemie) waardoor organen die 
van glucose afhankelijk zijn, zoals de hersenen, niet meer voldoende brandstof hebben. Het 
hormoon insuline wordt geproduceerd door de β-cellen van de pancreas als reactie op een 
maaltijd en is een van de belangrijkste spelers in de regulatie van glucose niveaus in het bloed; 
het remt de productie van glucose door de lever en stimuleert tegelijkertijd de opname van 
glucose uit het bloed door spier en vetweefsel. Het netto effect is een normalisatie van de 
glucose niveaus in het bloed. Diabetes wordt gekenmerkt door een verminderde gevoeligheid 
voor insuline (insuline resistentie) en een te lage insuline productie. In de beginfase van 
diabetes, als weefsels al minder gevoelig zijn voor de werking van insuline, is de productie 
van insuline verhoogd om te zorgen dat het effect van insuline gehandhaafd blijft ondanks de 
resistentie van de weefsels. Als β-cellen echter niet meer in staat zijn om de verhoogde insuline 
productie vol te houden, zullen de bloed glucose niveaus stijgen. Dit zal, als het onbehandeld 
blijft, leiden tot velerlei complicaties en mogelijk zelfs de dood. Insuline is niet alleen betrokken 
bij de glucose stofwisseling (metabolisme), maar ook bij het vet metabolisme. Het stimuleert 
de opslag van vet in wit vetweefsel en verlaagt de productie van VLDL (een deeltje dat vet uit 
de lever naar weefsels transporteert) door de lever. Hierdoor hebben diabetes patiënten ook 
vaak een verstoord vet metabolisme. De laatste jaren is duidelijk geworden dat de hersenen 
in belangrijke mate bijdragen aan de regulatie van het metabolisme. Zo is bijvoorbeeld 
aangetoond dat insuline de glucose productie door de lever deels remt via de hersenen. Als 
insuline niet zijn functie kan uitoefenen in de hersenen, dan is insuline minder effectief in het 
remmen van de glucose productie. In dit proefschrift hebben we onderzocht hoe de hersenen 
bijdragen in de ontwikkeling van insuline resistentie. 
Hoofdstuk 1 geeft een introductie in glucose en vet metabolisme. Ook wordt besproken 
hoe insuline en schildklierhormoon het glucose en vet metabolisme beïnvloeden. De hersenen 
zijn een belangrijke regulator van het metabolisme. De rol van de hersenen in de regulatie van 
het glucose en vet metabolisme wordt uiteengezet, met nadruk op de werking van insuline en 
schildklierhormoon in de hersenen. Verder wordt besproken wat diabetes mellitus type 2 is 
en wat de huidige behandel methodes zijn. Verstoringen in het dag-nacht (circadiaan) ritme, 
bv door ploegendiensten, zijn geassocieerd met de ontwikkeling van diabetes. De rol van de 
biologische klok in het circadiaanritme zal uiteengezet worden en verder worden besproken 
hoe verstoring van het circadiaan ritme tot diabetes kan leiden. Tenslotteworden de algemene 
hypothese en inhoud van het proefschrift gepresenteerd. 
Het eerste deel van dit proefschrift richtte zich op de rol van de biologische klok in 
insuline gevoeligheid. Verstoringen in het circadiaan ritme kunnen worden veroorzaakt door 
ploegendienst, jetlag, depressie en slaapstoornissen, maar ook als we ouder worden, is ons 
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circadiaan ritme verstoord. In hoofdstuk 2 onderzochten we de effecten van een verstoord 
circadiaan ritme op energiehuishouding en insuline gevoeligheid in muizen. Om het normale 
circadiaan ritme te verstoren werden muizen blootgesteld aan continu licht. Continu 
licht veroorzaakte geen stress bij de muizen, zoals dat bij mensen wel het geval zou zijn. 
Elektrofysiologische metingen in de hersenen van deze muizen toonden aan dat constante 
blootstelling aan licht onmiddellijk een verminderde activiteit in neuronen van de centrale 
klok (de suprachiasmatische nucleus, SCN) veroorzaakte. Verder resulteerde constant licht in 
een directe gewichtstoename van de muizen, zelfs voordat een hoog-vet dieet resulteerde in 
gewichtstoename. Muizen zijn nachtdieren; ’s nachts zijn ze actiever en eten dan ook meer. Om 
bloedsuikerspiegel efficiënter te normaliseren, zijn de muizen ’s nachts ook gevoeliger voor de 
werking van insuline dan overdag. Dit circadiaan ritme in energiehuishouding was na 5 weken in 
continu licht volledig weg: de muizen waren overdag net zo actief als ’s nachts, aten gedurende 
de hele dag en waren overdag net zo gevoelig voor de werking van insuline als ’s nachts. We 
concludeerden dat continue blootstelling aan licht direct leidt tot verminderde activiteit van 
de SCN, directe gewichtstoename en afwezigheid van circadiaan ritme in energiehuishouding 
en insuline gevoeligheid. 
In hoofdstuk 3 onderzochten we welke rol de centrale klok, de SCN, heeft in de regulatie 
van energiehuishouding en insuline gevoeligheid. Om dit te onderzoeken, hebben we in de 
hersenen de SCN weggebrand aan twee kanten (bilaterale SCN laesie). Als gevolg hiervan was 
het circadiaan ritme in de energiehuishouding volledig verloren gegaan: de muizen waren de 
hele dag door actief en aten hierdoor ook de hele dag. Ondanks dat het circadiaan ritme in 
energiehuishouding afwezig was, was de totale voedselinname en activiteit niet verandert door 
de SCN laesie. Toch waren de muizen met SCN laesie iets zwaarder dan de controle muizen door 
een kleine, maar significante toename in vet massa. Bovendien waren de muizen met SCN laesie 
erg ongevoelig voor insuline in de lever, wat niet verklaard kon worden door de kleine toename 
in vet massa. We concludeerden dat bilaterale laesies van de SCN leiden tot een kleine toename 
in lichaamsgewicht en tot ernstige insuline resistentie. Hoofdstuk 2 en 3 samen suggereerden 
dat verstoringen, bv door ploegendienst, of defecten van de centrale klok betrokken kunnen 
zijn bij de ontwikkeling van diabetes.
Het tweede deel van dit proefschrift richtte zich op de rol van de hersenen in het effect van 
insuline. Insuline normaliseert glucose niveaus na een maaltijd door glucose productie door de 
lever te remmen en door opname van glucose inspier en vetweefsel te stimuleren. Het effect 
van insuline op de glucose productie door de lever loopt deels via de hersenen. In hoofdstuk 4 
onderzochten wij de rol van de hersenen in insuline-gestimuleerde opname van glucose. Het 
effect van insuline in de hersenen kan geblokkeerd worden door tolbutamide (een remmer 
van ATP-gevoelige kalium (K
ATP
) kanalen)direct in hersenvloeistof in te spuiten. Inspuiten van 
tolbutamide in de hersenenvan muizen verminderde het vermogen van insuline om glucose 
productie door de lever te remmen, zoals al eerder is aangetoond. Daarnaast verminderde 
tolbutamide de insuline-gestimuleerde opname van glucose door spieren, maar niet door 
hart-of vetweefsel. In dieet-geïnduceerde, insuline resistente muizen heeft tolbutamide geen 
invloed op de effecten van insuline op glucose productie door de lever of glucose-opname 





kanaal activatie in de hersenen, net als het remmende effect van insuline op 
de glucose productie door de lever. Verder concludeerden we dat door dieet-geïnduceerde 
obesitas de effecten van insuline in de hersenen op lever en spieren verloren zijn.
Topiramaat is een geneesmiddel tegen verschillende vormen van epilepsie. Naast zijn anti-
epileptische actie, is topiramaat geassocieerd met verbetering van de insuline gevoeligheid. 
De mechanismen die hieraan ten grondslag liggen zijn onbekend. Aangezien topiramaat de 
insuline gevoeligheid kan verbeteren onafhankelijk van gewichtsverlies, zou het kunnen zijn 
dat de hersenen hierin een rol spelen. In hoofdstuk 5 onderzochten we of topiramaat de 
insuline gevoeligheid verbeterd via een effect in de hersenen. Hiertoe kregen muizen eerst 
een hoog-vet dieet te eten om insuline resistentie te ontwikkelen, voordat topiramaat door 
het dieet werd gemengd. Therapeutische concentraties van topiramaat verbeterde de insuline 
gevoeligheid, zonder dat het tot gewichtsverlies leidde. De verbeterde insuline gevoeligheid 
was het resultaat van verhoogde glucose opname door hart, spier en vetweefsel. Door 
tolbutamide in de hersenen in te spuiten, kon het effect van topiramaat volledig geblokkeerd 
worden. Op geïsoleerde spiercellen (gezond of insuline resistent) had topiramaat geen invloed 
op de glucose opname, wat suggereert dat topiramaat geen direct effect heeft op spiercellen, 
maar dat het werkt via de hersenen. We concludeerden dat topiramaat via de hersenen de 
insuline gevoeligheid verbeterd door de glucose opname door hart, spier en vetweefsel 
te stimuleren. 
Insuline is niet alleen betrokken bij glucose metabolisme, maar stimuleert ook de opslag van 
vetzuren in het vetweefsel. In hoofdstuk 6 onderzochten we de rol van de hersenen in insuline-
gestimuleerde vetzuur opslagin vetweefsel. Een verhoging van insuline niveaus in het bloed 
zorgde voor een toename in vetzuur opslag in wit vetweefsel, maar niet in andere weefsels 
zoals bruin vetweefsel. De vetzuren waren afkomstig van zowel triglyceriden als albumine-
gebonden (vrije) vetzuren. Inspuiten van insuline direct in hersenvloeistof gaf een vergelijkbaar 
resultaat. Inspuiten van tolbutamide in de hersenen blokkeerde deels het effect van insuline in 
het bloed op vetzuur opslag, wat suggereert dat insuline de vetzuur opslag in wit vetweefsel 
deels via de hersenen stimuleert. De vetzuur vervoerder CD36 is hier hoogstwaarschijnlijk bij 
betrokken, aangezien het effect van insuline in de hersenen op de vetzuur opslagafwezig was in 
CD36-deficiente muizen. In dieet-geïnduceerde, insuline resistente muizen had insuline via de 
hersenen geen effect meer op vetzuur opslag in vetweefsel. Wij concludeerden dat in insuline 
gevoelige muizen, insuline vetzuur opslag in wit vetweefsel deels stimuleert via K
ATP
 kanaal 
activatie in de hersenen.
Schildklierhormoon is eenbelangrijke regulator van het metabolisme. Het effect van 
schildklierhormoon loopt waarschijnlijk deels via de hersenen. In hoofdstuk 7 hebben we 
het effect van de schildklierhormoon status bestudeerd op de energiehuishouding. Ratten 
met verhoogde schildklierhormoon spiegels (hyperthyreoïdie) hadden een verhoogd 
energieverbruik en verhoogde vet verbranding, maar geen verandering in activiteit. Ratten 
met lage schildklierhormoon spiegels (hypothyreoïdie) hadden een verlaagd energieverbruik 
en verlaagde glucose verbranding. Vervolgens hebben we bestudeerd hoe deze veranderingen 
in de energiehuishouding samen gingen met vetzuur opname. Hyperthyreoïdie ging gepaard 
met vetzuur opslag afkomstig van triglyceriden in spier en hart, maar niet in vetweefsel. 
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Hypothyreoidie ging gepaard met vetzuur opslag afkomstig van triglyceriden in vetweefsel, 
maar niet in spier of hart. Een lokale toename in activiteit van het enzym lipoproteïne lipase 
zorgde ervoor dat vetzuren uit triglyceriden werden vrijgemaakt. Opname van albumine-
gebonden vetzuren was niet onderhevig aan weefsel-specifieke regulatie, maar voornamelijk 
bepaald door de concentratie van vetzuren in het bloed. We concludeerden dat de 
schildklierhormoon status de energiehuishouding bepaalt en dat dit samen gaat met weefsel-
specifieke veranderingen in vetzuur opslag afkomstig van triglyceriden. 
In hoofdstuk 8 worden de resultaten die gevonden zijn in de hoofdstukken 2, 3, 4, 5, 6 en 7 
besproken in de context van de aanwezige literatuur. Verder wordt besproken wat de klinische 
implicaties zijn van onze bevindingen en wat de mogelijke richtingen zijn voor toekomstig 
onderzoek.
Samengevat laten de studies in dit proefschrift zien dat de hersenen een belangrijke rol spelen 
in de ontwikkeling van diabetes. We hebben aangetoond dat verstoringen in het circadiaan 
ritme kan bijdragen aan de ontwikkeling van insulineresistentie. We hebben ook aangetoond 
dat het effect van insuline op het glucose en vetzuur metabolisme deels via de hersenen loopt. 
Het zou kunnen dat andere hormonen, bijvoorbeeld schildklierhormoon, ook deels werkt via 
de hersenen. Verder hebben we aangetoond dat topiramaat insuline gevoeligheidverbetert 
door de gevoeligheid voor insuline in de hersenen te verbeteren. Dit suggereert dat herstellen 
van insuline gevoeligheid in de hersenen een nieuwe therapeutische mogelijkheid zou kunnen 
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